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Background: The endothelium is crucial for the control of vascular function and for
the maintenance of vascular health. In addition to nitric oxide (NO) and prostacyclin
(PGI2), endothelium-derived hyperpolarising factor (EDHF) is a third endothelium-
derived vasodilator. It has also been implicated with a role in the release of the
endogenous fibrinolytic factor, tissue plasminogen activating factor (t-PA).
Potassium channels appear to be vital for its mechanism and gap junctions have been
implicated with a role, but the identity of EDHF remains elusive. Consequently, it
remains unmanipulated as a therapeutic target despite its involvement in a wide
variety of vascular diseases. Additionally, it has not previously been possible to
examine safely the in vivo interaction between thrombotic factors and endothelium-
derived mediators, including EDHF. Protease-activated receptor type 1 (PAR-1) is
the principal thrombin receptor in man. By examining the effects of direct PAR-1
receptor activation, it is possible to examine the in vivo vascular effects of thrombin
in isolation from its stimulatory effects upon the coagulation cascade in both health
and disease.
Objectives: 1) To assess the role of gap junctions and their connexin components in
EDHF-mediated vasorelaxation in human resistance arteries in vitro. 2) To evaluate
the vascular effects of potentiation of communication via the connexin 43 gap
junction subunit in vivo. 3) To evaluate the role of the endothelium and endothelium-
derived factors in the mediation of PAR-l evoked vasomotion and t-PA release in
vivo. 4) To examine the effect of cigarette smoking upon endothelial PAR-1
responses in vivo.
Methods: Fat biopsies were obtained from women undergoing elective caesarean
section. Subcutaneous resistance arteries were subsequently dissected out. Vascular
responses were assessed in a wire-myograph and the role of connexins assessed
using specific connexin antagonists, connexin mimetic peptides (CMPs). Dorsal hand
vein tone was assessed using the Aellig technique. Responses to local intravenous
infusion of SFLLRN, a synthetic PAR-1 activating peptide, were assessed before and
after venous endothelial denudation achieved by the local instillation of distilled
water. Forearm venous occlusion plethysmography, with venous blood sampling,
was used for the assessment of peripheral arterial blood flow and endogenous
fibrinolytic responses in vivo. Intra-brachial rotigaptide, a novel peptidic agent, was
used to assess the vascular effects of augmentation of intercellular communuication
via connexin 43. Intra-brachial SFLLRN was infused in the presence and absence of
aspirin, the 'nitric oxide clamp' and tetraethylammonium ion (TEA, a calcium-
activated potassium channel antagonist) to assess the contribution of PGI2, NO and
EDHF respectively, in the mediation of the vascular effects of PAR-1 activation. The
vascular effects of intra-brachial SFLLRN were compared in smokers and non¬
smoking matched control volunteers.
Results: EDHF-mediated vasorelaxation was abolished by the combined antagonism
of the three major vascular connexins in vitro. Inhibition of connexin 43 alone
reproduced this response but antagonism of the other vascular connexins alone was
without effect, despite immunohistochemical evidence of their expression. However,
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potentiation of communication via connexin 43 by intra-arterial rotigaptide did not
affect endothelium-dependent vasodilatation or t-PA release in vivo. PAR-1
activation caused venoconstriction in the presence and absence of endothelium.
PAR-1 mediated peripheral arterial vasodilatation was not affected by aspirin but
was attenuated by the 'nitric oxide clamp' and by TEA alone, and was almost
abolished by their combination. PAR-1 activation caused t-PA release that was not
affected by aspirin, the 'nitric oxide clamp' or TEA. PAR-1 evoked t-PA antigen
release was almost completely absent in cigarette smokers despite marked release in
non-smokers. Cigarette smokers displayed attenuated PAR-1 mediated peripheral
arterial vasodilatation.
Conclusions: Connexin 43 is vital for the mediation of EDHF activity in pregnant
human resistance vessels in vitro. However, augmentation of connexin 43
communication has no effect on arterial vasodilatation or t-PA release in the
peripheral circulation of healthy man. It remains to be established whether
augmentation of connexin 43 communication improves endothelial function in
patients with vascular disease. Acting via PAR-1, thrombin makes a major
interaction with arterial, but not venous, endothelium to cause vasodilatation via NO-
and EDHF-dependent pathways. It causes the endothelial release of t-PA that is
independent of PGE, NO and EDHF. The arterial effects of PAR-1 activation are
markedly impaired in association with endothelial dysfunction caused by smoking
cigarettes. Relative arterial stasis and near abolition of t-PA release will strongly
promote clot propagation and vessel occlusion. These findings highlight the
important interaction between thrombotic and endothelial factors at times of acute
arterial injury such as occurs during acute myocardial infarction and stroke.
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The vascular endothelium forms a single cell layer that covers the luminal surface of
all blood vessels under normal conditions. Despite knowledge of its existence since
the mid 1800s [Schwann, 1847; Hwa and Aird, 2007], its vital physiologic roles were
not recognised until more than a century later. Prior to the seminal work of Furchgott
and Zawadzki [Furchgott and Zawadzki, 1980], there had been little appreciation that
the endothelium was anything more than a passive, semi-permeable barrier between
intraluminal blood and vascular smooth muscle or the interstitial space. However,
our understanding of the critical roles it fulfils has now deepened. Not only is the
endothelium intimately involved with the regulation of vasomotion [Furchgott and
Zawadzki, 1980], it also plays a pivotal role in coagulation and fibrinolytic processes
[Emeis, 1992]. It is responsible for mounting a response to vascular injury, exerts
important anti-inflammatory activities and has powerful influence upon the
migration of vascular smooth muscle cells and the adhesion and aggregation of
platelets [Ones et al, 1998; Feletou and Vanhoutte, 2006; Rao et al, 2007], These
homeostatic properties are mediated by a variety of factors synthesised and released
by the endothelium in response to mechanical, neural and humoral stimuli.
1.2 ENDOTHELIUM-DERIVED FACTORS AND THE CONTROL OF
VASOMOTION
Endothelial stimulation results in the immediate release of a number of vasodilator
mediators including prostacyclin (PGL), nitric oxide (NO) and endothelium-derived
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hyperpolarising factor (EDHF). Moreover, the endothelium is also able to generate
and release vasoconstrictor mediators, such as angiotensin II and endothelin-1, and
hence provide a counter-regulatory tonic action on the adjacent vascular smooth
muscle [Haynes et al, 1996].
1.2.1 Nitric oxide
Nitric oxide was the first endothelium-derived vasodilator to be described [Furchgott
and Zawadzki, 1980] and is now well characterised. In addition to its potent
vasodilator effects, NO exerts many other vascular roles including the inhibition of
vascular smooth muscle proliferation and the regulation of interactions between
leucocytes and the blood vessel wall. Intravascular NO is principally taken up by
haemoglobin but also enters platelets to cause inhibition of their activation, adhesion
and aggregation [Moncada and Higgs, 2006].
Nitric oxide is produced during the oxidation of L-arginine to L-citrulline [Palmer et
al, 1988] under the enzymatic control of NO synthase. Endothelial nitric oxide
synthase (eNOS) is constitutively expressed and NO is responsible for the tonic
relaxation of blood vessels in the systemic and pulmonary circulations at rest
[Vallance et al, 1989; Haynes et al, 1993; Stamler et al, 1994], Endothelial nitric
oxide synthase may also be activated via a calcium-dependent mechanism and, in
addition to its role in the maintenance of basal vascular tone, NO is released from the
endothelium in response to a number of agonists and by shear stress. In the human
arterial circulation in vivo, agonists including bradykinin, substance P and
acetylcholine evoke vasodilatation by endothelium-dependent mechanisms including
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the stimulation of endothelial NO synthesis and release [Rongen et al, 1993;
Cockcroft et al, 1994] (Table 1.1).
Table 1.1 Endothelium-dependent vasodilator agonists









PAR-1 - protease-activated receptor type 1.
Once synthesised, the pathway via which NO acts to evoke vasodilatation is well
understood. Following its release from the abluminal aspect of the endothelium, it
activates smooth muscle guanylate cyclase and increases intracellular guanosine
monophosphate [Arnold et al, 1977]. The resultant decrease in the smooth muscle
intracellular concentration of calcium causes vascular relaxation [Collins et al,
1986], Exogenous NO donors, such as sodium nitroprusside and nitroglycerin, also
act via this mechanism [Kukovetz et al, 1979] but bypass the requirement for a
functional endothelium.
Constitutive NO synthase can be inhibited in vitro and in vivo with guanidine-
substituted analogues of L-arginine. These analogues inhibit NO synthase by
competition with L-arginine for the substrate binding site and include L-N°-




In addition to the production of NO, the endothelium is capable of the synthesis of
vasoactive prostanoids, including PGI2. As well as causing endothelium-dependent
vasodilatation, PGI2 exerts important antithrombotic and anti-platelet activity
[Moncada, 1982], It is produced from arachidonic acid via cyclooxygenase and is
rapidly synthesised and released in the endothelium in response to agonists including
bradykinin and adenosine nucleotides. Signal transduction involves the activation of
adenylate cyclase with consequent elevation of intracellular cyclic adenosine
monophosphate (cAMP) [Moncada et al, 1977a],
The vasodilating effects of PGI2 are less marked than those of NO in the majority of
vascular beds. However, it does contribute to resting vascular tone in the human
forearm although the reported magnitude of its contribution has varied considerably
between studies [Duffy et al, 1998; Campia et al, 2002; Singh et al, 2002],
Endothelium-dependent vasodilating agonists have been shown to act, in part, via
PGI2 in vitro [Toda, 1977] and in vivo in animals [Tiirker et al, 1982; Copeland et al,
1995], However, this finding has been less consistent in vivo in man [Benjamin et al,
1989; Davie and McMurray, 2002],
The synthesis of PGI2 can be blocked with inhibitors of cyclooxygenase such as
aspirin [Heavey et al, 1985] and indomethacin [Moncada et al, 1977b].
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1.2.3 Endothelium-derived hyperpolarising factor
In addition to NO and PGI2, evidence points to the existence of a third powerful
vasodilator called EDHF. Although the roles and mechanisms of NO and PGI2 are
well characterised, EDHF remains poorly understood.
After pharmacologic blockade of both NO and PGI2, a substantial degree of
endothelium-dependent vasodilatation is still observed and is associated with smooth
muscle hyperpolarisation. This activity is attributed to EDHF [Vanhoutte, 1987;
Beny and Brunet, 1988; Chen et al, 1988; Feletou and Vanhoutte, 1988; Chen et al,
1991; Mombouli et al, 1996; Feletou and Vanhoutte, 1999; Vanhoutte, 2004],
Furthermore, murine gene knockout models engineered to lack both cyclooxygenase
and eNOS also retain the capacity for endothelium-dependent vasodilatation
[Scotland et al, 2005].
Physiologic Role ofEDHF
In humans, EDHF-mediated vasodilatation has been described in various vascular
beds including coronary [Nakashima et al, 1993; Kemp and Cocks, 1997; Miura et
al, 2003], internal mammary [Liu et al, 2000; Deja et al, 2005; Wei et al, 2007],
radial [Hamilton et al, 2001; Wei et al, 2007], renal [Kessler et al, 1996], mesenteric
[Mackenzie et al, 2008], subcutaneous [Luksha et al, 2004; Mackenzie et al, 2008]
and cerebral arteries [Petersson et al, 1997]. Consistently, EDHF's role as a
vasodilator is most prominent in the smaller resistance arteries [Shimokawa et al,
1996; Urakami-Harasawa et al, 1997; Tomioka et al, 1999; Berman et al, 2002] that
are responsible for the control of systemic blood pressure and local tissue perfusion.
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Studies examining the role of EDHF in the maintenance of resting forearm arterial
tone have yielded inconsistent findings [Honing et al, 2000; Inokuchi et al, 2003] and
in vivo assessments of the role of EDHF in the control of systemic blood pressure in
man are lacking. Endothelium-derived hyperpolarising factor serves as an important
back-up mechanism when NO bioavailability is impaired and alterations in its
activity have commonly been noted in association with a wide variety of disease
states [Feletou and Vanhoutte, 2004].
Generation ofEndothelial Hyperpolarisation
Endothelium-derived hyperpolarising factor has been defined as a dilator process
which: (i) requires an intact endothelium; (ii) is distinct from both endothelium-
derived NO or PGE; (iii) dilates by hyperpolarising vascular smooth muscle; and (iv)
involves calcium-activated potassium channels (Kca) [Golding et al, 2002]
(Figure 1.1).
The mechanism via which endothelial cells generate hyperpolarisation in response to
agonists is reasonably well understood. Agonists evoke the release of calcium ions
(Ca2+) from intracellular stores via the activation of phospholipase C and inositol
triphosphate-gated calcium release channels. This initial increase in the intracellular
24"concentration of Ca elevates the transmembrane electrochemical gradient such that
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influx of Ca into the endothelium from the extracellular space is sustained to allow
the activation of endothelial small, intermediate and occasionally large conductance
calcium-activated potassium channels (SKca, IKCa and BKca respectively.) Potassium






















Figure 1.1 The endothelial generation of hyperpolarisation. The change in membrane potential that
initiates relaxation follows the opening of calcium (Ca2>) -activated K channels (Kef) by agonist-
induced elevations in cytosolic free Ca + entry (CCE) via store-operated channels (SOC) triggered by
depletion of the endoplasmic reticulum (ER) Ca2+ store. Endothelial hyperpolarisation is conducted to
subjacent smooth muscle cells via myoendothelial gap junctions. Elevations in cytosolic Ca2+ may
also elevate cAMP levels by stimulating adenylyl cyclase, thereby enhancing the electrical
conductance of myoendothelial gap junctions (Section 1.3). Tetraethylammonium ion (TEA) exerts
antagonistic actions at KCa [Griffith et al, 2004].
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as demonstrated by several lines of investigation: (i) studies employing radiolabeled
rubidium to track the passage of potassium ions (K+) demonstrates their efflux in
association with hyperpolarisation of suitably loaded endothelial cells [Gordon and
Martin, 1983]; (ii) there is an inverse relationship between the amplitude of agonist-
induced changes in endothelial membrane potential and the prevailing concentration
of extracellular K+ [Mehrke and Daut, 1990]; and (iii) hyperpolarisation is either
attenuated or abolished in the presence of peptidic inhibitors of Kca [Edwards et al,
1998; Frieden et al, 1999; Ohashi et al, 1999; Griffith, 2004] and in a murine model
engineered to lack endothelial IKca [Si et al, 2006]. Importantly, SKca>IKcaand BKca
have all been isolated in endothelial cells [Nilius and Droogmans, 2001].
KcaA.ntagGn.ists
Endothelium-dependent hyperpolarisation and EDHF-mediated vasodilatation is
inhibited in vitro by a variety of Kca antagonists, but most consistently by the dual
application of apamin (SKca antagonist) and charybdotoxin (non-selective IKca and
BKCa antagonist, with additional effects at voltage-dependent potassium channels)
[Edwards et al, 1998; Frieden et al, 1999; Ohashi et al, 1999; Eichler et al, 2003;
Griffith, 2004]. Of note, the in vitro application of charybdotoxin and apamin blocks
EDFlF-mediated responses when selectively applied to the endothelium but not when
applied to the adventitia [Doughty et al, 1999].
These peptides are toxic in vivo and therefore tetraethylammonium ion (TEA) has
been employed as an inhibitor of KCa in clinical studies [Honing et al, 2000;
Inokuchi et al, 2003; Bellien et al, 2005; Bellien et al, 2006; Pickkers et al, 2006;
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Mortensen et al, 2007]. At concentrations of <1 mmol/L, TEA is a non-selective
antagonist of vascular Kca [Nelson and Quayle, 1995; Ledoux et al, 2006] and, in
bioassay experiments, it inhibits acetylcholine-mediated vasorelaxation of rabbit
aortic endothelial rings when applied to the endothelium. Importantly, these effects
are endothelium-specific and application to vascular smooth muscle that has been
denuded of endothelium has no effect upon vascular tone [Demirel et al, 1994].
Furthermore, spectrofluorimetry studies reveal that TEA inhibits acetylcholine-
2"binduced elevation of intracellular Ca concentration and patch-clamp recordings
indicate that it inhibits the outward endothelial K+ current [Demirel et al, 1994],
Tetraethylammonium ion attenuates forearm arterial vasodilatation induced by
bradykinin [Honing et al, 2000] and substance P but does not affect vasodilatation in
response to acetylcholine [Inokuchi et al, 2003], This is in line with data from other
groups demonstrating that, relative to bradykinin and substance P, acetylcholine does
not evoke a strong NO-independent component for its endothelium-dependent
vasodilator response [Shiramoto et al, 1997; Schrage et al, 2005], Inokuchi et al
report that TEA causes an increase in resting forearm arterial vascular tone [Inokuchi
et al, 2003] although Honing et al report that it has no effect [Honing et al, 2000],
The reason for this discrepancy is unclear and warrants further investigation.
Putative Diffusible Mediators ofEDHF
The role of Kca in the generation of endothelial hyperpolarisation is now well
established but the identification of a single 'universal' mediator via which
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endothelial hyperpolarisation may be transmitted to the underlying smooth muscle
has proved to be substantially more challenging.
Nitric oxide and PGI2 may both cause a degree of smooth muscle hyperpolarisation
but there is extensive evidence to refute the hypothesis that EDHF simply represents
'residual' NO or PGI2 remaining after the incomplete inhibition of NO synthase or
cyclooxygenase [Illiano et al, 1992; Nagao et al, 1992; Griffith, 2004; Parkington et
al, 2004], Indeed, rather than augmenting EDHF, NO evokes a tonic inhibitory
influence upon EDHF activity and EDHF-type activity remains after dual NO
synthase/cyclooxygenase type 1 gene knockout [Bauersachs et al, 1996; Griffith,
2004; Vanhoutte, 2004; Scotland et al, 2005].
Many diffusible factors have been proposed to represent EDHF and include K+
[Edwards et al, 1998; Dawes et al, 2002], hydrogen peroxide [Shimokawa et al,
1996; Matoba et al, 2000; Matoba et al, 2002; Matoba and Shimokawa, 2003; Miura
et al, 2003; Griffith et al, 2004; Shimokawa and Matoba, 2004; Shimokawa and
Morikawa, 2005], cytochrome P450 metabolites of arachidonic acid [Campbell and
Harder, 1999; Fisslthaler et al, 1999; Quilley and McGiff, 2000; Halcox et al, 2001]
and C-type natriuretic peptide [Chauhan et al, 2003; Chauhan et al, 2004], However,
none has consistently been shown to act as EDHF in all species and vascular beds
and significant heterogeneity is observed between different experimental models, in
the responses evoked by different pharmacologic agonists and in the presence or
absence of interacting co-morbid conditions. Indeed, subsequent to the activation of
vascular Kca, EDHF may represent the final common pathway of a number of
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different mediators. As such, the term endothelium-derived hyperpolarising factor
may be misleading and EDHF may represent a mechanism rather than a specific
factor per se.
1.3 VASCULAR GAP JUNCTIONS
Gap junctions are found at points of cell-cell contact where they form an aqueous
pore through which small hydrophilic molecules (<1 kDa) and ionic charge may
pass. They are found in all tissues with the exception of skeletal muscle and non-
nucleated cells such as red blood cells and platelets. They frequently aggregate to
form 'plaques' at points of cellular contact where their characteristic pentalaminar
structure may be seen under electron microscopy [Sandow and Hill, 2000], Each gap
junction comprises two hemichannels, or connexons that are composed of six
connexin (Cx) subunits. The connexins traverse the cellular membrane four times and
expose two extracellular peptide loops (Figure 1.2). Otherwise, they are a
heterogeneous family classified by molecular weight in kDa and, although each
connexon may be composed of a mix of connexin subtypes, Cx37, Cx40 and Cx43
(and occasionally Cx45) are particularly associated with mammalian endothelium
and vascular smooth muscle [Christ et al, 1996; Figueroa et al, 2004; Sohl and
Willecke, 2004], The molecular structure of individual connexin subtypes is well
conserved between species but large variation in their expression in both the
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1.3.1 Regulation of connexin expression and function
Factors influencing connexin expression are poorly understood but physical
influences may exert marked alterations of connexin expression, particularly Cx43.
Cx43 expression is elevated by vascular shear stress [Gabriels and Paul, 1998;
Depaola et al, 1999; Inai et al, 2004; Figueroa et al, 2006] and vascular injury [Yeh
et al, 1997]. However, the effects of hypertension upon Cx43 expression are more
variable and both an increase [Haefliger et al, 2006] and a decrease [Yeh et al, 2006]
have been reported in hypertensive animal models. Connexin 43 expression also
appears to be under the regulatory control of oestrogen - ovariectomy decreases
Cx43 expression whilst oestrogen supplementation causes an increase [Liu et al,
2002; Chataigneau and Schini-Kerth, 2005], The reported influence of
hyperlipidaemia, statin treatment and inflammation upon the expression of various
connexins has been variable [van Rijen et al, 1998; Sato et al, 2002; Yeh et al, 2003;
Rignault et al, 2005], Furthermore, expression of vascular connexin subtypes appears
to be an interdependent phenomenon with connexin subtypes regulating the
expression of others [Isakson et al, 2006].
Phosphorylation sites on the connexin COOH- terminus have been demonstrated and
it is understood that both protein kinase A and C can affect connexin
phosphorylation. Cyclic AMP increases gap junction permeability and, as such,
metabolites of arachidonic acid may enhance communication via gap junctions
[Griffith et al, 2002], Additionally, phosphorylation may influence the assembly of
connexons and modulate the permeability of the gap junction and the time that the
connexin spends in residence at the gap junction before internalisation (usually in the
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region of 2-5 hours). However, very little is known of how these processes influence
in vivo function [Figueroa et al, 2004],
1.3.2 Gap junctions and edhf
The cell membrane is impermeable to hydrophilic dyes such as Lucifer yellow or
propidium bromide but they are small enough (<1 kDa) to pass through gap junctions
and myoendothelial dye transfer via this route has been observed [Beny, 1999;
Griffith, 2004], Myoendothelial gap junctions are, therefore, ideally suited to the
radial transfer of either electrotonic charge or one or more chemical mediators of
hyperpolarisation from the endothelium to the underlying smooth muscle. Gap
junctions would, therefore, permit specific and sensitive signalling and avoid the
inevitable dilution associated with diffusible signalling molecules, such as NO.
Electrical myoendothelial coupling was initially suggested by bioassay experiments
performed with 'sandwich' preparations in which the donor endothelium and
detector vascular smooth muscle are uncoupled but closely apposed. In the presence
of NO synthase inhibition, these vessels fail to demonstrate vasorelaxation in
response to endothelium-dependent vasodilator agonists whilst intact 'electrically
coupled' specimens relax normally [Chaytor et al, 1998; Griffith, 2004], This raises
the possibility that EDHF involves the passive electrotonic spread of
hyperpolarisation via a contact mechanism. Indeed, myoendothelial gap junctions are
perfectly located for this purpose and electrical coupling between the endothelium
and smooth muscle has been demonstrated [Yamazaki and Kitamura, 2003].
Furthermore, gap junction plaques are most abundant in small resistance arteries and
25
their distribution is proportional to the magnitude of the EDHF-mediated response
[Shimokawa et al, 1996; Sandow and Hill, 2000; Berman et al, 2002; Sandow et al,
2002],
Observations from murine knockout models provide direct evidence for a role of gap
junctions and specific connexins in the control of vascular tone. Mice lacking Cx40
are hypertensive [de Wit et al, 2003] and spontaneously hypertensive mice have a
reduced expression of vascular Cx40 [Rummery el al, 2002; Rummery and Hill,
2004], On the contrary, mice lacking endothelial Cx43 are hypotensive. However,
these mice have a complex phenotype associated with a large elevation in plasma
NO concentration [Liao et al, 2001], It should also be noted that, in addition to being
suited for the mediation of radial communication, gap junctions between adjacent
homotypic smooth muscle or endothelial cells, provide a mechanism for the
longitudinal conduction of vasomotion. Indeed, Cx40 deficient mice display
irregular, uncoordinated vasomotion [de Wit et al, 2003],
The role of gap junctions in EDHF-mediated vascular responses in vivo in man
remains unknown. Furthermore, the contribution of individual connexin subtypes to
the mediation of EDHF responses remains unexplored in humans.
1.3.3 GAP JUNCTION BLOCKERS
Diverse agents have been employed as putative gap junction blockers. Of these, the
anaesthetic halothane [Beny and Pacicca, 1994] and the liquorice derivative
18a-glycyrrhetinic acid have been most frequently used but they have other non-
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specific EDHF-independent effects that limit their use [Chaytor et al, 2000;
Matchkov et al, 2004], In contrast, the connexin mimetic peptides (CMPs) are highly
selective and specific gap junction inhibitors and permit assessment of individual
connexin subtypes in EDHF-mediated vasodilatation [Dora et al, 1999; Evans and
Boitano, 2001; Dhein, 2004], These short synthetic peptides correspond to amino
acid sequences in the first (Gap26) and second (Gap27) extracellular loops of Cxs37,
40 and 43 (Figure 1.3) and cause reversible disruption of connexin function and gap
junction communication. Their exact mechanism of action remains unclear but they
are thought to interfere with connexin gating properties [Evans and Boitano, 2001],
They do not suppress endothelial hyperpolarisation directly and do not exert non-gap
junctional effects [Matchkov et al, 2006]. Unlike 18a-glycyrrhetinic acid, they do
not affect the structural integrity, number or distribution of connexins [Berman et al,
2002],
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Figure 1.3 Top: schematic representation ofthe connexin and the extracellular Gap26 and
Gap27 regions to which the connexin mimetic peptides correspond. Bottom: amino acid
sequences ofGap27 and Gap26 ofCx37, 40 and 43 (note homology). Adapted from Griffith,
2004[Griffith, 2004a].
In confluent COS fibroblasts expressing Cx43, intracellular transfer of Lucifer
yellow is blocked by 37'43Gap27 (SRPTEKTIFII) but not by 40Gap27
(SRPTEKNVFIV) [Chaytor et al, 1999b], Targeting CMPs against a single connexin
subtype attenuates EDHF-mediated vasodilatation and the magnitude of this effect
correlates with the relative expression of the connexin [Chaytor et al, 2005],
However, combined inhibition of the three predominant connexins generally
produces more marked effects [Chaytor et al, 2003], This not only reflects the
heterogeneous expression of the connexins but also a propensity for the remaining
connexins to compensate and maintain gap junction function [Griffith, 2004b],
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Connexin mimetic peptides attenuate subintimal vascular smooth muscle
hyperpolarisation and relaxation induced by acetylcholine, substance P and
bradykinin in various ex vivo arterial and venous preparations from rabbit, rat, pig
and guinea pig [Chaytor et al, 1997; Chaytor et al, 1998; Chaytor et al, 1999; Kwak
and Jongsma, 1999; Chaytor et al, 2001; Berman et al, 2002; Sandow et al, 2002;
Chaytor et al, 2003; Ujiie et al, 2003; Griffith et al, 2005]. Despite relatively large
numbers of ex vivo studies using CMPs, concerns about the potential for systemic
side-effects (for example, interference with gap junction-mediated cardiac
conduction) have limited their use to just a handful of in vivo animal studies [De
Vriese et al, 2002; Takenaka et al, 2008a; Takenaka et al, 2008b] and they have
never been administered to man. In 2002, de Vriese et al examined the effects of the
CMPs on NO and PGD-independent renal artery vasodilatation and blood flow in
rats. With concurrent NO synthase and cyclooxygenase inhibition, bolus of
37"43Gap27 into the renal artery partially inhibited the increase in blood flow evoked
by acetylcholine whereas 40Gap27 abolished the response entirely. Both peptides
significantly decreased baseline renal blood flow and none of these effects were seen
in response to a control 'scrambled' peptide [De Vriese et al, 2002].
1.3.4 Potentiators of communication via gap junctions
Gap junctions are distributed almost ubiquitously in the body and are particularly
important in the coordinated conduction of the cardiac action potential. Therefore,
the search for drugs that act to potentiate communication via gap junctions has been
the topic of a substantial body of pharmaceutical research. Peptides with this
property were first described in the 1980s [Aonuma et al, 1980] and were shown to
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increase gap junction intracellular communication in the absence of changes in
membrane conduction or basal current [Muller et al, 1997], However, the clinical
development of the original peptides was limited by their instability and very short
half-life. Rotigaptide (ZP123) is a rotation-inversion of the original peptide that
incorporates the unnatural D-configuration of the amino acids (Ac-D-Tyr-D-Pro-D-
Hyp-Gly-D-Ala-Gly-NH2) to provide much improved proteolytic stability [Kjolbye et
al, 2003].
This novel hexpapetide antiarrhythmic agent has been safely administered to healthy
humans [Udata et al, 2006] and is now in Phase II clinical trials [Kjolbye et al,
2003], It prevents spontaneous ventricular [Xing et al, 2003; Herman et al, 2006] and
atrial [Shiroshita-Takeshita et al, 2007] arrhythmias in canine models of myocardial
infarction and is effective in suppressing the development of atrial fibrillation in a
canine model of mitral regurgitation [Guerra et al, 2006]. It promotes electrical
coupling between ventricular myocytes by increasing gap junction conductance
[Eloff et al, 2003; Clarke et al, 2006] via alterations in the phosphorylation status of
Cx43 [Axelsen et al, 2006; Kjolbye et al, 2008] and it increases the number of gap
junctions in the ischaemic myocardium [Herman et al, 2006]. It exhibits no binding
to a large array of receptors including numerous ion channels [Haugan et al, 2005]
but potentiates gap junction-mediated dye transfer via Cx43 expressing HeLa cells
but not via Cx26 or Cx32 [Clarke et al, 2006]. Rotigaptide's effects on electrical
conduction and dye transfer via Cx37 and Cx40 have yet to be assessed.
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Rotigaptide's effects upon resting vascular tone and endothelium-dependent agonist
induced vasodilatation have not been examined. It remains unclear whether
augmentation of communication via vascular gap junctions potentiates EDHF-
mediated vascular actions.
1.4 ENDOGENOUS FIBRINOLYSIS
In addition to its central role in the control of vasomotion, the endothelium fulfils
important fibrinolytic functions. The release of endogenous fibrinolytic factors
protects the circulation from the propagation of intravascular fibrin deposition and
thrombosis that would otherwise result in vascular occlusion and tissue ischaemia. In
man, the principal endogenous fibrinolytic factor is tissue-type plasminogen activator
(t-PA). This serine protease is stored in endothelial granules and, during the initiation
of thrombus formation, its acute calcium-dependent release is stimulated by
members of the clotting cascade including thrombin and factor Xa [van den Eijnden-
Schrauwen et al, 1997]. In the circulation, t-PA catalyses the conversion of
plasminogen to plasmin and the ensuing enzymatic process results in the cleavage of
fibrin with consequent generation of fibrin degradation products [Cruden and
Newby, 2005],
The fibrinolytic efficacy of t-PA is inversely proportional to the circulating
concentration of its major serpin inhibitor, plasminogen activator inhibitor type 1
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1.4.1 Endothelial mechanisms of t-pa release
In addition to stimulation by members of the coagulation cascade, a variety of other
agonists evoke the endothelial release of t-PA in vivo in man. Of these, bradykinin is
the best characterised in vivo - acting via the B2 kinin receptor, it causes marked
t-PA release that is not attenuated by inhibition of NO and PGI2 generation
[Browne/ al, 2000], Similarly, both adenosine and uridine triphosphate evoke the
release of t-PA in the human forearm via a NO- and PGE-independent mechanism
[Hrafnkelsdottir et al, 2001]. As such, it has been suggested that EDHF may be
responsible for their induction of t-PA release. Smith et al observed that the
inhibition of NO synthesis augments bradykinin-induced t-PA release [Smith et al,
2003] and it is conceivable that, in the absence of NO, EDHF may become up-
regulated with consequential augmentation of endogenous fibrinolytic activity.
Consistent with this hypothesis, elevated basal concentrations of t-PA are found in a
genetically engineered murine model lacking eNOS [Iafrati et al, 2005].
Although it has been demonstrated that relatively prolonged intra-arterial infusion of
acetylcholine causes the release of t-PA in the human forearm [Giannarelli et al,
2007], the majority of studies to examine the effects of intra-arterial acetylcholine
have not demonstrated any effect upon t-PA release [Brown et al, 1999; Minai et al,
2001; Chia et al, 2003]. Similar to acetylcholine, methacholine is an agonist at
muscarinic receptors but, in contrast, it consistently evokes t-PA release [Stein et al,
1998; Pretorius et al, 2002]. Interestingly, acetylcholine mediates forearm arterial
vasodilatation almost entirely via the NO pathway. This contrast with bradykinin.
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methacholine, ATP and UTP which act via EDHF to a greater extent [Chowienczyk
et al, 1993; Hrafnkelsdottir et al, 2001; Pretorius et al, 2002].
It is of note that NO donors such as sodium nitroprusside do not evoke t-PA release
despite causing potent arterial vasodilatation. This evidence has been used to further
argue against a direct role for NO in the induction of t-PA release. However, the
argument is complicated by the observation that substance P-induced t-PA release is
attenuated by NO synthase inhibition [Newby et al, 1998]. Nitric oxide may,
therefore, exert a permissive role upon substance P-induced t-PA release but this
effect is not a universal feature and may be agonist-specific.
The observation that NO donors evoke vasodilatation without associated t-PA release
also provides evidence that endothelial t-PA release is not simply a flow-related
phenomenon. This finding is further reinforced in the observation that intra-arterial
tumour necrosis factor-alpha (TNF-a) evokes t-PA release in the forearm circulation
but it attenuates endothelium-dependent vasodilatation [Chia et al, 2003] and
norepinephrine induces t-PA release in association with vasoconstriction [Jern et al,
1994; Oliver et al, 2005].
Thus, endothelial mechanisms underlying t-PA release are complex and incompletely
understood but may be either mediated or influenced by EDHF, or substances related
to this mechanism. Indeed, Muldowney and colleagues examined mechanisms of
thrombin-mediated t-PA release from cultured endothelial cells. They demonstrated
that, although thrombin-mediated release of t-PA in vitro is not blocked by inhibitors
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of NO or PGI2 synthesis, it is abolished by inhibition of the generation of 5,6-
epoxyeicosatrienoic acid (5,6-EET) [Muldowney et al, 2007]. Although there is
substantial evidence that EETs contribute to the EDHF mechanism [Feletou and
Vanhoutte, 2006a], it should be noted that inhibitors of Kca did not influence t-PA
release in this model and any extrapolation of findings from this in vitro study to the
in vivo situation should be cautious.
A direct assessment of the role of EDFIF in human t-PA release in vivo has not been
made. Specifically, the role of Kca and gap junctions in this process remains
unknown.
1.5 THROMBIN
Thrombin (factor Ha) is the principal effector protease of the coagulation cascade
(Figure 1.5) and is an integral mediator both in vascular physiology and in
pathophysiology. In addition to its pivotal procoagulant role it displays other
important vascular haemostatic, vasomotor and inflammatory properties [Coughlin,
2000; Coughlin, 2005],
Thrombin generation is triggered when vascular integrity is disrupted and plasma
coagulation factors are allowed contact with extra-vascular tissue factor. It causes the
conversion of circulating fibrinogen to fibrin monomer which polymerises to form
fibrin, the fibrous matrix of blood clots (Figure 1.5). Additionally, thrombin acts as a
potent cellular stimulant - it is the most powerful platelet activating factor known
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[Gailani and Renne, 2007], it evokes smooth muscle proliferation [Koenig, 2003]
and it causes vascular hyperpermeability and oedema [Lum and Malik, 1994], By
inducing the expression of chemokines and endothelial adhesion molecules including
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), P-selectin and von Willebrand factor (vWF), it causes increased
recruitment of platelets and leucocytes to the endothelial surface [Coughlin, 2005].
Via these actions, it acts not only as an essential inflammatory and haemostatic factor
localising appropriate repair to sites of vascular injury, but can also be deleterious
and is central to the pathophysiology of atherothrombosis [Croce and Libby, 2007].



























Figure 1.5 Coagulation cascade. Inhibitors of coagulation denoted by red dotted lines;
positive feedback denoted by green dotted lines (TFPI=tissue factor pathway inhibitor).
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1.5.1 Vascular protease-activated receptors
An extensive search for a receptor responsible for thrombin's extra-coagulant
cellular actions culminated in the discovery and cloning of protease-activated
receptor type 1 (PAR-1) [Vu et al, 1991], Subsequently, three further protease-
activated receptors have been characterised: PAR-2, -3 and -4. PAR-1, -3 and -4 are
all activated by thrombin but PAR-2 is principally activated by trypsin [Ossovskaya
and Bunnett, 2004], Protease-activated receptor type 1 is the principal factor Ha
receptor in man and is activated by the presence of thrombin at sub-nanomolar
concentrations by virtue of a hirudin-like sequence that resides in the N-terminal
extracellular domain of PAR-1, but not PAR-4 which is activated by higher
concentrations of thrombin [Ossovskaya and Bunnett, 2004; Leger et al, 2006].
Protease-activated receptor type 3 is a high affinity thrombin receptor in animals
other than primates [Leger et al, 2006]. All belong to the seven transmembrane a-
helical receptor superfamily and are characterised by a unique mechanism of action.
Firstly, proteolytic cleavage of the amino-terminal extracellular domain exposes a
'cryptic' ligand that remains attached to the N-terminal domain of the protease-
activated receptor. This tethered ligand subsequently undergoes intramolecular
rearrangement to allow ligand and receptor moieties to interact (Figure 1.6) to evoke
their biological effects via G-protein coupling. Once activated, PAR is rapidly
uncoupled from G-protein mediated signalling and internalised in lysosomes for
degradation [Vu et al, 1991; Coughlin, 2000; Barnes et al, 2004],
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Protease-activated receptor type 1 is expressed on cardiomyocytes, smooth muscle
cells, the vascular endothelium, fibroblasts and on platelets as well as in many
locations outside the vasculature [Ossovskaya and Bunnett, 2004]. It is of note,
however, that murine and rat platelets do not express PAR-1 [Kinlough-Rathbone et
al, 1993; Derian et al, 1995] and consequently studies of PAR-1 in these animals are
not always of direct relevance to man.
Figure 1.6 Mechanism ofprotease-activated receptor type 1 (PAR-1) activation. Thrombin
(large green sphere) recognises the N-terminal domain of the G-protein coupled thrombin
receptor PAR-1. This interaction uses sites at N-terminal (small blue sphere) and C-terminal
(small pink oval) to the thrombin cleavage site. Thrombin cleaves the peptide bond between
receptor residues Arg 41 and Ser 42. This serves to unmask a new N terminus, beginning
with the sequence SFLLRN (diamond) that functions as a tethered ligand, docking with the
body of the receptor to effect transmembrane signalling. From Coughlin, 2000 [Coughlin,
2000].
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PAR I Activating Peptide
Proteolytic cleavage of the N-terminal domain of PAR-1 by thrombin reveals the
amino acid sequence, SFLLRN, which is the active, tethered ligand that causes
autoactivation of the receptor [Vu et al, 1991], Similarly, synthetic exogenous
SFLLRN acts directly upon PAR-1 without the requirement for proteolytic cleavage
of the receptor but otherwise mimics the cellular actions of thrombin [Scarborough et
al, 1992]. Indeed, SFLLRN has been used extensively as a PAR-1 activating peptide
and is a valuable tool for the examination of PAR-1 and thrombin's cellular effects in
the vasculature. By use of the PAR-1 activating peptide, the cellular effects of
thrombin can be examined without the confounding and potentially harmful effects
of potent stimulation of the coagulation cascade [Coughlin, 2005],
PAR-J Antagonists
Inhibition of PAR-1 mediated actions has captured the interest of the pharmaceutical
industry. The development of a drug with the potential to antagonise the cellular
effects of thrombin without affecting its actions in the coagulation cascade could
represent an important antithrombotic treatment strategy that may be associated with
less bleeding complications than conventional antithrombin inhibitors
[Chackalamannil, 2006]. Indeed, a PAR-1 antagonist (SCH 530348) has displayed
these properties in a phase II clinical trial and is currently being evaluated in phase
III studies [Husted, 2007],
Due to the diverse cellular actions of thrombin including cellular proliferation and
inflammation and the widespread expression of PAR-1, these antagonists have also
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been proposed for the treatment of restenosis, atherosclerosis, inflammation,
[Chackalamannil, 2006] stroke [Olson et al, 2004] and non-vascular conditions
including cancer metastasis [Kaufmann et al, 2007] and neurodegeneration [Hamill
et al, 2007], Therefore, the examination of PAR-1 mediated effects is pertinent not
only to our understanding thrombin's cellular effects in physiology and
pathophysiology, but is also important to inform the clinical development of PAR-1
antagonists.
Vascular Effects ofPAR-1 Activation
In vitro activation of PAR-1 causes endothelium-dependent vasorelaxation in various
animal arterial preparations [Kawabata et al, 2004a; Kawabata et al, 2004b] and in
human coronary [Hamilton et al, 1998] and pulmonary [Hamilton et al, 2001b]
arteries. Furthermore, systemic intravenous administration of SFLLRN to rodents
culminates in a sustained drop in blood pressure that is attenuated by L-NAME
[Sicker et al, 2001], In addition to a requirement for NO, EDHF appears to make a
large contribution to PAR-1 induced arterial vasodilatation. Kawabata and colleagues
demonstrated that rat gastric arterial vasodilatation induced by PAR-1 activating
peptide is markedly reduced by the Kca antagonists, charybdotoxin and apamin,
whilst the further addition of antagonists of NO and PGF> production abolished the
response. They characterised the EDHF component of the vasodilator response
further and found no role for cytochrome P450 metabolites of arachidonic acid or for
hydrogen peroxide. However, the putative gap junction blockers carbenoxolone and
18a-glycyhrretinic acid significantly attenuated the EDHF-mediated response
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[Kawabata et al, 2004b], In contrast, activation of smooth muscle PAR-1 causes
arterial vasoconstriction [Ku and Dai, 1997],
Our group has recently, and for the first time, demonstrated that PAR-1 activation in
vivo in healthy human subjects causes arterial vasodilatation, venous constriction,
t-PA release and platelet activation [Gudmundsdottir et al, 2006], It has been
proposed that, acting via PAR-1, thrombin evokes these vascular responses as a
protective feedback mechanism in an attempt to maintain vessel patency. In the
presence of developing thrombus, arterial PAR-1 activation would cause arterial
vasodilatation and increase the release of t-PA to ensure rapid clearance and clot
dissolution. As veins do not have resting tone venous dilatation would not be
beneficial but venoconstriction would potentially limit thrombus propagation and
embolisation [Gudmundsdottir et al, 2006], The role of the endothelium and
endothelium-derived factors including NO, PGI2 and EDHF in these responses
remains unknown.
1.6 ENDOTHELIAL DYSFUNCTION
The formation of atherosclerosis is a complex inflammatory process that involves a
series of interactions with many cell types including the endothelium [Hansson,
2005]. As well as a wide variety of disease states now known to predispose to
atherosclerosis, classical 'risk factors' including smoking [Newby et al, 1999;
Newby et al, 2001; Pretorius et al, 2002; Takashima et al, 2007],
hypercholesterolaemia [Celermajer et al, 1992; Stroes et al, 1995], diabetes mellitus
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[Calver et al, 1992], hypertension [Lauer et al, 2005] and a family history of
premature vascular disease [Celermajer et al, 1992] are all associated with
endothelial dysfunction [Feletou and Vanhoutte, 2006b], Furthermore, the disruption
of endothelial haemostatic mechanisms increases the risk of reduced blood flow,
local thrombus formation and consequent vessel occlusion and tissue infarction.
1.6.1 Endothelial dysfunction and vasomotion
The assessment of endothelial function has been performed principally via the
examination of endothelium-dependent vasodilatation. The response to endothelial
stimulants is often examined in the peripheral resistance vasculature [Wilkinson and
Webb, 2001] and the response to both pharmacologic stimulation and to reactive
hyperaemia is measured in conduit vessels [Felmeden and Lip, 2005]. Similar to the
diminished peripheral arterial endothelium-dependent vasodilation seen in patients
with atherosclerosis and its risk factors, endothelium-dependent vasodilator
responses are also impaired in the coronary arterial circulation of these subjects
[Ludmer et al, 1986; Zeiher et al, 1995a; Zeiher et al, 1995b; Kugiyama et al, 1996].
Therefore, it is proposed that impaired endothelial responses are a systemic feature
of atherosclerosis and its risk factors.
Furthermore, impaired endothelium-dependent vasomotor dilatation in the peripheral
[Heitzer et al, 2001; Perticone et al, 2001] and coronary [Suwaidi et al, 2000; Halcox
et al, 2002] circulations independently predicts the risk of future adverse
cardiovascular events even in subjects without angiographic evidence of significant
coronary disease [Suwaidi et al, 2000],
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1.6.2 Nitric oxide, edhf and endothelial dysfunction
Although endothelial dysfunction occurs in many different disease states, oxidative
stress is the common pathophysiological denominator [Feletou and Vanhoutte,
2006b]. The synthesis and activity of NO is particularly susceptible to oxidative
stress but EDHF appears to be relatively resistant [Kaw and Hecker, 1999]. Indeed,
EDHF frequently acts as a back-up mechanism, undergoing up-regulation in the face
of reduced NO bioavailability in a variety of disease states including heart failure
[Malmsjo et al, 1999; Katz and Krum, 2001], coronary artery disease [Miura et al,
2003], type II diabetes mellitus [Triggle et al, 2004] and after ischaemia/reperfusion
[Marrelli, 2002] and angioplasty [Thollon et al, 2002]. The effect of
hypercholesterolemia upon EDHF-mediated responses remains unclear with both an
increase [Brandes et al, 1997] and decrease [Urakami-Harasawa et al, 1997] in its
activity reported. Similarly, the role of EDHF in the cause and consequences of
hypertension remains unclear with both increased [Taddei et al, 2006] and decreased
[Fujii et al, 1993] activity described in different models. Conditions specifically
associated with impairment of EDHF-mediated responses are in the minority but
include type I diabetes mellitus [Fukao et al, 1997; Wigg et al, 2001; Angulo et al,
2003] and pre-eclampsia [Kenny et al, 2002], Whilst cigarette smoking primarily
affects NO bioavailability [Ambrose and Barua, 2004], its effect upon EDHF activity
has not been assessed in vivo. However, a small in vitro study of rat mesenteric and
human middle cerebral arteries exposed to lipid soluble smoke particles revealed a
concomitant attenuation of both NO and EDHF-mediated vasodilatation [Zhang et al,
2006],
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1.6.3 Endothelial dysfunction and endogenous fibrinolysis
The assessment of endothelium-dependent vasomotion has been the mainstay of the
in vivo assessment of endothelial function. However, endothelium-dependent
vasomotion may not be representative of other important endothelial functions such
as the regulation of endogenous fibrinolysis.
In the absence of appropriate endothelial release of t-PA, subclinical microthrombi
that would normally undergo lysis may be given the opportunity to propagate and
cause vessel occlusion and tissue infarction [Oliver et al, 2005]. Indeed, a reduction
in basal t-PA activity or release is associated with an increased incidence of major
cardiovascular events in patients with stable [Held et al, 1997] and unstable
[Hoffmeister et al, 1995] angina.
The measurement of resting t-PA concentrations is of interest but the assessment of
the endothelium's capacity for the dynamic release of t-PA is more
pathophysiologically relevant and not reflected by basal concentrations
[Hrafnkelsdottir et al, 2004a], Indeed, efficient fibrinolysis requires the local and
timely release of t-PA stimulated by the presence of a developing thrombus [Fox et
al, 1985], In patients with cardiovascular disease our group has recently
demonstrated that impaired release of pharmacologically stimulated t-PA predicts the
risk of future adverse cardiovascular events [Robinson et al, 2007],
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Acute coronary t-PA release is inversely proportional to the atherosclerotic burden
[Newby et al, 2001]. Furthermore, t-PA release stimulated by intra-arterial substance
P or bradykinin is impaired in the coronary and peripheral circulation of smokers
[Newby et al, 1999; Newby et al, 2001; Pretorius et al, 2002; Takashima et al,
2007]. Of note, the impairment of stimulated t-PA release found in smokers
[Pretorius et al, 2002] and patients with hypertension [Hrafnkelsdottir et al, 1998;
Hrafnkelsdottir et al, 2004b] has been reported in the absence of a change in
endothelium-dependent vasomotor responses. Therefore, in some circumstances the
assessment of acute stimulated t-PA release may represent a more sensitive marker
of endothelial function. Conversely, patients with hypercholesterolaemia display
impaired endothelium-dependent vasomotor responses without any alteration in the
capacity for the acute stimulated release of t-PA [Newby et al, 2002], Not only does
this underline the complexity of vascular endothelial function, but it also reinforces
the requirement for broader assessment of endothelial functions without undue
reliance upon a single surrogate marker of endothelial health.
1.6.4 PAR-1 ACTIVATION AND THE ASSESSMENT OF ENDOTHELIAL FUNCTION
Healthy excised human coronary arteries dilate in response to PAR-1 activation but,
in those with severe atherosclerosis, this response is either absent or marked
vasoconstriction occurs [Ku and Dai, 1997], In the context of endothelial
dysfunction, the loss of protective arterial dilatation could have marked effects upon
the delicate balance dictating whether a developing thrombus undergoes successful
fibrinolysis or expands to cause clinically relevant vessel occlusion.
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The dynamic in vivo assessment of regional t-PA release has employed the intra¬
arterial administration of a variety of pharmacologic stimulants, most frequently in
the forearm and coronary circulations. Of these stimulants, our group and others have
most frequently used substance P and bradykinin [Newby et al, 1997a; Newby et al,
2001; Pretorius et al, 2002; Takashima et al, 2007], However, although substance P
has been a useful pharmacologic tool, it is a neurotransmitter and evidence to suggest
that it plays any role as a pathophysiological mediator in atherothrombosis is limited.
Bradykinin may have a more direct role since it is released during the contact phase
of coagulation and there is enhanced activation of the kallikrein system and
bradykinin release in patients with acute coronary syndromes [Hoffmeister et al,
1995],
Given its central role in thrombosis and inflammation, thrombin is the most powerful
and pathophysiologically relevant mediator of atherothrombosis [Coughlin, 2005],
However, safety concerns, particularly with regard to its potent procoagulant effects,
have precluded its direct intra-arterial administration in man. However, by intra¬
arterial administration of SFLLRN, the examination of PAR-1 responses allow the
assessment of thrombin's cellular effects in the absence of activation of the
coagulation cascade. Such a pathophysiologically relevant and potentially more
sensitive assessment of endothelial function in vivo in subjects with atherosclerosis
and its risk factors has previously not been made.
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1.7 AIMS
The aims of this thesis were:
In human subcutaneous resistance arteries (Chapter 3):
• To clarify the relative contributions of NO, PGI2 and EDHF to endothelium-
dependent vasodilatation.
• To determine whether EDHF-mediated vasodilatation can be abolished using
a combination of CMPs.
• To establish the presence of the three major vascular connexin subtypes.
• To determine whether any of the three major vascular connexins contributes
to the EDHF mechanism to a relatively greater extent than the others.
In isolated rabbit myocardium (Chapter 4):
• To establish the biological activity of rotigaptide.
In healthy volunteers (Chapter 4):
• To establish, using intra-arterial rotigaptide, whether basal forearm vascular
tone, agonist-induced vasodilatation and t-PA release can be augmented by
increasing communication via gap junctions containing connexin 43.
• To establish whether rotigaptide specifically augments EDHF-mediated
vasodilatation.
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In healthy volunteers (Chapter 5):
• To establish the role of the endothelium, and endothelial factors including
NO, PGI2 and EDHF in the vascular effects of PAR-1 activation in vivo.
• To clarify that EDHF-mediated actions can be inhibited in vivo by
antagonism of calcium-activated potassium channels using TEA.
• To establish whether EDHF is responsible for bradykinin and PAR-1
activation-induced t-PA release.
In otherwise healthy volunteers who smoke (Chapter 6):
• To establish the effect that smoking cigarettes has upon vascular endothelial
responses to PAR-1 activation.
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1.8 HYPOTHESES
The following hypotheses will be addressed:
Connexins, gap junctions and their involvement in the EDHF mechanism:
1. Gap junction blockade with connexin mimetic peptides inhibits
EDHF-mediated vasorelaxation in pregnant human subcutaneous
resistance arteries.
2. Connexins 37, 40 and 43, the three principal vascular connexins, are
expressed in pregnant human subcutaneous resistance arteries.
3. Potentiation of communication via gap junctions with rotigaptide
enhances EDHF-mediated actions to increase human forearm arterial
basal blood flow, agonist-induced vasodilatation and endothelial t-PA
release.
PAR-1 activation and endothelial responses:
1. Activation of PAR-1, the principal vascular thrombin receptor, causes
vasodilatation via the endothelial release of NO, PGE and EDHF in
the human forearm arterial circulation.
2. PAR-1 activation evokes t-PA release via EDHF in the human
forearm arterial circulation.
3. Endothelial dysfunction caused by smoking cigarettes results in an
impairment of PAR-1 mediated vasodilatation and t-PA release in the





Many techniques have been developed and refined for the examination of vascular
responses both in vitro and in vivo. An overview of the techniques employed in this
thesis is presented below. Details specific to each study can be found in the methods
section of subsequent chapters.
2.1.1 Myography
Vascular responses can be examined in isolated vessels using myography. This
widely used technique is very useful for the assessment of novel compounds before
assessment of their in vivo effects and for the assessment of compounds with the
potential for systemic toxicity. The arrangement allows for precise changes to be
made to the controlled environment of the organ bath.
Myography has been used extensively to assess the contribution and mechanism of
EDHF in vasorelaxation [Griffith, 2004; Chaytor et al, 2005; Mackenzie et al, 2008],
The vast majority of these assessments have been made in vessels obtained from
animals and in a wide range of vascular beds. However, the EDHF response is
particularly variable between vascular bed, vessel size and species making
comparisons of results difficult [Griffith, 2004], Indeed, direct examination of the
role of gap junctions and connexin subtypes in EDHF-mediated responses in the
human vasculature had not previously been made. In this thesis, human subcutaneous
resistance arteries were used to make this assessment for the first time. Other aspects
of the pharmacology of these vessels have been examined in some depth previously
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and indicate a large EDHF-mediated component to their vasorelaxant mechanism
[Coats et al, 2001; Mclntyre et al, 2001; Luksha et al, 2004],
Furthermore, segments from the same vessels examined using myography can be
preserved for the immunohistochemical visualisation of relevant receptors or protein
constituents, including the vascular connexins.
2.1.2 Forearm venous occlusion plethysmography
Whilst myograpy provides a precisely controlled environment in vitro, bilateral
forearm venous occlusion plethysmography allows a direct assessment of peripheral
vascular responses in vivo. Coupled with unilateral brachial artery infusion, it is a
powerful and reproducible technique that allows the direct assessment of forearm
vascular responses to agonists and antagonists at doses 10- to 1000-fold lower than
required to evoke a systemic effect. This dose reduction allows a reduction in the risk
of unwanted or potentially harmful side-effects and simultaneously minimises the
possibility of confounding cardiac, renal and neural reflexes that can occur with
systemic dosing [Benjamin et al, 1995; Wilkinson and Webb, 2001].
Venous occlusion plethysmography relies upon the intermittent prevention of venous
drainage from the arm. This is achieved using upper arm cuffs inflated above venous,
but not arterial, pressure. Thus, blood is allowed to enter the forearm normally but
cannot escape. This causes a linear increase in forearm volume over time, which is
proportional to arterial blood inflow. Under resting conditions, approximately 70%
of total forearm blood flow (FBF) is through skeletal muscle and the measured
52
vascular response is predominantly a reflection of flow through the forearm
resistance arterial system. It is, therefore, a particularly useful technique for the
assessment of EDHF-mediated responses. As the hand contains a high proportion of
arteriovenous shunts with a different pharmacology and physiology, it is excluded
from the circulation by the application of inflation cuffs at suprasystolic pressure
during FBF [Wilkinson and Webb, 2001].
The technique of bilateral FBF measurement is highly reproducible within
individuals [Walker et al, 2001; Wilkinson and Webb, 2001] and can be combined
with intermittent venous sampling for the measurement of plasma fibrinolytic factors
[Newbyeta/, 1997a].
2.1.3 Aellig dorsal hand vein technique
The assessment of venous compliance in a single dorsal hand vein using the Aellig
displacement technique permits the direct effect of locally active, subsystemic doses
of infused drugs to be examined without systemic influences [Aellig, 1981; Aellig,
1994a; Aellig, 1994b]. In addition to allowing the in vivo assessment of venomotor
responses, it allows direct assessment of the role of the endothelium in these
responses without recourse to pharmacologic blockade of endothelium-derived
factors. Whilst it is not possible to safely remove the endothelium from the arterial
circulation, the endothelium lining a short segment of the dorsal hand vein can be
disrupted in vivo via the instillation of distilled water [Collier and Vallance, 1990;
Sogo et al, 2000],
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2.1.4 Electrophysiologic optical mapping
The putative gap junction potentiating peptide, rotigaptide, has been developed as an
antiarrhythmic agent. Therefore, it has a body of complementary electrophysiologic
data to support its efficacy in this respect [Haugan et al, 2005a; Haugan et al, 2005b;
Guerra et al, 2006; Haugan et al, 2006; Herman et al, 2006; Shiroshita-Takeshita et
al, 2007], Custom-synthesised, pharmaceutical grade rotigaptide was obtained for
use in the clinical vascular studies but before application in these studies, its
biological activity was verified using an electrophysiologic optical mapping system
[Bayly et al, 1998; Walker et al, 2007].
2.2 GENERAL
2.2.1 Ethical considerations
All human studies were undertaken in accordance with the Declaration of Helsinki
and with the approval of the local Research Ethics Committee. The written informed
consent of each subject was obtained before entry into the study.
2.2.2 Subcutaneous fat biopsies
Subcutaneous fat biopsies were obtained from healthy women undergoing elective
caesarean section following uncomplicated pregnancy. Biopsies were taken from the
incision margin and resistance arteries subsequently dissected out. Biopsies were not
taken from women with a history of diabetes mellitus, hypertension or any other
significant past medical history.
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2.2.3 Perfused rabbit left ventricular wedge preparation
Male New Zealand white rabbits were killed with a single intravenous injection of
100 mg/kg pentobarbital sodium and their hearts subsequently excised. These
procedures conform to the standards set out in the Animals (Scientific Procedures)
Act 1986.
2.2.4 Subject preparation
In the in vivo studies, none of the volunteers received vasoactive or non-steroidal
anti-inflammatory drugs in the week before each phase of the study. All subjects and
patients abstained from alcohol for 24 hours and from food, tobacco and caffeine-
containing drinks for at least 4 hours prior to the study. Studies were performed in a
quiet, temperature controlled room maintained at 22-25°C.
2.2.5 Blood pressure measurement
During forearm venous occlusion plethysmography and dorsal hand vein studies,
blood pressure was monitored in the non-infused arm at intervals throughout each
study using a semi-automated non-invasive oscillometric sphygmomanometer
(Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).
2.3 MYOGRAPHY
2.3.1 Tissue preparation
Subcutaneous fat biopsies were taken from the caesarean section incision margin and
immediately placed in cold physiological salt solution (PSS) (NaCl 119 mmol/L,
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KC1 4.7 mxnol/L, CaCl2 2.5 mmol/L, MgS04 1.17 mmol/L, NaHC03 25 mmol/L,
KH2PO4 1.18 mmol/L, EDTA 0.026 mmol/L, glucose 5.5 mmol/L). Resistance
arteries (approximate internal diameter 100-300 pm) were dissected free of
surrounding fat and connective tissue, and cut into segments approximately 2 mm
long. All arteries were kept in PSS at 4°C and used on the day of biopsy.
2.3.2 Changes in vessel tension
Arterial segments were mounted in the organ baths of a four-channel wire-myograph
(multimyograph, model 610, Danish Myo Technology; Aarhus, Denmark). Two
stainless steel wires (25 pm in diameter) were threaded through the lumen of each
artery segment. One wire was attached to a force transducer and the other to a
micropositioner in order to measure vessel tension. Each organ bath contained
warmed (37°C) PSS and was continuously bubbled with 5% carbon dioxide and 95%
oxygen. Following a 30-minute equilibration period, a passive circumference-tension
curve was created for each segment in order to set optimum resting tension. This
resting tension is calculated to simulate an in vivo transmural pressure of 100 mmHg.
Arteries were then set at 90% of this tension to enable optimal contractile conditions
with a low resting tension [Mulvany and Halpern, 1976], This semi-automated
procedure also allows the calculation of arterial diameter. All solutions were
refreshed every 30 minutes.
Arterial segments were caused to constrict five times as part of a standard 'start
procedure' [Aalkjaer et al, 1987]. The first, second and fifth contractions were
evoked by high (124 mmol/L) potassium solution (KPSS; made by equimolar
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substitution of KC1 for NaCl in PSS) containing 10 pmol/L norepinephrine. The third
and fourth were obtained with 10 pmol/L norepinephrine or KPSS alone. Arteries
that failed to produce constriction equivalent to 100 mmHg when constricted with
KPSS containing 10 pmol/LNE were rejected.
Prior to the addition of vasodilators, constriction was elicited using norepinephrine
(3 pmol/L). Endothelial viability was assessed by the addition of a single dose of
bradykinin (1 pmol/L) to each chamber. Arteries that did not achieve at least 60%
vasorelaxation to bradykinin were excluded.
2.3.3 Data analysis
Calibration and data processing were performed using Myodac software (version 2.1,
Danish Myo Technology). Vasorelaxation is expressed as a percentage of the return
to basal tone produced by the highest concentration of bradykinin (3 pmol/L) after
preconstriction with norepinephrine (3 jimol/L). Vasodilator concentration-response













Freshly isolated artery segments were cryopreserved in optimal cutting temperature
compound (Ted Pella, Inc, Redding, CA, USA) cooled by liquid nitrogen. Transverse
10 pm cryosections were prepared and mounted onto slides, air-dried, and stored at
-20°C.
2.4.2 IMMUNQSTAINING
Before immunostaining, sections were fixed in acetone for 10 minutes at 4°C and
rehydrated in Tris buffer solution, pFl 7.6. One per cent hydrogen peroxide (H2O2)
was added for 10 minutes to inhibit endogenous peroxidase and non-specific binding
was blocked by incubation with 0.2% triton-XlOO and 2% bovine serum albumin for
1 hour at room temperature. Immunostaining was performed with polyclonal rabbit
antibodies against connexin 37, connexin 40 (1:50 dilution) or connexin 43 (1:100
dilution) at 4°C overnight (Zymed Laboratories, Inc., San Francisco, CA, USA).
Negative control sections were incubated with non-immune goat IgG (SDS,
Falkenberg, Sweden). Sections were subsequently washed in Tris buffer solution and
incubated for 1 hour with biotinylated goat anti-rabbit IgG (1:300; Vector
Laboratories, Burlingame, CA, USA). After rinsing with Tris buffer solution and
application of 3,3-diaminobenzidine in FI2O2 (DAB-Kit, Vector Laboratories), bound
antibodies were treated with an avidin-biotin complex with peroxidase (Vectastain
ABC Elite, Vector Laboratories) for 30 minutes. All slides were counterstained with
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hematoxylin, dehydrated and mounted with Pertex (Histolab, Gothenburg, Sweden).
Visualisation was achieved using conventional light microscopy.
2.5 ELECTROPHYSIOLOGIC OPTICAL MAPPING
2.5.1 Tissue preparation
Hearts were excised from male New Zealand white rabbits and placed in chilled
Tyrode's solution (containing, [mmol/L]: Na 134.5, Mg 1.0, K 5.0, Ca 1.9, CI 101.8,
S04 1.0, H2PO4 0.7, HCO3 20, acetate 20 and glucose 10). The left coronary artery
was cannulated and perfused with oxygenated (95% O2 and 5% CO2) Tyrode's
solution maintained at pH 7.4 and 37°C. Perfused left ventricular wedge preparations
were dissected out and mounted in a custom built chamber which allowed access to
the transmural surface for imaging. A transmural pseudo-electrocardiogram was
recorded from two silver-silver chloride disc electrodes arranged across the
ventricular wall. Two bipolar platinum stimulating electrodes were arranged directly
opposite one another, at the border of the transmural surface with the endocardium
and at the border of the transmural surface with the epicardium. The preparation was
paced at 1.5 x diastolic threshold using a 2 ms pulse at a basic cycle length of
350 ms. Perfusion pressure and electrocardiogram were monitored throughout.
2.5.2 Transmural optical mapping
An optical mapping system was used to record transmural optical action potentials.
Via a port in the perfusion cannula, the preparation was loaded with 100 pL of
voltage sensitive dye (RH237, Molecular Probes, Eugene, OR, USA) dissolved in
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dimethyl sulfoxide (DMSO; 1 mg/mL). 15 mmol/L 2,3-butanedione monoxime
(Sigma-Aldrich, Dorset, UK) was used to eliminate motion artifact during optical
recordings. Light from four 75 W tungsten-halogen lamps was passed through band¬
pass (525±25 nm) filters onto the transmural surface of the preparation. Emitted light
was collected by the camera lens, long-pass filtered (>695 nm) and focused onto a
charge-coupled device array (Redshirt Imaging, Decatur, GA, USA). Optical action
potentials were recorded at 5 Hz from 676 sites.
2.53 Data analysis
Data analysis was performed using custom written software (Dr Francis Burton,
University of Glasgow). A 2x2 Gaussian spatial filter was used and an automated
analysis algorithm applied to all transmural optical action potentials (AP). A single
investigator verified results visually. Activation time (AT) was defined as the
midpoint between baseline and the peak of the action potential upstroke. Transmural
conduction velocity was calculated using the activation time from the earliest
activation on the edge of the stimulated transmural surface, to the earliest activation
on the opposite side. Isochronal maps were constructed using algorithms written in
Matlab software (MathWorks Inc., Natick, MA, USA).
2.6 FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY
2.6J Brachial artery cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-gauge steel
needle (Cooper's Needle Works Ltd, Birmingham, UK) under 2% lignocaine (Xylocaine;
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Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthesia. The cannula was
attached to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK) and patency
maintained by infusion of saline (0.9%; Baxter Healthcare Ltd, Thetford, UK) via an
IVAC P6000 syringe pump (Alaris Products, Basingstoke, UK). The total rate of intra¬
arterial infusions was maintained constant throughout all studies at 1 mL/min.
2.6,2 Isolation of ediif activity
As appropriate, cyclooxygenase activity was inhibited with a single 600 mg dose of
oral aspirin (Dagra Pharma BV, Diemen, Netherlands) 1 hour prior to each study.
This dose of aspirin rapidly inhibits bradykinin-stimulated endothelial production of
PGI2 by at least 85% with recovery developing over the next 6 hours [Heavey et al,
1985],
Nitric oxide production was inhibited with L-NMMA in the 'nitric oxide clamp'.
After a 20-minute intra-arterial infusion of 0.9% saline, L-NMMA (8 pmol/min) was
infused via the brachial artery. To compensate for L-NMMA induced basal
vasoconstriction, forearm blood flow was restored to baseline using a titrated dose of
exogenous NO in the form of intra-brachial sodium nitroprusside (90-900 ng/min).
The titrated dose of sodium nitroprusside (SNP) was co-infused with L-NMMA
throughout the study. This arrangement allows a constant 'clamped' delivery of
exogenous NO whilst endogenous NO synthase activity is inhibited [Honing et al,
2000; Ueda et al, 2004],
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2.6.3 Inhibition of platelet aggregation during par-i activation
In studies including the intra-arterial administration of SFLLRN, the PAR-1 activating
peptide, platelet aggregation was inhibited by the concurrent intra-arterial infusion of the
platelet glycoprotein Ilb/IIIa inhibitor, tirofiban (1250 ng/min; approximate local
forearm concentration 50 ng/mL based upon estimated FBF of 25 mL/min). This dose of
tirofiban inhibits SFLLRN-induced platelet aggregation without affecting platelet
activation, FBF or the release of endogenous fibrinolytic factors [Gu5mundsdottir et al,
2006],
2.6.4 Blood flow measurement
Blood flow was measured in the infused and non-infused forearms by venous occlusion
plethysmography using mercury-in-silastic strain gauges that were applied to the widest
part of the forearm [Wilkinson and Webb, 2001], During measurement periods, the
hands were excluded from the circulation by rapid inflation of the wrist cuffs to a
pressure of 220 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson Inc, Washington,
USA). Upper arm cuffs were inflated intermittently to 40 mmHg pressure for 10 seconds
in every 15 seconds to achieve venous occlusion and obtain plethysmographic
recordings. Analogue voltage output from an EC-4 strain gauge plethysmograph (D.E.
Hokanson Inc.) was processed by a PowerLab analogue-to-digital converter and Chart™
software (version 5.0.1, AD Instruments) and recorded onto a Dell Latitude laptop
computer (Dell Computers Ltd, UK). Calibration was achieved using the interna!
standard of the plethysmograph.
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2.6.5 Sample size calculation
Based on power calculations derived from previous studies, a sample size of 8 gives
90% power of detection of a 22% change in FBF at a significance level of 5%.
Colleagues have previously described the influence of a range of factors on blood
flow in these vascular beds using sample sizes of 6-12 subjects [Newby et al, 1997;
Newby et al 1998; Newby et al, 1999; Labinjoh et al 2001; Witherow et al, 2001;
Cruden et al, 2005]. A smaller sample size was used in one instance in this thesis
(Chapter 4, Protocol 1) in which tolerability and safety of ascending doses of a novel
agent were assessed. The vasomotor effects of the top two doses used in that protocol
were assessed further in a subsequent protocol with a greater sample size.
2.6.6 Data analysis
Plethysmographic data were extracted from the Chart™ data files and FBF was
calculated for individual venous occlusion cuff inflations by use of a template
spreadsheet (Microsoft Excel for Mac 2004; Microsoft Corporation, USA). Recordings
from the first 60 seconds after wrist cuff inflation were not used because of the
variability in blood flow that this incurs [Benjamin et al, 1995]. Usually, the last five
flow recordings in each 3-minute measurement period were calculated and averaged for
each arm. The non-infused arm acted as a contemporaneous control for systemic effects
and external influences upon FBF.
Analysis of all data collected during the forearm plethysmography study was
undertaken by a single operator in a blinded fashion as appropriate. Forearm blood
flow responses are reported as absolute blood flow responses (mL/100 mL
tissue/min) in the infused and non-infused arm.
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Figure 2.3 Typicalforearm plethysmography traces.
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2.7 FIBRINOLYTIC AND HAEMOSTATIC PARAMETERS
2.7.1 Forearm venous sampling
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossa in both arms. Ten millilitres of blood were withdrawn
simultaneously from each arm and collected into acidified buffered citrate (Stabilyte,
Trinity Biotech Pic, Co. Wicklow, Ireland) and citrate (BD Vacutainer, BD UK Ltd,
Oxford, UK) tubes, and kept on ice before being centrifuged at 2000 g for 30
minutes at 4°C. Platelet-free plasma was decanted and stored at -80°C before assay.
2.7.2 Plasma haemostatic and fibrinolytic assays
Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit, Technoclone,
Vienna, Austria) and PAI-1 antigen and activity (Elitest PAI-1 antigen and Zymutest
PAI-1 Activity, Hyphen Biomed, Neuville-Sur-Oise, France) concentrations were
determined by enzyme-linked immunosorbant assays. Intra-assay coefficients of
variation were 7.0% and 5.5% for t-PA and PAI-1 antigen, and 4.0% and 2.4% for
activity, respectively. Inter-assay coefficients of variability were 4.0%, 7.3%, 4.0%
and 7.6% respectively. The sensitivities of the assays were 0.5 ng/mL, 2.5 ng/mL,
0.10 IU/mL and 5 AU/mL respectively. Von Willebrand factor antigen (Dako A/S,
Glostrup, Denmark) and beta thromboglobulin antigen (Asserachrom Btg,
Diagnostica Stago, France) were also determined using by enzyme-linked
immunosorbent assays, both with sensitivities of 0.05 IU/mL. The intra-assay
coefficients of variability were 5.2% and 5.4% respectively. The inter-assay
coefficients of variation were 7.3% and 6.5% respectively.
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2.7.3 Haematocrit measurement
Haematocrit was determined using an automated Coulter counter (Beckman-Coulter
ACt.8 Coulter Counter, High Wycombe, United Kingdom).
2.7.4 Data analysis
Estimated net release of t-PA and PAI-1 activity and antigen was defined as the
product of the infused FBF (based on the haematocrit [Hct] and the infused forearm
blood flow [FBF]) and the concentration difference between the infused ([t-PA]Inf)
and non-infused arms ([t-PA]Non-inf) [Oliver et al, 2005].
Estimated net forearm t-PA release = FBF x {1-Hct} x {[t-PA]Inf - [t-PA]Non-inf}
)
2.8 THE AELLIG DORSAL HAND VEIN TECHNIQUE
2.8.1 Intravenous administration
A 23-gauge butterfly cannula (Hospira, Donegal Town, Ireland) was inserted into the
dorsal hand vein in the direction of flow and attached to a 16-gauge epidural catheter
(Portex Ltd, Hythe, UK). Patency was maintained by infusion of saline via an IVAC
P6000 syringe pump (Alaris Products, Basingstoke, UK). The total rate of
intravenous infusions was maintained constant throughout all studies at 0.25 mL/min
and the same hand vein was used for each study.
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2.8.2 Dorsal hand vein measurement
The left hand was supported above the level of the heart by means of an arm rest.
The internal diameter of the dorsal hand vein, distended by inflation of an upper arm
cuff to 40 mmHg, was measured by the technique first decribed by Aellig [Aellig,
1981; Aellig, 1994a; Aellig, 1994b] using a linear variable differential transducer
(LVDT; model 025 MHR, Lucas Schaevitz Inc). The LVDT was mounted on the
dorsum of the hand using a small tripod, and a magnetised rod was passed through
the core to rest on the summit of the vein approximately 1 cm proximal to the tip of
the infusion cannula. Vertical displacement of the rod causes a linear change in the
voltage generated by the LVDT reflecting changes in the internal diameter of the
vein. The voltage output from the LVDT was transferred to a Macintosh Classic II
computer (Apple Computer Inc, Cupertino, CA) using a MacLab analogue-to-digital
converter (AD Instruments Ltd, Castle Hill, NSW, Australia) and Chart™ software
(Version 5.4.2, AD Instruments).
2.8.3 Sample size calculation
Based on power calculations from previous studies, a sample size of 6 gives 90%
power to detect an 18% change in venous calibre at a significance level of 5%
[Masumori et al, 1997; Sogo et al, 2000; Gudmundsdottir et al, 2006].
2.8.4 Data analysis
Baseline vein diameter was calculated as the mean of the last three measurements
during the initial infusion of saline, before the start of active drug infusion. In order
to minimise the effects of any inter-subject and inter-study variability in hand vein
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diameter, responses following infusion of agonists are expressed as percentage
change in vein diameter from baseline [Haynes et al, 1994; GuSmundsdottir et al,
2006],
2.9 STATISTICS
Data were examined by analysis of variance (ANOVA) with repeated measures and
two-tailed paired Student's /-test as appropriate using GraphPad Prism (GraphPad
Software, California, USA). All results are expressed as mean±standard error of the
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3.1 SUMMARY
This study assessed the role of gap junctions in EDHF-mediated relaxation of human
arteries using CMPs designated 37'43Gap27, 40Gap27 and 43Gap26 according to
homology with the major vascular connexins (Cx37, 40 and 43). Resistance arteries
were obtained from subcutaneous fat biopsies of healthy pregnant women
undergoing elective caesarean section. Endothelium-dependent vasodilatation to
bradykinin was assessed using wire-myography. A^-nitro-L-arginine-methyl ester
and indomethacin (NO synthase and cyclooxygenase inhibitors respectively)
attenuated maximal relaxation to bradykinin (Rmax) by ~50%. Co-incubation with L-
NAME, indomethacin and the combined CMPs (37'43Gap27, 40Gap27 and 43Gap26)
almost abolished relaxation to bradykinin (Rmax 12.2±3.7%). In arteries incubated
with L-NAME and indomethacin, the addition of either 37'43Gap27 or 40Gap27 had no
significant effect on Rmax whilst 43Gap26 caused marked inhibition (Rmax 21+6.4%,
P=0.005 vs. L-NAME plus indomethacin alone) that was similar to the triple
combination. Endothelium-independent vasorelaxation was unaffected by CMPs, L-
NAME or indomethacin. Immunohistochemistry demonstrated connexin 37, 40 and
43 expression in the endothelium and vascular smooth muscle. These results
demonstrate that, in pregnant women, EDHF-mediated vasorelaxation of
subcutaneous resistance arteries is dependent on connexin 43 and gap junctions.
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3.2 INTRODUCTION
Nitric oxide, the original endothelium-derived relaxing factor, and PGI2 have now
been well characterised. The elucidation of their roles in vascular physiology and
pathophysiology has been fundamental to recent advances in the treatment and
prevention of many cardiovascular diseases.
Evidence points to the existence of a third powerful vasodilator called EDHF [Busse
et al, 2002; Griffith, 2004; Sandow, 2004]. Endothelium-derived hyperpolarising
factor's contribution to endothelium-dependent vasorelaxation is greatest in small
resistance arteries [Herman et al, 2002] and, as such, is ideally suited to the control of
systemic blood pressure and local tissue perfusion. As well as its involvement in
normal physiological responses, EDHF is believed to play an important role in
vascular pathophysiology. It has been suggested to act as a 'back-up' mechanism in
conditions associated with decreased NO bioavailability, such as heart failure
[Malmsjo et al, 1999; Katz and Krum, 2001]. Furthermore, failure of EDHF to
compensate in this way has been implicated in the pathogenesis of pre-eclampsia
[Kenny et al, 2002],
Despite intensive research, the exact nature of EDHF and its mechanism of action
remain unclear. This lack of understanding has precluded its manipulation as a
therapeutic target [Feletou and Vanhoutte, 2004], Multiple candidates have been
proposed but none have been confirmed as a unifying agent constituting EDHF. As
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such, the term endothelium-derived hyperpolarising factor may be misleading and
EDHF may represent a mechanism rather than a specific factor per se.
The case for gap junctions as a central component of the EDHF mechanism has
strengthened [Sandow et al, 2002; Griffith, 2004], These aqueous pores facilitate the
transfer of either small hydrophilic molecules or ionic charge for the conduction of
hyperpolarisation from the endothelium to smooth muscle and from smooth muscle
cell to smooth muscle cell. Gap junctions are composed of two hemichannels
comprising six connexin subunits each. Cx37, Cx40 and Cx43 are particularly
associated with mammalian endothelium and vascular smooth muscle [Griffith,
2004],
Diverse agents have been employed as putative gap junction blockers but their other
non-specific, EDHF-independent effects have limited their use. In contrast, the
CMPs are highly selective and specific [Griffith, 2004; Matchkov et al, 2004], These
short synthetic peptides correspond to conserved amino acid sequences in the first
(Gap 26) and second (Gap 27) extracellular loops of Cxs37, 40 and 43 and cause
disruption of connexin function [Chaytor et al, 1999].
Pregnancy is associated with a decrease in peripheral vascular resistance and
enhanced endothelium-dependent vasodilatation [Gillham et al, 2003], It has
previously been reported that EDHF accounts for approximately 50% of
endothelium-dependent vasodilatation in these arteries. Furthermore, using the
putative gap junction blocker 18a-glycyrrhetinic acid, a potential role of gap
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junctions was identified in EDHF responses [Luksha et al, 2004]. In this study, we
tested the hypothesis that gap junction blockade with CMPs inhibits EDHF-mediated
vasorelaxation in resistance vessels from pregnant women. Furthermore, we
examined the expression of the three main vascular connexin subtypes in these
vessels. Using CMPs, the current study represents the first assessment of the
functional role of gap junctions and their connexin components in EDHF-mediated
relaxation in the human vasculature.
3.3 MATERIALS AND METHODS
3.3.1 Biopsy collection and vessel preparation
The investigation was undertaken with the approval of the local Research Ethics
Committee, with the written informed consent of each patient, and in accordance
with the principles outlined in the Declaration of Helsinki.
Subcutaneous fat biopsies were obtained from healthy women undergoing elective
caesarean section. Women with a history of diabetes mellitus, hypertension or any
other significant past medical history were excluded from participation. Women with
abnormal renal or hepatic function were also excluded. Biopsies were taken from the
incision margin and immediately placed in cold PSS (NaCl 119 mmol/L, KC1 4.7
mmol/L, CaCl2 2.5 mmol/L, MgSCL 1.17 mmol/L, NaHCCL 25 mmol/L, KH2PO4
1.18 mmol/L, EDTA 0.026 mmol/L, glucose 5.5 mmol/L).
Resistance arteries were dissected free of surrounding fat and connective tissue, and
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cut into segments approximately 2 mm long. All arteries were kept in PSS at 4°C and
used on the day of biopsy. Arteries were mounted in the organ baths of a four-
channel wire-myograph (multimyograph, model 610, Danish Myo Technology;
Aarhus, Denmark) as described previously [Luksha et al, 2004], Following a 30-
minute equilibration period, a passive circumference-tension curve was created for
each segment in order to set optimum resting tension, as described previously
[Mulvany and Halpern, 1976; Luksha et al, 2004], This semi-automated procedure
also allows the calculation of arterial diameter. Calibration and data processing were
performed using Myodac software (version 2.1, Danish Myo Technology) on a
personal computer. All solutions were refreshed every 30 minutes.
Constriction was elicited using norepinephrine 3 pmol/L. Endothelium-dependent
vasodilatation was assessed by the addition of a single dose of bradykinin (1 pmol/L)
to each chamber. Arteries that did not achieve at least 60% vasorelaxation to
bradykinin were excluded from the study.
3.3.2 Experimental protocols
Arteries were incubated for 40 minutes in either PSS alone or with the NO synthase
inhibitor L-NAME; 300 pmol/L, and the cyclooxygenase inhibitor indomethacin
(10 pmol/L), to block the production of NO and PGL respectively. Arteries were
then preconstricted with norepinephrine (3 pmol/L) and the concentration-response
curve for bradykinin (0.001-3 pmol/L) assessed. Arteries then underwent 90 minutes
incubation with CMPs, with or without L-NAME and indomethacin as detailed
below. The concentration-response curve to bradykinin was then reassessed. At the
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end of each experiment, endothelium-independent vasorelaxation was assessed in
response to sodium nitroprusside (0.1 mmol/L). The doses of the CMPs used were
based upon prior published work [Chaytor et al, 2003; Griffith, 2004],
3.3.3 Gap junction inhibition with and without no
synthase/cyclooxygenase inhibition
Arteries initially incubated in PSS alone were incubated with PSS plus the combined
CMPs 37'43Gap27 (300 pmol/L), 40Gap27 (300 pmol/L) and 43Gap26 (300 pmol/L).
The contribution of gap junctions to EDHF-mediated vasorelaxation with concurrent
NO synthase/cyclooxygenase inhibition was assessed by pre-incubating with
L-NAME and indomethacin before administering the combined CMPs (as above) in
the continued presence of L-NAME and indomethacin.
3.3.4 Contribution of connexin subtypes to edhf-mediated relaxation
Arteries pre-incubated with L-NAME and indomethacin alone were incubated with
L-NAME and indomethacin plus either i) 37'43Gap27 plus 40Gap27 (450 pmol/L
each); ii) 37'43Gap27 (900 pmol/L); iii) 40Gap27 (900 pmol/L); or iv) 43Gap26
(900 pmol/L). Total peptide concentration in each experiment was kept constant at
900 pmol/L.
3.3.5 The effects of 43gap26 alone on endotiielium-dependent and
independent vasorelaxation
Arteries initially incubated in PSS alone were incubated with 43Gap26 (900 pmol/L)
for 90 minutes. A concentration-response curve to bradykinin was constructed (as
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above), before and after 43Gap26. In further experiments, a concentration-response
curve was constructed for either sodium nitroprusside (0.001-1 pmol/L) or the
endothelium-independent, ATP-sensitive potassium channel opener, pinacidil
(0.001-1 pmol/L) before and after incubation with 43Gap26 (again without L-NAME
and indomethacin).
3.3.6 IMMUNOHISTOCHEMISTRY
Freshly isolated artery segments were cryopreserved in optimal cutting temperature
compound cooled by liquid nitrogen. Transverse 10 pm cryosections were prepared
and mounted onto slides, air-dried, and stored at -20°C. Sections were
immunostained with polyclonal rabbit antibodies against mouse connexins (Cx37
and Cx40 (1:50 dilution) or Cx43 (1:100 dilution) at 4°C overnight (Zymed
Laboratories, Inc., San Francisco, CA, USA) [Li et al, 1998; Nakamura et al, 1999].
Negative control sections were incubated with non-immune goat IgG (SDS,
Falkenberg, Sweden). All slides were counterstained with hematoxylin, dehydrated
and mounted with Pertex (Histolab, Gothenburg, Sweden).
3.3.7 Drugs and chemicals
All drugs and chemicals except the CMPs and antibodies were obtained from Sigma
(St. Louis, MO). The CMPs, 37'43Gap27 (SRPTEKTIFII), 40Gap27 (SRPTEKNVFIV)
and 43Gap26 (VCYDKSFPISHVR) were purchased from American Peptide
Company, Inc. (Sunnyvale, CA). All drugs except indomethacin and L-NAME were
dissolved in PSS before every experiment. Indomethacin was dissolved in pure
ethanol. L-NAME was dissolved in distilled water.
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3.3,8 Data analysis
All data are expressed as mean+SEM. Maximum vasorelaxation (Rmax) is expressed
as percentage return to basal tone produced by the highest concentration of
badykinin (3 pmol/L) after norepinephrine preconstriction. Analysis of variance was
used to compare paired bradykinin concentration-response curves before and after
incubation with CMPs and between groups. Bonferroni's correction for multiple
comparisons was used for the analysis of pooled data. Paired Student's /-test was
used to compare norepinephrine preconstriction before and after incubation with
different agents (GraphPad Prism v4.0). Statistical significance was taken at the 5%
level.
3.4 RESULTS
Subcutaneous fat biopsy specimens were obtained from 14 pregnant women
(5 nulliparous) with a median age of 27 years (range 25-42) and a median gestational
age of 38 weeks (range 37-40) undergoing planned caesarean section due to breach
presentation (n=4), previous caesarean section (n=8) and for psychological reasons
(n=2).
A total of 31 arteries dissected from 14 biopsies were included in the experiment.
Mean internal diameter of artery segments used was 221±8 pm. Vessels with an
internal diameter of 100-300 pm were considered to represent resistance arteries, in
line with previous definitions [Christensen and Mulvany, 2001], There were no
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significant differences between artery segments used in each protocol with respect to
internal diameter and initial constrictor response to norepinephrine (data not shown).
3.4.1 Contribution of edhf to bradykinin-mediated vasorelaxation
Compared with all arteries incubated in PSS alone (n=18), incubation with L-NAME
and indomethacin (n=27) reduced maximal vasorelaxation to bradykinin by
approximately 50% (Rmax 90.3+2.2% PSS alone vs. 48.1±2.6%
L-NAME/indomethacin, P<0.0001). Pilot studies confirmed that bradykinin
concentrations of more than 3 pmol/L failed to further relax vessels incubated in PSS
alone.
Gap junction inhibition with the combined CMPs (37'43Gap27 plus 40Gap27 plus
43Gap26 [300 pmol/L each]) substantially reduced maximal relaxation to bradykinin
(Rmax 46.6+2.8% combined CMPs vs. 89.4+3.5% PSS, P=0.023 [n=6]). The
inhibition of gap junction mediated communication with combined CMPs decreased
maximal bradykinin-induced vasorelaxation to a similar extent as L-NAME plus
indomethacin alone (Figure 3.1).
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Figure 3.1 Concentration response curves for bradykinin (BK) in subcutaneous arteries incubated in
physiological salt solution (PSS) (n=18), L-NAME plus indomethacin (Indo) (n=25) or the combined
connexin mimetic peptides (37,43Gap27, 40Gap27 and 43Gap26 at 300 pmol/L each) with or without L-
NAME plus indomethacin (n=6for both).
*P<O.OOI vs. PSS; IP<0.001 vs. L-NAME and indomethacin alone.
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Combined NO synthase, cyclooxygenase and gap junction inhibition with the
combined CMPs plus L-NAME and indomethacin almost abolished the
vasorelaxation to bradykinin (Rmax 12.2+3.7% combined CMPs plus L-NAME and
indomethacin vs. 49.0±5.1% L-NAME and indomethacin, P=0.0004 [n=6]; Figure
3.1).
3.4.2 Contribution of different connexin subtypes to edhf-mediated
vasorelaxation
Incubation with 37'43Gap27 (450 pmol/L) plus 40Gap27 (450 pmol/L) in addition to
L-NAME and indomethacin did not reduce maximal vasorelaxation to bradykinin
when compared with the same vessels incubated in L-NAME and indomethacin
alone (Rmax 38.2+5.6% L-NAME and indomethacin plus 37'43Gap27, 40Gap27 vs.
40.6±6.1% L-NAME plus indomethacin, P=0.319 [n=5]; Figure 3.2).
The addition of 37'43Gap27 (900 pmol/L) or 40Gap27 (900 pmol/L) to L-NAME and
indomethacin had no effect on maximal bradykinin-induced vasorelaxation
compared to the same arteries incubated with L-NAME and indomethacin alone
(Rmax 43.6±1.4% 37,43Gap27 with L-NAME plus indomethacin vs. 49.6+4.87% L-
NAME plus indomethacin alone, P=0.39 [n = 5]; Rmax 46.3+5.5% 40Gap27 with L-
NAME plus indomethacin vs. 45.0 ± 2.2% L-NAME plus indomethacin alone,
P=0.37, [n=4]; Figure 3.2). However, the inhibition of connexin 43 with 43Gap26
(900 pmol/L) in combination with L-NAME plus indomethacin resulted in a marked
decrease in maximal vasorelaxation to bradykinin when compared to the same
arteries incubated with L-NAME plus indomethacin alone (Rmax 21.0+6.4% for
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Figure 3.2 Concentration response curves for bradykinin (BK) in subcutaneous arteries incubated in
physiological salt solution (PSS) (n=18), L-NAME and indomethacin (Jndo) alone (n=25) or with L-
NAME and indomethacin plus: a) 37,43Gap27 and 40Gap27 (450 pmol/L each; n=5), b) 37,43Gap27
(900 pmol/L; n=5), or c) 40Gap27 (900 pmol/L; n=4).
P>0.05 for L-NAME and indomethacin alone vs. L-NAME and indomethacin in combination with
37,43Gap27 and/or 40Gap27.
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43Gap26 with L-NAME plus indomethacin v,s\ 52.45+8.3% for L-NAME plus
indomethacin alone, P=0.0047 [n=5]). Maximal bradykinin-induced relaxation after
incubation with L-NAME plus indomethacin with 43Gap26 (900 pmol/L) was not
different from maximal relaxation after incubation with the three combined CMPs
(each at 300 pmol/L) (unpaired data, P=0.397; Figure 3.3).
3.4.3 The effects of 43gap26 alone on endothelium-dependent
vasorelaxation
Incubation with 43Gap26 (900 pmol/L) (without L-NAME and indomethacin)
reduced maximal bradykinin-induced relaxation when compared with the same
arteries incubated in PSS alone (Rmax 40.6+15.8% for 43Gap26 alone vs. 85.8+5.5%
for PSS; P=0.039 [n=5]). Maximal bradykinin-induced relaxation after incubation
with 43Gap26 (900 pmol/L) alone was not significantly different from that observed
after incubation with the three combined CMPs (each at 300 pmol/L) in PSS (Rmax
40.6+15.8% for 43Gap26 alone vs. 46.6+2.8% combined CMPs in PSS; P=0.69)
3.4.4 endothelium-independent vasorelaxation and vasoconstriction
Relaxation evoked by the exogenous NO donor, sodium nitroprusside (SNP; 0.1
mmol/L) were unaffected throughout all studies (data not shown). Norepinephrine-
induced vasoconstriction of 2.1+0.07 mN/mm' and was unaffected by any of the
incubation protocols. 43Gap26 alone had no effect upon responses to the
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Figure 3.3 Concentration response curves for bradykinin (BK) in subcutaneous arteries incubated in
physiologicial salt solution (PSS) (n=18), L-NAME and indomethacin (Indo) alone (n-25) or with L-
NAME and indomethacin plus: a) 37'43Gap27, 40Gap27 and 43Gap26 (300 pmol/L each; n=6), or b)
43Gap26 (900 pmol/L; n-5).
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Figure 3.4 Concentration response curvesfor a) bradykinin (BK), b) sodium nitroprusside (SNP) and
c) pinacidil in subcutaneous arteries incubated in physiological salt solution (PSS) and 43Gap26 (900




Immunohistochemistry demonstrated the consistent presence of Cx37, 40 and 43 in
arterial segments (Figure 3.5). Connexins 37, 40 and 43 were seen in both vascular
smooth muscle and endothelial cells although Cx40 was predominantly found in the
endothelium.
3.5 DISCUSSION
We have made the first assessment of the role of gap junctions and connexin
subtypes in EDHF-mediated vasorelaxation of human arteries using highly specific
gap junction inhibitors. We have shown that EDHF-mediated vasorelaxation relies
upon gap junction communication acting principally through the connexin 43
subtype.
We have confirmed that subcutaneous resistance arteries obtained from pregnant
women retain approximately 50% of their endothelium-dependent relaxant capacity
after the inhibition of endothelial NO and PGI2 synthesis with L-NAME and
indomethacin respectively. This L-NAME and indomethacin insensitive component
of endothelium-dependent vasorelaxation is widely regarded to reflect EDHF
activity. Furthermore, incubation with a combination of 37'43Gap27, 40Gap27 and
43Gap26 (300 pmol/L each) attenuated vasorelaxation to bradykinin to a similar
extent as L-NAME and indomethacin alone and revealed that gap junctions are
required for approximately 50% of bradykinin- induced vasorelaxation.
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Figure 3.5 Immunohistochemistry of pregnant human subcutaneous resistance arteries. A, C:
Staining for Cx43 seen in both smooth muscle and endothelial cell layers. B, D: Staining for Cx40
principally seen in the endothelium. E, F: Staining for Cx37 seen in endothelium and smooth muscle.
G: control images of arteries incubated without primary antibodies show no staining for connexins.
All images x40.
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Co-incubation of the triple CMP combination with L-NAME and indomethacin
virtually abolished bradykinin-induced vasorelaxation. That is, the L-
NAME/indomethacin insensitive component of bradykinin-induced relaxation was
inhibited by gap junction blockade. This provides further evidence of a pivotal role
for gap junctions in EDHF-mediated relaxation in these vessels. These findings are
in keeping with a previous study in similar vessels [Luksha et al, 2004] where
bradykinin-mediated relaxation was abolished by a combination of L-NAME,
indomethacin and 18a-glycyrrhetinic acid.
We went on to assess the effects of each of the three CMPs in order to infer the
relative functional importance of Cxs37, 40 and 43 . 43Gap26 exerted marked
inhibition of EDHF-mediated relaxation to bradykinin. Indeed, at 900 pmol/L, its
inhibitory effect did not differ from that seen after incubation with the triple
combination of CMPs. The marked inhibition of vasodilatation achieved by
incubation with 43Gap26 contrasts with the lack of inhibition seen after incubation
with 37'43Gap27 and 40Gap27 in combination (450 pmol/L each) and individually
(900 pmol/L). Furthermore, in the absence of L-NAME and indomethacin, 43Gap26
caused a significant attenuation in maximal vasodilatation to bradykinin. Taken
together, this suggests that the combined inhibitory effect of all three CMPs is
derived predominantly from 43Gap26 activity and implicates Cx43 as the dominant
connexin isoform involved in the mediation of EDHF responses in these vessels.
Data from combined eNOS/cyclooxygenase knockout mice imply a greater role for
EDHF in females than in males [Scotland et al, 2005] whilst other animal models
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have demonstrated dynamic Cx43 expression under the influence of oestrogen.
Pregnant rats exhibit enhanced EDHF-mediated vasodilatation and up-regulation of
vascular Cx43 expression [Dantas et al, 1999], These effects are markedly
diminished in ovariectomised animals but can be restored by exogenous oestrogen
supplementation [Liu et al, 2002], Furthermore, an increase in Cx43 expression in
response to increased shear stress and mechanical load has been demonstrated
[Rummery and Hill, 2004]. The rise in circulating blood volume associated with
normal human pregnancy could invoke similar changes in Cx43 expression and
function and account for the predominant functional importance of Cx43 in our
study. Although diversity exists between species and the sexes, EDHF makes a large
contribution to endothelium-dependent vasodilatation in various vascular beds in
men and non-pregnant women [Nakashima et al, 1993; Ohlmann et al, 1997;
Urakami-Harasawa et al, 1997; Wallerstedt and Bodelsson, 1997; Buus et al, 2000;
Coats et al, 2001; Mclntyre et al, 2001]. The present study supports a clear role for
Cx43 in vascular responses of pregnant women [Dantas et al, 1999], Whether or not
Cx43 is of such fundamental importance in men, non-pregnant women and in other
vascular beds remains to be established.
The interpretation of results using older putative gap junction blockers has been
limited by their non-specific effects. Indeed, 18a- glycyrrhetinic acid can affect ion
channel conduction to attenuate endothelial cell hyperpolarisation directly.
Confidence with the CMPs growing: they do not suppress endothelial
hyperpolarisation directly and do not exert non-gap junctional effects [Griffith, 2004;
Matchkov et al, 2006], Their exact mechanism of action remains unclear but they are
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thought to interfere with connexin gating properties. Unlike 18a- glycyrrhetinic acid,
they do not affect the structural integrity, number or distribution of connexins
[Berman et al, 2002], When administered in combination and individually in this
study, the CMPs did not have any influence upon vasorelaxation to sodium
nitroprusside or preconstriction to norepinephrine, suggesting that they specifically
inhibit endothelium-dependent vasorelaxation without interfering with vascular
smooth muscle function. Whilst 43Gap26 alone significantly attenuates maximal
relaxation to bradykinin, it does not have any influence upon the concentration-
response curve obtained after exposure to the endothelium-independent vasodilators,
sodium nitroprusside and pinacidil. This provides more robust evidence that this
CMP does not exert non-specific or toxic effects upon smooth muscle function.
If Cx43 has a dominant role then one might expect EDHF-mediated vasorelaxation
to be inhibited by 37,43Gap27 as well as by 43Gap26. 37'43Gap27 shares sequence
homology with the Gap27 domain of both connexin 37 and 43 whereas 43Gap26
shares homology with the Gap26 domain of Cx43 only. Both 37,43Gap27 and 43Gap26
have been shown to act in a connexin-specific manner [Chaytor et al, 1999; Berman
et al, 2002] but our findings concur with others who have reported differential
activity between these two CMPs. In 2003, Chaytor and Griffith reported that
37'43Gap27 and 40Gap27 partially inhibited the transmission of hyperpolarisation from
endothelium to smooth muscle in the rabbit iliac artery. However, the addition of
43Gap26 was required to abolish this phenomenon completely, implying that
37'43Gap27 causes incomplete inhibition of Cx43 [Chaytor et al, 2003], Because each
of these peptides shares homology with different extracellular loops, these data
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suggest that targeting 37' 3Gap27 and 43Gap26 vary in their propensity to inhibit Cx43
by acting at different sites. It is unclear whether Gap26 plays a greater role than
Gap27 in Cx43 gating and/or docking.
Immunohistochemistry revealed Cx37 and Cx43 expression in both the endothelium
and smooth muscle. Cx40 was also seen in these cells but expression was
predominantly seen in the endothelium. Whilst myoendothelial gap junctions are
proposed to allow the transfer of hyperpolarisation generated in the endothelium to
the underlying smooth muscle, homocellular gap junctions between adjacent smooth
muscle or endothelial cells are also an ideal conduit for the longitudinal conduction
of hyperpolarisation and coordinated regulation of vascular tone. Indeed, mice
genetically engineered to lack vascular Cx40 display not only hypertension but also
irregular vasomotion [de Wit et al, 2003]. Our own study has not differentiated
whether the inhibition of EDHF-mediated vasodilatation is due to the inhibition of
Cx43 in myoendothelial junctions, in homocellular junctions, or in both. Irrespective,
we have demonstrated a critical role for this connexin in endothelium-dependent
vasorelaxation. Furthermore, we have shown that endothelium-independent
vasorelaxation is unaffected by gap junction and, specifically, Cx43 inhibition.
3.6 CONCLUSION
In summary, we have shown that EDHF accounts for approximately 50% of
bradykinin-induced vasorelaxation in resistance arteries from pregnant women.
Using CMPs, we have provided functional evidence that EDHF mediates its
vasorelaxatory actions via gap junctions. We have demonstrated the expression of
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three major connexin isoforms and highlighted a predominant functional role for
Cx43 in the mediation of EDHF responses in this vascular bed. The extension of
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4.1 SUMMARY
Endothelium-derived hyperpolarising factor causes vasorelaxation and may
contribute to the release of the endogenous fibrinolytic factor, t-PA. Rotigaptide
enhances communication via the connexin 43 gap junction subunit and may
potentiate the vascular actions of EDHF. The aims of this study were to determine
whether rotigaptide influences basal and stimulated endothelium-dependent
vasodilatation and t-PA release in vivo in man. Using venous occlusion
plethysmography, forearm blood flow was measured in 27 healthy volunteers during
intra-brachial infusions of rotigaptide (0.25-25 nmol/min) alone, or co-administered
with endothelium-dependent (acetylcholine [5-20 pg/min] and bradykinin [30-300
pmol/min]) and independent (sodium nitroprusside [2-8 pg/min]) vasodilators in the
presence or absence of the 'nitric oxide clamp' and aspirin. Basal blood flow was
unaffected by rotigaptide (P=NS). Acetylcholine, bradykinin and sodium
nitroprusside all caused dose-dependent vasodilatation in the presence and absence
of aspirin and the 'nitric oxide clamp' (P<0.005 for all). These responses were
unaffected by rotigaptide (P=NS). Bradykinin caused t-PA antigen and activity
release (P=0.04, P0.0001, respectively) that was unaffected by rotigaptide. These
results demonstrate that augmentation of connexin 43 communication has no effect
on basal vascular tone and does not enhance endothelium-dependent or independent
vasodilatation, or t-PA release in the forearm arterial circulation of healthy men. It
remains to be established whether augmentation of connexin 43 communication
improves endothelial function in patients with vascular disease.
96
4.2 INTRODUCTION
The endothelium plays a major role in the regulation of vascular tone and is
responsible for the release of the endogenous fibrinolytic factor, t-PA. The
elucidation of their roles in vascular physiology and pathophysiology has been
fundamental to recent advances in the treatment and prevention of many
cardiovascular diseases.
After blockade of both NO and PGI2 generation, a substantial degree of endothelium-
dependent vasodilatation remains and is attributed to EDHF [Vanhoutte, 1987],
Consistently, its contribution is most prominent in the small resistance arteries
IUrakami-Harasawa et al, 1997; Berman et al, 2002.] that regulate systemic blood
pressure and local tissue perfusion. Furthermore, the release of t-PA from the
endothelium is independent of both NO and PGI2 production [Labinjoh et al, 2000;
Hrafnkelsdottir et al, 2001] and it has been suggested that EDHF may mediate its
release [Brown et al, 2000; Hrafnkelsdottir et al, 2001], Thus, alterations in EDHF
activity may contribute to endothelial dysfunction and its manipulation presents an
exciting opportunity to restore vascular health and reduce the burden of
cardiovascular disease [Feletou and Vanhoutte, 2004],
The transmission of hyperpolarisation from the endothelium to the underlying
smooth muscle occurs via undefined mediators and pathways. Various mediators
have been proposed but none has emerged as a universal EDHF in all species and
vascular beds [Griffith, 2004; Feletou and Vanhoutte, 2006a], However, there is
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considerable evidence that gap junctions are required [Chaytor et al, 1998; Rummery
et al, 2002; de Wit et al, 2003; Griffith, 2004], These aqueous pores are found at
points of cell-cell contact and allow the intercellular transfer of small molecules
(<1 kDa). Myoendothelial gap junctions are, therefore, ideally suited to the radial
transfer of electrotonic charge or second messenger between the endothelium and
underlying smooth muscle. Each gap junction hemichannel is composed of six
connexin subunits including Cx37, 40 and 43 in the mammalian vasculature. Indeed,
using specific connexin antagonist peptides, we have previously demonstrated the
critical importance of Cx43 in EDHF-mediated vasodilatation of human resistance
arteries in vitro [Lang et al, 2007].
It has not previously been possible to make a direct assessment of the role of gap
junctions in the mediation of EDHF responses in vivo in man. However, rotigaptide
is a synthetic hexapeptide (Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NFf) that acts
upon Cx43 to potentiate communication via gap junctions [Xing et al, 2003; Clarke
et al, 2006; Axelsen et al, 2007; Kjolbye et al, 2008]. In addition to its clinical
development as an antiarrhythmic agent [Kjolbye et al, 2003; Udata et al, 2006], it
has been promoted as an important new tool to aid in the dissection of the
physiologic role of gap junctions [Axelsen et al, 2007], Here, we have conducted the
first clinical assessment of the role of gap junctions, and specifically Cx43, in the
peripheral vascular EDHF-mediated responses. We tested the hypothesis that, by
increasing communication via gap junctions, rotigaptide would enhance EDHF-




4.3.1 Preliminary validation study
The biological activity of rotigaptide was assessed through in vitro measurements of
its effect on transmural conduction velocity in rabbit ventricular myocardium. Hearts
from four male New Zealand white rabbits were used for these experiments, which
conform to the standards set out in the Animals (Scientific Procedures) Act 1986.
Rabbits (n=4) were killed with a single intravenous injection of 100 mg/kg
pentobarbital sodium. Hearts were excised, placed in chilled Tyrode's solution
(containing [mmol/L]: Na 134.5, Mg 1.0, K 5.0, Ca 1.9, CI 101.8, S04 1.0, H2P04
0.7, HCO3 20, acetate 20 and glucose 10) and perfused via the left coronary artery
with oxygenated (95% €>2-5% CO2) Tyrode's solution maintained at pH 7.4 and
37°C. Perfused left ventricular free wall wedge preparations were dissected out and
mounted in a custom built chamber which allowed access to the transmural surface
for imaging. The preparation was stimulated using a bipolar electrode placed on the
epicardial surface at 1.5 x diastolic threshold using a 2 ms pulse at a basic cycle
length of 350 ms. Perfusion pressure and electrocardiogram were monitored
throughout. An optical mapping system was used to record optical action potentials
as previously described [Walker et al, 2007]. Motion artefact was minimised using
15 mmol/L 2,3 butanendione monoxime. Measurements were taken at 15-minute
intervals. After two control recordings the perfusate was changed to Tyrode's
solution containing butanendione monoxime and 1 pmol/L rotigaptide for a further
15 minutes and measurements were repeated.
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4.3.2 Clinical study
This clinical study was performed with the approval of the local Research Ethics
Committee in accordance with the Declaration of Helsinki and with the written
informed consent of each subject.
Subjects
Healthy non-smokers (mean age 22 years; range 19-25 years) were recruited into the
study. Participants were excluded if they had clinically significant conditions
including hypertension, hyperlipidaemia, diabetes mellitus, asthma and
coagulopathy. No participant had suffered a recent infective or inflammatory
condition, or had taken any medications in the 7 days prior to the study. On the day
of study, participants had fasted and abstained from caffeine and tobacco for at least
4 hours and from alcohol for 24 hours.
Drugs
Pharmaceutical grade bradykinin (Clinalfa AG, Laufelfingen, Switzerland),
acetylcholine (Novartis Ltd, Middlesex, UK), L-N(G)-monomethyl arginine citrate
(Clinalfa), sodium nitroprusside (Hospira Inc., CA, USA) and rotigaptide (American
Peptide Inc., CA., USA) were dissolved in physiological saline. Aspirin was obtained
from Dagra Pharma, Diemen, Netherlands.
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Forearm Venous Occlusion Plethysmography
All subjects underwent cannulation of the brachial artery with a 27-gauge standard
wire steel needle under controlled conditions. All studies were performed with
patients lying supine in a quiet, temperature controlled (22-25 °C) room. The intra¬
arterial infusion rate was kept constant at 1 mL/min throughout all studies. Forearm
blood flow was measured in the infused and non-infused arms by venous occlusion
plethysmography using mercury-in-silastic strain gauges as described previously
[Newby et al, 1997a; Newby et al, 1999], Supine heart rate and blood pressure were
monitored at intervals throughout each study using a semi-automated non-invasive
oscillometric sphygmomanometer.
Intra-Arterial Drug Administration
Protocol 1: Effect of rotigaptide on basal forearm blood flow
Five participants attended once each. They received intra-arterial rotigaptide at 0.25,
0.75, 2.5, 7.5 and 25 nmol/min for 6 minutes at each dose. Assuming basal FBF of
25 mL/min, this would give tissue rotigaptide concentrations of 0.01-1.0 pmol/L.
Forearm blood flow was measured during the final 3 minutes of infusion of each
dose.
Protocol 2: Effect of rotigaptide on agonist-induced vasodilatation and tissue
plasminogen activator release
Twelve volunteers attended on each of three occasions. After a 20-minute intra¬
arterial infusion of 0.9% saline, participants received either intra-arterial placebo
(0.9% saline), 2.5 nmol/min rotigaptide or 25 nmol/min rotigaptide using a
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randomised double-blind crossover design. Rotigaptide or placebo was administered
alone for 20 minutes before being co-infused with ascending doses of bradykinin (an
endothelium-dependent vasodilator that causes the release of t-PA;
30-300 pmol/min), acetylcholine (an endothelium-dependent vasodilator that does
not cause the release of t-PA; 5-20 pg/min) and sodium nitroprusside (an
endothelium-independent vasodilator that does not cause the release of t-PA;
2-8 pg/min). Co-infused drugs were separated by a 20-minute infusion of 0.9%
saline. The order of agonist infusion was randomised between participants but
maintained constant for each of the three visits.
Protocol 3; Effect of rotigaptide on EDHF-mediated vasodilatation
Ten volunteers were recruited to attend on two occasions. Endothelium-derived
hyperpolarising factor activity was isolated by inhibiting the production of both PGI2
and NO on each of the two visits. Cyclooxygenase activity was inhibited with a single
600 mg dose of oral aspirin 1 hour prior to each study. Nitric oxide production was
inhibited with L-NMMA in the 'nitric oxide clamp'. After a 20-minute intra-arterial
infusion of 0.9% saline, L-NMMA (8 pmol/min) was infused via the brachial artery. To
compensate for L-NMMA induced basal vasoconstriction, FBF was restored to baseline
using a titrated dose of exogenous NO in the form of intra-brachial sodium nitroprusside
(90-900 ng/min). The titrated dose of sodium nitroprusside was co-infused with L-
NMMA throughout the study. This arrangement allows a constant 'clamped' delivery of
exogenous NO whilst endogenous NO synthase activity is inhibited [Floning et al,
2000].
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Either rotigaptide (25 nmol/min) or saline placebo was co-infused with the 'nitric oxide
clamp' in a double-blind randomised crossover design. Subsequently, ascending doses
of bradykinin (30-300 pmol/min), acetylcholine (5-20 pg/min) and sodium nitroprusside
(2-8 pg/min) were co-infused and separated by a 20-minute infusion of 0.9% saline. The
order of agonist co-infusion was randomised between participants but maintained
constant between visits.
Blood Sampling
Seventeen-gauge venous cannulae were inserted into left and right antecubital fossae
during Protocol 2. Blood samples were drawn simultaneously from each arm before
bradykinin infusion and after the maximum dose of bradykinin (300 pmol/min).
Blood was collected into acidified buffered citrate (Stabilyte, Biopool International,
UK; for t-PA assays) and into citrate (BD Vacutainer, BD UK Ltd, UK; for
measurement of t-PA's major endogenous inhibitor, PAI-1). Samples were kept on
ice before centrifugation at 2000 g for 30 minutes at 4°C. Platelet-free plasma was
decanted and stored at -80°C before assay. Plasma t-PA antigen and activity (t-PA
Combi Actibind Elisa Kit; Technoclone, Austria) and PAI-1 antigen and activity
(Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity; Hyphen Biomed, France)
concentrations were determined by enzyme-linked immunosorbant assays.
Haematocrit was measured at baseline and at the end of the study.
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4.3.5 Data analysis and statistics
Optical Mapping Validation Study
Data analysis was performed using custom software. Activation time was determined
at the midpoint between baseline and the peak of the action potential upstroke.
Transmural conduction velocity was calculated for each time point using activation
time from the earliest activation on the epicardial edge of the transmural surface to
the earliest activation on the endocardial side.
Clinical Study
Forearm plethysmographic data were analysed as described previously [Newby et al,
1997a], Estimated net release of plasma t-PA and PAI-1 has been defined previously
as the product of the infused forearm plasma flow (based on the mean haematocrit
and the infused FBF) and the concentration difference between the infused and non-
infused arms [Newby et al, 1997b],
Variables are reported as mean±SEM and analysed using repeated measures
ANOVA with post-hoc Bonferroni corrections and two-tailed Students /-test as
appropriate. Statistical analysis was performed with GraphPad Prism (Graph Pad
Software) and statistical significance taken at the 5% level.
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4.4 RESULTS
4.4.1 Effect of rotigaptide on myocardial conduction velocity in vitro
In all experiments, transmural conduction velocity remained constant during control
perfusion (20.8±1.7 vs. 21.4±1.6 cm/s, P=NS). Following perfusion with rotigaptide,
an increase in transmural conduction velocity was observed (29.4±1.7 cm/s,
PO.OOl, ANOVA; Figure 4.1).
4.4.2 Effect of rotigaptide on basal forearm bood flow
At doses of 0.25-25 nmol/min, rotigaptide had no effect upon basal FBF (P=NS,
ANOVA; Figure 4.2).
4.4.3 Effect of rotigaptide on agonist-induced vasodilatation and
tissue plasminogen activator release
Acetylcholine, bradykinin and sodium nitroprusside each caused dose-dependent
arterial vasodilatatation (P<0.0001 for all, ANOVA) that was unaffected by either
2.5 or 25 nmol/min rotigaptide (P=NS for both, in the presence vs. the absence of
rotigaptide, ANOVA; Figure 4.3).
At baseline, net t-PA antigen release was 0.09±0.05 ng/lOOmL/min and net release
of t-PA activity was 0.54±1.4 IU/100 mL/min. This was unchanged by the presence
of rotigaptide (P=NS for all, ANOVA). Bradykinin (300 pmol/min) caused the



























Figure 4.1 Effect of 1 fimol/L rotigaptide on transmural conduction velocity in perfused rabbit
ventricular myocardium.
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(6.15±2.20 IU/100 mL/min; P<0.0001, ANOVA) but this was unaffected by either
2.5 or 25 nmol/min rotigaptide (P=NS for all, ANOVA).
Net release of PAI-1 antigen and activity was unaffected by bradykinin
(300 pmol/min) in the presence or absence of rotigaptide (P=NS for all, ANOVA;
data not shown).
4.4.4 Effect of rotigaptide on edhf-mediated vasodilatation
Intra-arterial L-NMMA (8 pmol/min) reduced basal FBF by approximately 38%
(from 2.40±0.20 reduced to 1.50+0.20 mL/100 mL tissue/min; P0.0001) and was
unaffected by rotigaptide (P=NS, 2-way ANOVA). Forearm blood flow was restored
to baseline levels by the titration of sodium nitroprusside (P=NS, ANOVA).
After the inhibition of endothelial NO and PGI2 synthesis, dose-dependent
vasodilatation was evoked by acetylcholine, bradykinin and sodium nitroprusside
(P<0.005 for all, ANOVA). This response was not altered by the presence of
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4.5 DISCUSSION
For the first time, we have assessed the role of connexin 43 and gap junctions in the
control of vascular tone and t-PA release in vivo in man. We have shown, in healthy
volunteers, that potentiation of Cx43-mediated intercellular communication with
rotigaptide does not affect basal forearm arterial blood flow or agonist-induced
vasodilatation and t-PA release in the presence or absence of concomitant inhibition
of PGI2 and NO production.
To date, there has been no direct assessment of the role of gap junctions, nor
individual connexin subtypes, in the regulation of vascular function in vivo in man.
The use of connexin antagonists has been limited by concerns about the potential for
toxicity and older putative gap junction blockers exert a range of non-endothelial
effects and alter ion channel permeability [Chaytor et al, 2000; Matchkov el al,
2004], However, rotigaptide offers a novel means for the assessment of gap
junction-dependent phenomena in vivo. Not only has it been safely administered to
healthy humans [Kjolbye et al, 2003; Udata et al, 2006] but its actions are specific to
Cx43. Indeed, it augments communication via gap junctions in the absence of
changes in membrane conduction or basal current [Muller et al, 1997], and it
exhibits no binding to a large array of receptors including numerous ion channels
[Haugan et al, 2005]. It enhances intercellular dye transfer between HeLa cells
expressing Cx43 but not between those expressing Cx26 or Cx32 [Clarke et al,
2006] and promotes electrical coupling between ventricular myocytes via alterations
in the phosphorylation status of Cx43 [Axelsen et al, 2006; Kjolbye et al, 2008],
Indeed, phosphorylation of Cx43 maintains it an open state [Ek-Vitorin et al, 2006]
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and Kjolbye and co-workers have recently demonstrated that the antiarrhythmic
effects of rotigaptide are associated with the inhibition of Cx43 dephosphorylation
[Kjolbye et al, 2008].
We have previously demonstrated that EDHF-mediated vasodilatation of
subcutaneous resistance arteries from pregnant women depends upon the presence of
functional Cx43 whilst Cx37 and Cx40 are not required [Lang et al, 2007]. Indeed,
in comparison to Cx37 and Cx40, the vascular expression of Cx43 appears to be
particularly labile. It is up-regulated by oestrogen [Liu et al, 2002], at the leading
edge of atherosclerotic plaques [Kwak et al, 2002], after vascular injury [Yeh et al,
1997] and at sites of increased shear stress [Gabriels and Paul, 1998; Depaola et al,
1999], Furthermore, type I diabetes mellitus is associated with an impairment of
EDHF-mediated vascular responses [Feletou and Vanhoutte, 2004; Fitzgerald et al,
2005], and elevated glucose concentrations cause the isolated down-regulation of
Cx43 expression [Sato et al, 2002] and permeability [Kuroki et al, 1998] in vitro.
The examination of Cx43-mediated responses is, therefore, of particular relevance
not only to our understanding of vascular physiology, but might also represent a
major therapeutic target to attenuate endothelial dysfunction and improve vascular
health.
Despite theoretical indications, we have failed to demonstrate a major vascular effect
of rotigaptide even during inhibition of both NO and PGF production. Was the
rotigaptide inactive or used at an inadequate dose? Using an electrophysiological
optical mapping system, the biological activity of rotigaptide at 1 pmol/L was
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confirmed. The maximum dose of rotigaptide assessed in the clinical study was
25 nmol/min which, based upon FBF of 25 mL/min, equates to an estimated tissue
concentration of approximately 1 pmol/L. This concentration is in excess of the
effective antiarrhythmic concentration employed in previous animal models [Xing et
al, 2003; Guerra et al, 2006; Herman et al, 2006; Shiroshita-Takeshita et al, 2007]
and is similar to the maximum tissue concentration of rotigaptide achieved in
clinical trials [Udata et al, 2006], Furthermore, it is in excess of the concentration
recently shown to be required for the prevention of Cx43 dephosphorylation
[Kjolbye et al, 2008]. We therefore do not believe that the preparation was inactive
or used at the wrong dose.
Connexin 43 is expressed abundantly in a wide range of resistance arteries obtained
from a variety of species [Griffith, 2004] including humans [Lang et al, 2007],
Whilst our previous assessment of the role of connexin subtypes in human EDHF-
mediated responses demonstrated a critical role for Cx43 and not Cx37 or 40 [Lang
et al, 2007], it is possible that, in the non-pregnant state, the vasomotor and EDHF-
mechanism requires a contribution from all of these subtypes. Rotigaptide
specifically augments Cx43-mediated signalling but the augmentation of vascular
gap junction mediated communication may therefore require the combined
potentiation of all three of the major vascular connexin subtypes.
The present study made an examination of vascular responses in healthy young men.
It is conceivable that vasomotor and endogenous fibrinolytic responses cannot be
augmented because the endothelium is already maximally active with a high baseline
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open-state probability for Cx43. Indeed, the antiarrhythmic activity of rotigaptide is
particularly potent in the context of acidosis and metabolic stress during which the
open-state probability of Cx43 is relatively low [Haugan et al, 2005], Furthermore,
we were careful to dissect out EDHF-mediated activity by the inhibition of PGI2 and
NO with oral aspirin and the 'nitric oxide clamp' respectively. EDHF has activity
that is reciprocal to NO [Bauersachs et al, 1996] and becomes up-regulated to
compensate for impaired NO bioavailability in a variety of disease states [Feletou
and Vanhoutte, 2004]. Therefore, the argument that EDHF is maximally active in the
studied population becomes more pertinent in the presence of NO and PGI2
inhibition.
4.6 CONCLUSION
In conclusion, we have demonstrated that intra-arterial rotigaptide does not augment
vasomotion or endogenous fibrinolysis in healthy subjects. Whether enhancement of
connexin 43-mediated intercellular communication influences vascular function in
conditions associated with specific impairment of EDHF-mediated activity, such as
type I diabetes mellitus or pre-eclampsia, remains to be evaluated. Not only would
this assessment provide important mechanistic insights to the pathophysiology of
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5.1 SUMMARY
Thrombin is central to the pathophysiology of atherothrombosis and its cellular
actions are mediated via PAR-1. Activation of PAR-1 causes arterial vasodilatation,
venoconstriction, platelet activation and t-PA release in man. The objective of this
study was to determine the role of the endothelium in the vascular actions of PAR-1
activation in vivo in man. Dorsal hand vein diameter was measured in six healthy
volunteers before and after endothelial denudation. Forearm arterial blood flow and
plasma fibrinolytic factors were measured in 24 healthy volunteers during venous
occlusion plethysmography. The effects of inhibition of PGI2, NO and endothelium-
derived hyperpolarising factor on PAR-1 responses were assessed during co¬
administration of aspirin, the "nitric oxide clamp' L-NMMA and sodium
nitroprusside and TEA respectively. Endothelial denudation did not affect PAR-1
evoked venoconstriction (SFLLRN; 0.05-15 nmol/min). Although aspirin had no
effect, SFLLRN-induced vasodilatation (5-50 nmol/min) was attenuated by the
'nitric oxide clamp' (PO.OOOl) and TEA (PO.05), and abolished by their
combination (P<0.01). The "nitric oxide clamp' augmented SFLLRN-induced t-PA
and PAI-1 antigen (P<0.0001) release whilst TEA and aspirin had no effect. These
results show that, acting via PAR-1, thrombin causes contrasting effects in the
human vasculature and has a major interaction with the endothelium. This highlights
the critical importance of endothelial function during acute arterial injury and




Thrombin plays a central role in the coagulation cascade and thrombosis [Patterson
et al, 2001], It is one of the most powerful physiological agonists in the
cardiovascular system and its actions are fundamental to the processes of
atherosclerosis and its thrombotic consequences.
In addition to the enzymatic generation of fibrin, thrombin stimulates a range of cell
types including platelets, endothelium and vascular smooth muscle cells. An extensive
search for thrombin receptors ultimately culminated in the identification of a group of
G-protein coupled receptors termed protease-activated receptors. These receptors are
characterised by a unique mechanism of activation whereby the receptor undergoes
proteolytic cleavage, unmasking a short peptide sequence that remains tethered and
autoactivates the receptor [Vu et al, 1991; Swift et al, 2006], To date, four different
types of PARs have been identified: PAR-1, 3 and 4 are all activated by thrombin. PAR-
2 is mainly activated by trypsin but transactivation of PAR-2 by cleaved PAR-1 has
been recognised [O'Brien et al, 2000; Hollenberg and Compton, 2002],
PAR-1 receptors are the principal thrombin receptors in man and have been extensively
studied in small animals and cell cultures suggesting a diverse and important role in
various organs. Their activation stimulates a network of G-protein coupled signalling
pathways that involve phospholipase C(3, protein kinase C, calcium release, mitogen-
activated protein kinases and potassium channels [Coughlin, 2000; Ossovskaya and
Bunnett, 2004], However, there is significant species heterogeneity with pre-clinical
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studies of limited relevance to man [Kinlough-Rathbone et al, 1993]. Exploring the role of
PAR-1 receptors in the human vasculature would deepen our understanding of the
physiological role of thrombin and be important in the clinical development of new
therapeutic strategies.
To understand the physiological actions of thrombin in the human vasculature is
challenging because direct thrombin instillation has the potential to cause acute
thrombosis in situ and hence vascular occlusion. The use of a PAR-1 receptor agonist,
however, permits the direct assessment of cellular responses to thrombin without the
enzymatic activation of the coagulation cascade and fibrin formation. Using the short
peptide mimetic SFLLRN, the in vivo effects of PAR-1 activation in platelets,
endothelium and vascular smooth muscle in man have recently been described by
GuQmundsdottir et al. For the first time, it was shown that PAR-1 activation has unique
and contrasting effects in the human vasculature including arterial dilatation, venous
constriction, platelet activation and t-PA release [Gudmundsdottir et al, 2006]. Given the
central role of thrombin in the pathophysiology of cardiovascular disease, it is important
to establish the mechanisms of these PAR-1 mediated effects and, in particular, the role
of the endothelium. We therefore set out to explore the role of the endothelium in the




Thirty healthy non-smokers (mean age 22 years; range 19-37 years) were recruited
into the study. The study was approved by the local Research Ethics Committee and
conducted in accordance with the Declaration of Helsinki and with the written
informed consent of all volunteers. Participants were screened and excluded for
clinically significant conditions including hypertension, hyperlipidaemia, diabetes
mellitus, asthma and coagulopathy. No participant had suffered a recent infective or
inflammatory condition or had taken any medications in the 7 days prior to the
study.
5.3.2 Vascular assessments
All studies were carried out in a quiet, temperature controlled room (22-24°C).
Participants were semi-recumbent (venous studies) or supine (arterial studies) and
had abstained from alcohol for 24 hours, and from food and caffeine-containing
drinks for at least 4 hours prior to the study.
5.3.3 Venous studies
A 23-gauge needle was sited in a dorsal hand vein and total infusion rate kept
constant at 0.25 mL/min in all studies. The hand was supported above the level of
the heart and an upper arm cuff inflated to 40 mmHg to obstruct venous return. The
internal diameter of the dorsal hand vein was measured by the Aellig technique
[Aellig, 1981] in six healthy volunteers. In brief, a magnetised lightweight rod rested
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on the summit of the infused vein approximately 1 cm downstream from the tip of
the infusion needle. The rod passes through the core of a linear variable differential
transformer, supported above the hand by a small tripod. Changes in diameter of the
vein cause vertical displacement of the rod, leading to a linear change in the voltage
generated by the transformer. This enables calculation of absolute changes in vein
size.
Protocol 1: Venous Effects ofPAR-1 Activation
First we established the presence of functional endothelium. As dorsal hand veins do
not have resting tone, norepinephrine (1-128 ng/min) was used to induce 70%
reduction in vein diameter. Once stable venoconstriction was obtained, acetylcholine
(1 nmol/min; Novartis Pharmaceuticals UK Ltd, Frimley, UK) was co-infused with
norepinephrine for 8 minutes to demonstrate endothelium-dependent venodilatation
and an intact, functional endothelium. Following a 20-minute saline infusion, the
PAR-1 activating peptide, SFLLRN-NH2 (0.05-15 nmol/min; Clinalfa; Switzerland),
was administered intravenously before a final 20-minute saline washout infusion.
Protocol 2: Venous Effects of PAR-1 Activation Following Endothelial
Denudation
At the end of Protocol 1, the endothelium of the venous segment was denuded as
previously described [Sogo et al, 2000], In brief, a second 23-gauge butterfly needle
was sited 3-4 cm downstream from the tip of the infusion-needle, and this segment
of the vein isolated by the use of occlusion wedges. Distilled water was infused
through the venous segment at a rate of 5 mL/min for 15 minutes, thereby causing
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endothelial denudation that persists for at least 2 days [Sogo et al, 2000], Aspirin
(300 mg orally), was given 30 minutes prior to start of the first study, and on each of
the two subsequent days to prevent venous thrombosis. On the second day following
denudation, subjects reattended and Protocol 1 was repeated.
5.3.4 Arterial studies
All subjects underwent cannulation of the brachial artery with a 27-gauge standard
wire steel needle under controlled conditions. The intra-arterial infusion rate was
kept constant at 1 mL/min throughout all studies. Forearm blood flow was measured
in the infused and non-infused arms by venous occlusion plethysmography using
mercury-in-silastic strain gauges as described previously [Newby et al, 1997a;
Newby et al, 1999], Supine heart rate and blood pressure were monitored at intervals
throughout each study using a semi-automated non-invasive oscillometric
sphygmomanometer. Tirofiban (1.25 pg/min) was co-infused during the studies to
inhibit potential PAR-l activation induced platelet aggregation in vivo
[GuSmundsdottir et al, 2006]. This dose of tirofiban does not affect platelet-
monocyte binding, FBF or baseline concentration of t-PA [GuSmundsdottir et al,
2006],
Protocol 3: Role ofNitric Oxide and Prostacyclin in PAR-l Induced Vasodilatation
Forearm blood flow was measured by venous occlusion plethysmography in response to
brachial artery infusion of SFLLRN (PAR-l agonist; 5-50 nmol/min) with tirofiban
(1.25 pg/min) in eight healthy volunteers on four visits using a randomised controlled
crossover study employing a two-by-two factorial design: with and without aspirin
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(600 mg orally; to inhibit PGI2 synthesis) and the 'nitric oxide clamp'. Assuming total
FBF of 25 mL/min, this will achieve end-organ concentrations of 0.2-2.0 pM SFLLRN.
The 'nitric oxide clamp' was used to determine the contribution of NO in PAR-1
mediated vascular effects. Following baseline intra-arterial tirofiban infusion, the NO
synthase inhibitor, L-NMMA (8 pmol/min), was co-infused. To compensate for
L-NMMA induced basal vasoconstriction, FBF was returned to baseline using a titrated
dose of exogenous NO in the form of intra-brachial sodium nitroprusside
(90-900 ng/min). This dose of sodium nitroprusside was co-infused with L-NMMA and
continued throughout the study.
Protocol 4: Role of Calcium-Activated Potassium Channels/EDHF in PAR-1
Induced Vasodilatation
Forearm blood flow was measured in a further eight healthy volunteers in whom
intrabrachial SFLLRN (5-50 nmol/min), bradykinin (30-300 pmol/min) and sodium
nitroprusside (2-8 microg/min) were co-infused with either saline placebo or TEA
(1 mg/min) on either of two visits using a randomised double-blind crossover design.
Again, agonists were co-infused with intra-arterial tirofiban (1.25 pg/min), which was
continued throughout the study. At the dose used, TEA is a non-selective potassium
channel antagonist [Champion and Kadowitz, 1997; Honing et al, 2000; Inokuchi el al,
2003],
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Protocol 5: Role of Endothelium-Dependent Vasodilators in PAR-1 Induced
Vasodilatation
In the final series of studies, TEA or saline placebo was co-infused with ascending doses
of bradykinin and SFLLRN in eight volunteers using a randomised double-blind
crossover design. In this series, EDHF activity was isolated by inhibiting NO and PGI2
production on both visits. The 'nitric oxide clamp' was employed as described above
(Protocol 3), and cyclooxygenase activity was inhibited with a single 600 mg dose of
oral aspirin 1 hour prior to each study.
Blood Sampling
Seventeen-gauge venous cannulae were inserted into left and right antecubital
fossae. Blood samples were drawn simultaneously from each arm at baseline. Blood
samples were also drawn before SFLLRN or bradykinin infusion and after each dose
of SFLLRN or bradykinin. Blood was collected into acidified buffered citrate
(Stabilyte, Biopool International, UK; for t-PA assays) and into citrate (BD
Vacutainer, BD UK Ltd, UK; for PAI-1, beta thromboglobulin and vWF assays).
Samples were kept on ice before centrifugation at 2000 g for 30 minutes at 4°C.
Platelet-free plasma was decanted and stored at -80°C before assay. Plasma t-PA
antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Austria), PAI-1
antigen and activity (Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity; Hyphen
Biomed, France), beta thromboglobulin (Asserachrom Btg, Diagnostica Stago,
France) and vWF (Dako, Glostrup, Denmark) concentrations were determined by
enzyme-linked immunosorbant assays. Full blood count was measured at baseline
and at the end of the study.
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5.3.5 Data analysis and statistics
Dorsal hand venous [Haynes et al, 1995] and forearm plethysmographic [Newby et al,
1997a] data were analysed as described previously. Variables are reported as
means±SEM and analysed using repeated measures ANOVA with post-hoc Bonferroni
corrections and two-tailed Students /-test as appropriate. Statistical analysis was
performed with GraphPad Prism (Graph Pad Software) and statistical significance taken
at the 5% level.
5.4 RESULTS
5.4..1 Endothelium and par-i induced venocqnstrictiqn
The role of the endothelium in PAR-1 induced vasomotor effects was assessed by
comparing venous responses before and after local endothelial denudation. This was
achieved through brief instillation of distilled water in an isolated dorsal hand vein
segment. After preconstriction with norepinephrine, the presence or absence of
functional endothelium was confirmed by the co-infusion of acetylcholine (1 nmol/min).
Acetylcholine caused venodilatation in the presence of endothelium and
venoconstriction in its absence (Figure 5.1; from 35±4% to 55±7% in the presence of
endothelium v.v. 33±7% to 18±6% in the absence of endothelium; P<0.01 for both,
ANOVA). After endothelial denudation, there appeared to be a trend toward enhanced
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Figure 5.1 Dorsal hand vein responses to acetylcholine and SFLLRN (after preconstriction with
norepinephrine) Before (closed triangles) and after (open triangles) endothelial denudation.
*P<0.05 and NS=non-significant (P=0.09); presence vs. absence ofthe endothelium; Analysis ofvariance
(ANOVA).
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5.4.2 ENDOTHELIUM-DERIVED VASODILATORS AND PAR-1 INDUCED VASODILATATION
SFLLRN caused an increase in FBF that was unaffected by PGI2 inhibition with oral
aspirin (600 mg; Figure 5.2A). The NO synthase inhibitor, L-NMMA, caused -50%
decrease in basal FBF from 3.04±0.37 to 1.49±0.19 mL/100mL tissue/min; PO.OOl.
Intra-brachial sodium nitroprusside (90-900 ng/min), an exogenous NO donor, was
titrated to restore FBF back to baseline levels (2.77±0.24 mL/100mL tissue/min; P=0.46
clamp dose SNP vs. baseline; paired Student's t-test). The inhibition of endogenous NO
synthesis by the 'nitric oxide clamp' attenuated SFLLRN-induced vasodilatation
(Figure 5.2B).
Potassium channel antagonism with TEA (1 mg/min) did not affect baseline blood flow
(P=0.76; data not shown). It attenuated vasodilatation to SFLLRN (Figure 5.2C) whilst
the combination of PGI2, NO synthase and potassium channel inhibition appeared to
abolish SFLLRN-induced vasodilatation (Figure 5.2D).
Both with and without concurrent NO synthase and PGI2 synthase inhibition, TEA
attenuated, but did not abolish arterial vasodilatation to the control endothelium-
dependent vasodilator, bradykinin (Figure 5.3A and 5.3B). Tetraethylammonium ion did
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Figure 5.2 SFLLRN-induced forearm arterial vasodilatation. In the presence (closed symbols) and
absence (open symbols) of A) aspirin (squares); NS=non-significant (P=0.53) in the presence v.v. the
absence ofaspirin; Analysis ofvariance (ANOVA), B) the 'nitric oxide (NO) clamp' (circles); *P<0.0001
in the presence vs. the absence of the 'NO clamp' (ANOVA), C) tetraethylammonium (TEA) (triangles);
fP<0.05 in the presence v.s\ the absence of TEA (ANOVA), and D) aspirin, the 'NO clamp' and TEA
(diamonds).


























































Figure 5.3 Bradykinin- and sodium nitroprusside-induced forearm arterial vasodilatation. Forearm
arterial vasodilatation induced by (A) bradykinin (squares), (B) bradykinin in the presence of the 'nitric
oxide clamp' and aspirin (circles) and (C) sodium nitroprusside (diamonds), in the presence (closed
symbols) and absence (open symbols) oftetraethylammonium (TEA).
*P<0.05, fP=0.0001, NS=non-significant (P=0.41) in the presence vs. the absence of TEA, analysis of
variance (ANOVA).
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5.4.3 ENDOTHELIUM-DERIVEl) VASODILATORS AND PAR-1 INDUCED RELEASE OF
FIBRINOLYTIC, COAGULANT AND PLATELET FACTORS
SFLLRN increased net t-PA antigen and activity and PAI-1 antigen release but did not
affect net PAI-1 activity (Figure 5.4). This increase was augmented by the 'nitric oxide
clamp' (Figure 5.4) but not affected by aspirin or TEA (data not shown; P=NS,
ANOVA). Bradykinin caused a dose-dependent increase in net t-PA antigen (P<0.05,
ANOVA) and activity (PO.OOOl, ANOVA) release but did not affect PAI-1 antigen and
activity release (P=NS for both, ANOVA). TEA did not alter bradykinin induced PAI-1
or t-PA release (P=NS for both, ANOVA). Unpaired analysis between the two subject
groups (Protocol 4 v.v. Protocol 5) suggests that the 'nitric oxide clamp' did not alter
bradykinin-induced t-PA or PAI-1 release (P=NS for all, ANOVA). Neither bradykinin
nor SFLLRN affected vWF release (data not shown; P=NS, ANOVA). SFLLRN
increased beta-thromboglobulin (PO.OOl, ANOVA) that was augmented during the
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Figure 5.4 SFLLRN-induced tissue type plasminogen activator and plasminogen activator inhibitor
release. Net tissue plasminogen activator (t-PA; squares) and plasminogen activator inhibitor type 1
(PAI-1; circles) antigen (solid lines) and activity (dashed lines) in response to intra-brachial SFLLRN in
the presence (closed symbols) and absence (open symbols) of the 'nitric oxide (NO) clamp
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Figure 5. 5 SFLLRN-induced beta-thromboglobulin release. In the presence (closed circles) and absence
(open circles) of the 'nitric oxide (NO) clamp
*P<0.01 net beta-thromboglobulin release induced by SFLLRN (50 nmol/min) in the presence vs. the
absence ofthe 'NO clampanalysis ofvariance (ANOVA).
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5.5 DISCUSSION
Thrombin is one of the most powerful physiological agonists in the cardiovascular
system and its actions are fundamental to the processes of atherothrombosis. In a series
of studies, we have here described the contrasting role of the endothelium in the PAR-1
mediated vascular actions of thrombin in vivo in man. Whilst not providing a major
contribution to venoconstriction or PAI-1 release, the endothelium mediates PAR-1
induced arterial vasodilatation and t-PA release. Our findings provide clear evidence of
a major interaction between the vascular endothelium and thrombin in vivo in man.
Furthermore, it highlights the critical importance of endothelial function at the time of
acute arterial injury and intravascular thrombosis, such as during acute coronary
syndromes.
5.5.1 Rolf of the endothelium in par-i induced vasomotion
The unexpected finding of PAR-1 induced venoconstriction in man has previously been
described by [Gudmundsdottir et al, 2006]. Whilst not caused by platelet aggregation
[Gudmundsdottir et al, 2006], this effect could be mediated by either a direct action on
vascular smooth muscle or via the release of endothelium-derived vasoconstrictors, such
as endothelin or angiotensin II. To address this question, we assessed PAR-1
venoconstriction before and after endothelial denudation by instillation of distilled
water. There was a modest trend towards enhanced venoconstriction after endothelial
denudation and we cannot exclude a small contribution from the endothelium that may
also include the release of venodilatory mediators such as NO. Flowever, PAR-1
continued to induce a marked dose-dependent venoconstriction even in the absence of
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the endothelium suggesting a dominant and direct effect of PAR-1 on the vascular
smooth muscle cells.
In contrast to effects on the venous circulation, PAR-1 agonism causes potent arterial
vasodilatation. This suggests a different effect on the arterial vasculature that is likely to
be mediated by the endothelium. It would be difficult and ethically challenging to
conduct comparable in vivo endothelial denudation studies in the arterial circulation of
man. We chose, therefore, to use a pharmacological approach to the inhibition of the
three main known mediators of endothelium-dependent vasodilatation: PGI2, NO and
EDHF. Although PGI2 inhibition appeared to have no effect, inhibition of NO and
potassium channels both attenuated the PAR-1 induced vasodilatation. Consistent with
some cross-talk and compensatory up-regulation, combined inhibition of all vasodilator
mechanisms appeared to produce greater inhibition, if not abolition, of the vasodilator
actions of PAR-1 agonism. This suggests that, unlike the venous circulation, PAR-1
mediated arterial actions are dominated by, and dependent upon, the vascular
endothelium.
5.5.2 PAR-1 INDUCED RELEASE OF ENDOTHELIUM-DERIVED FACTORS
In addition to vasomotion, PAR-1 has important effects on the release of endothelium-
derived coagulant and fibrinolytic factors. In keeping with a wide range of other
endothelial G-protein coupled receptor dilator agonists [Oliver et al, 2005], we
confirmed earlier findings that PAR-1 agonism causes endothelial t-PA release without
affecting vWF. However, we also report here that SFLLRN-induced t-PA release
appeared to be augmented by the inhibition of endogenous NO production. Smith et al
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[Smith et al, 2003] have reported similar findings when they examined bradykinin
evoked t-PA release in the presence and absence of L-NMMA. Because t-PA release is
independent of NO and cyclooxygenase activity, it has been suggested that EDHF is
responsible for its release [Brown et al, 2000], One could speculate that, by inhibiting
NO activity, EDHF is up-regulated and accounts for the augmented t-PA release induced
by SFLLRN in our study and by bradykinin in Smith's study. However, in contrast to
TEA's inhibitory effects on SFLLRN-induced arterial vasodilatation, it had no effect on
SFLLRN evoked t-PA release. Similar findings have recently been reported by
Muldowney and colleagues [Muldowney et al, 2007] who examined the role of EDHF in
an in vitro model of thrombin-induced endothelial t-PA release. A variety of potassium
channel antagonists, including TEA, had no effect on thrombin-induced t-PA release
whilst antagonists of specific epoxyeicosatrienoic acids appeared to inhibit thrombin-
induced release of t-PA.
One further novel finding in our study was the increase in PAI-1 release, especially
during NO synthase inhibition. To date, there have been no reports of acute increases in
plasma PAI-1 concentrations following the administration of endothelial agonists,
especially using the forearm model [Oliver et al, 2005]. Whilst the endothelium is an
important source of PAI-1, we believe our findings are consistent with acute platelet
release of PAI-1. There are several reasons to support our contention. First, although
PAI-1 antigen concentrations increased, there was no corresponding rise in PAI-1
activity. Indeed, PAI-1 activity fell during marked release of t-PA. Plasminogen
activator inhibitor type 1 is stored in platelet a-granules where its activity is very low
(<5% of the activity seen in plasma) due to the absence of the stabilising effect of
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vitronectin. In contrast, endothelial-derived PAI-1 would be anticipated to remain active.
Second, there was no concurrent rise in vWF confirming a selective effect on the
endothelium with isolated t-PA release. Third, we also demonstrated the concomitant
release of beta-thromboglobulin which is also stored in the a-granules of platelet.
Finally, PAR-1 induced PAI-1 release was augmented during the 'nitric oxide clamp'.
Nitric oxide has important anti-platelet effects and, in the presence of its inhibition,
increased platelet activation may have led to greater PAI-1 release.
5.5.3 Clinical relevance
Until recently, it has not been possible to undertake a safe clinical assessment of the
vasomotor effects of thrombin due to its potent stimulatory effects upon the coagulation
cascade. However, the synthetic activating peptide, SFLLRN, allows the examination of
activation of the human PAR-1 thrombin receptor without activation of the coagulation
cascade. This also permits the assessment of PAR-1 actions independent of the potential
confounding effects that the activated coagulation pathway may have upon vascular
responses.
We have demonstrated that many of the arterial effects of PAR-1 agonism are dependent
upon, and mediated through, the endothelium and can therefore be used to assess
endothelial function. To date, many endothelial G-protein coupled receptor agonists
have been used to assess endothelial function, such as acetylcholine and substance P.
However, such agents are unlikely to have a major role in vascular physiology or
pathophysiology and, as pharmacological tools, their relevance to the assessment of
endothelial vasomotor function has limitations. As a more physiologically relevant tool,
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PAR-1 agonism may be a more appropriate method of assessing endothelial function in
the context of atherothrombosis. These novel insights into the vascular actions of PAR-1
agonism will not only contribute to our understanding of human physiology and
pathophysiology but also promises to inform the clinical development of novel
antithrombotic PAR-1 receptor antagonists.
5.5.4 Study limitations
We chose to use SFLLRN as a PAR-1 agonism for several reasons. First, the vast
majority of published work has employed SFLLRN as a PAR-1 activating peptide and
its actions have been widely characterised. Second, we have previous clinical experience
of the in vivo actions of SFLLRN and this has facilitated the comparability of our
current findings with our previous 'first-into-man' clinical studies. Finally, SFLLRN is
identical to the active cleaved sequence of the human PAR-1 receptor and represents a
more physiologically relevant agonist of the receptor.
Whilst SFLLRN is selective for the PAR-1 receptor, it does have agonist activity at the
PAR-2 receptor: 4-fold greater selectivity for the PAR-1 v,v. PAR-2 receptor [Kawabata
et al, 1999], Therefore, there remains a possibility that a contribution of the observed
actions of SFLLRN may represent PAR-2 agonism. Fiowever, we do not believe this is
likely for several reasons. First, Gudmundsdottir et al have previously shown that
SLIGKV, a highly selective PAR-2 activating peptide, causes only modest arterial
vasodilatation at high doses and, in contrast to PAR-1 activation, causes marked
venodilatation and does not cause arterial t-PA release in vivo [Gudmundsdottir et al,
2006], Moreover, the predicted end-organ concentration of the highest dose of SFLLRN
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used in our current and previous studies is 4-fold lower than the EC50 for the PAR-2
receptor [Kawabata et al, 1999]. However, we do accept that, in future studies,
consideration should be given to the use of the more selective PAR-1 activating peptide,
TFLLRN [Kawabata et al, 1999; Ossovskaya and Bunnett, 2004],
The role of NO in bradykinin-induced t-PA release remains controversial [Oliver et
al, 2005] and the present study has not definitively addressed this issue. Whilst NO
donors do not induce t-PA release [Newby et al, 1997b; Stein et al, 1998], inhibition
of NO synthesis has been reported either to have no effect [Smith et al, 2003], or to
increase [Brown et al, 2001], bradykinin-induced t-PA release. Our own unpaired
analysis of data from different subject populations is in keeping with the findings of
Nancy Brown's group [Brown et al, 2001] and suggests that bradykinin-induced
t-PA release is unaffected by either NO or PGI2 inhibition. Further research into the
pathways involved in bradykinin-induced t-PA release is needed to clarify the role of
NO and other potential mediators.
5.6 CONCLUSION
Activation of PAR-1 causes contrasting effects in the human vasculature. It causes
endothelium-dependent arterial vasodilatation and t-PA release as well as
endothelium-independent venoconstriction and PAI-1 release. There appears to be a
major interaction between the vascular endothelium and thrombin's PAR-1 mediated
effects in vivo in man. This highlights the critical importance of endothelial function
particularly at the time of acute arterial injury and intravascular thrombosis, such as
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6.1 SUMMARY
The objective of this study was to test the hypothesis that cigarette smoking
adversely alters PAR-1 mediated vascular effects in vivo in man. Forearm blood flow
was measured by venous occlusion plethysmography in 12 cigarette smokers and 12
age- and sex-matched non-smokers during intra-brachial infusions of PAR-1
activating peptide (SFLLRN; 5-50 nmol/min), bradykinin (100-1000 pmol/min) and
sodium nitroprusside (2-8 pg/min). Plasma tissue plasminogen activator and PAI-1
antigen and activity concentrations were measured at intervals throughout. All
agonists caused dose-dependent increases in FBF (P0.0001 for all). Whilst
bradykinin and sodium nitroprusside caused similar vasodilatation, SFLLRN-
induced vasodilatation was attenuated in smokers (P=0.04). Smokers had modest
reductions in bradykinin-induced active t-PA release (reduced by 37%, P=0.03) and
had a marked impairment of SFLLRN-induced t-PA antigen (P=0.02) and activity
(P=0.006) release, with a 96% reduction in overall net t-PA antigen release.
SFLLRN also caused similar (P=NS) increases in inactive PAI-1 in both cigarette
smokers and non-smokers (P<0.002 for both). These results demonstrate that
cigarette smoking causes marked impairment of PAR-1 mediated endothelial
vasomotor and fibrinolytic function. Relative arterial stasis and near abolition of
t-PA release will strongly promote clot propagation and vessel occlusion. These
findings suggest a major contribution of impaired endothelial PAR-1 action to the
increased atherothrombotic risk of cigarette smokers.
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6.2 INTRODUCTION
Smoking tobacco remains one of the most important and consistent modifiable risk
factors for myocardial infarction and fatal coronary artery disease [Ambrose and
Barua, 2004], The recent INTERHEART study revealed that smoking tobacco
increases the risk of non-fatal myocardial infarction by up to 7-fold [Teo et al, 2006].
The pathophysiological mechanisms underlying this association are likely to be a
combination of accelerated atherosclerosis [Zieske et al, 2005] and a propensity to
acute coronary thrombosis [Burke et al, 1997; Ambrose and Barua, 2004].
The endogenous fibrinolytic system is responsible for the dissolution of arterial
thrombi that are frequently found on the surface of atherosclerotic plaques at areas of
endothelial denudation [Davies et al, 1988; Oliver et al, 2005]. It is regulated by the
pro-fibrinolytic factor, t-PA, and its endogenous inhibitor, PAl -1 [Jansson et al,
1993; Meade et al, 1993; Nordenhem et al, 2005], The rapid mobilisation of t-PA
from the endothelium is crucial, with thrombus dissolution being much more
effective if t-PA is incoiporated during, rather than after, thrombus formation [Fox et
al, 1985], Indeed, acute stimulated t-PA release predicts the future risk of
cardiovascular events [Robinson et al, 2007],
Thrombin plays a central role in the coagulation cascade and thrombosis. It is one of the
most powerful physiological agonists in the cardiovascular system and its actions are
fundamental to the processes of atherothrombosis. Distinct from its enzymatic role in the
coagulation cascade, thrombin causes direct cellular activation through stimulation of a
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novel family of G-protein coupled receptors, protease-activated receptors [Coughlin,
2000],
Protease activated receptor type 1 is the principal receptor that mediates the
cardiovascular actions of thrombin. The hexapeptide, SFLLRN, represents the short
peptide sequence revealed during PAR-1 activation and can be used as a selective
agonist of the human PAR-1 thrombin receptor without activation of the coagulation
cascade. Using SFLLRN, it has been have shown that acting via PAR-1 thrombin has
unique and contrasting effects in the human vasculature including arterial dilatation,
venous constriction, platelet activation and t-PA release [GuQmundsdottir et al, 2006].
Pharmacological stimulation of acute t-PA release in the peripheral [Newby et al, 1999;
Pretorius et al, 2002] and coronary [Newby et al, 2001; Takashima et al, 2007] arterial
circulations is markedly attenuated in smokers. In this study we hypothesised that
smokers have impaired PAR-1 mediated vascular responses. We, therefore, examined
PAR-1 mediated t-PA release and vasomotor responses in the forearm circulation of
cigarette smokers and healthy non-smoking control subjects.
6.3 MATERIALS AND METHODS
6.3.1 Subjects
Twelve healthy cigarette smokers (5-20 cigarettes/day) and 12 age- and sex-matched
non-smokers between 20 and 46 years old participated in the study, which was
undertaken with the approval of the local Research Ethics Committee and in
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accordance with the Declaration of Helsinki. The written informed consent of each
subject was obtained before entry into the study. Exclusion criteria included a history
of asthma, hypertension, diabetes mellitus, coagulopathy, hyperlipidaemia or
vascular disease. Control subjects were lifelong non-smokers and were not exposed
to regular environmental tobacco smoke. Smokers had a history of regular daily
cigarette smoking of at least 5 years and maintained their normal smoking habits in
the week before attendance.
None of the subjects received vasoactive or non-steroidal anti-inflammatory drugs in
the week before the study, and all abstained from alcohol for 24 hours before and
from food, tobacco, and caffeine-containing drinks on the day of the study. All
studies were performed in a quiet, temperature controlled room maintained at 22°C
to 24°C.
6.3.2 Arterial drug administration
All subjects underwent brachial artery cannulation with a 27-gauge standard wire
steel needle. The intra-arterial infusion rate was kept constant at 1 mL/min
throughout all studies. Forearm blood flow was measured in the infused and non-
infused arms by venous occlusion plethysmography using mercury-in-silastic strain
gauges as described previously [Newby et al, 1997a; Newby et al, 1999]. Supine
heart rate and blood pressure were monitored at intervals throughout each study
using a semi-automated non-invasive oscillometric sphygmomanometer.
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After a 20-minute intra-arterial infusion of 0.9% saline, the glycoprotein Ilb/IIIa
antagonist, tirofiban (1.25 pg/min; Merck, Sharp and Dohme, Hoddesdon, UK), was
infused and continued throughout the study to inhibit potential PAR-1 induced
platelet aggregation. This dose of tirofiban does not affect FBF [Gudmundsdottir et
al, 2006].
During tirofiban administration, subjects received intra-arterial infusions of the
PAR-1 activating peptide, SFLLRN (5, 15 and 50 nmol/min; Clinalfa, Laufelfingen,
Switzerland), bradykinin (an endothelium-dependent vasodilator that causes the
release of t-PA; 100, 300 and 1000 pmol/min; Clinalfa) and sodium nitroprusside (an
endothelium-independent vasodilator that does not release t-PA; 2, 4 and 8 pg/min;
David Bull Laboratories, Warwick, UK). Study drags were infused in random order
for 10 minutes at each dose and were separated by a 20-minute infusion of 0.9%
saline.
Blood Sampling
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossae of both arms. Blood samples were drawn simultaneously from
each arm at the beginning of the study and during infusion of each dose of PAR-1
activating peptide (SFLLRN), bradykinin and sodium nitroprusside. Venous blood
was collected into acidified buffered citrate (Stabilyte, Trinity Biotech Pic, Co.
Wicklow, Ireland; for t-PA assays) and into citrate (BD Vacutainer, BD UK Ltd,
Oxford, UK; for PAI-1 and vWF assays). Samples were kept on ice before
centrifugation at 2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and
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stored at 80°C before assay. Plasma t-PA antigen and activity (t-PA Combi Actibind
Elisa Kit, Technoclone, Vienna, Austria), PAI-1 antigen and activity (Elitest PAI-1
antigen and Zymutest PAI-1 Activity, Hyphen Biomed, Neuville-Sur-Oise, France)
and vWF antigen (Dako A/S, Glostrup, Denmark) concentrations were determined
by enzyme-linked immunosorbant assays. Full blood count and haematocrit were
measured at baseline and the end of the study.
63.3 Data analysis and statistics
Forearm plethysmographic data were analysed as described previously [Newby et al,
1997a], Estimated net release of plasma t-PA, PA-1 and vWF has been defined
previously as the product of the infused forearm plasma flow (based on the mean
haematocrit and the infused forearm blood flow) and the concentration difference
between the infused and non-infused arms [Newby et al, 1997b], Variables are reported
as mean±SEM and analysed using repeated measures ANOVA and two-tailed Students
t-test as appropriate. Statistical analysis was performed with GraphPad Prism (Graph
Pad Software) and statistical significance taken at the 5% level.
6.4 RESULTS
There were no differences in baseline characteristics between cigarette smokers and
non-smokers (Table 6.1). There were no changes in blood pressure, heart rate or
haematocrit (data not shown) during the study. Smokers had a mean cigarette
consumption of 15±1 cigarettes per day over a mean period of 9±2 years (7+1 pack
years).
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6.4.1 Forearm blood flow
Tirofiban did not affect FBF (data not shown). Intra-arterial sodium nitroprusside,
bradykinin and the PAR-1 activating peptide, SFLLRN, all caused dose-dependent
vasodilatation in the infused arm of smokers and non-smokers (PO.OOOl for all,
ANOVA). There were no changes in blood flow in the non-infused arm (data not
shown).
Although there was no difference with bradykinin (P=0.64, ANOVA smokers vs.
non-smokers), vasodilatation to SFLLRN was attenuated in smokers (P=0.044,
ANOVA smokers v.v. non-smokers). Endothelium-independent vasodilatation evoked
by sodium nitroprusside was similar in both groups (P=0.74, ANOVA smokers v.y.
non-smokers; Figure 6.1).
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Table 6.1 Baseline subject characteristics
Non-smokers Smokers
Age, y 26±2 29±2
Sex, M/F 12/0 12/0
•j
Body mass index, kg/m 24±1 27±1
Mean arterial pressure, mm Hg 97±2 99±2
Heart rate, bpm 66±2 64±2
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Figure 6.1 Forearm arterial vasodilatation in smokers and non-smokers. Forearm arterial
vasodilatation induced by SFLLRN (squares), bradykinin (circles) sodium nitroprusside (triangles) in
smokers (closed symbols) and non-smokers (open symbols).
*P<0.05, NS=non-significant; Analysis ofvariance (ANOVA), smokers v.s\ non-smokers).
6.4.2 Plasma fibrinolytic and haemostatic factors
Baseline plasma t-PA antigen and activity (Table 6.2) and vWF antigen (data not
shown) concentrations were similar in smokers and non-smokers. There appeared to
be a trend towards higher absolute plasma PAI-1 antigen and activity concentrations
in smokers but this difference did not reach statistical significance (smokers vs. non-
smokers: PAI-1 antigen, P=0.07 and P=0.10, and PAI-1 activity, P=0.18 and P=0.24;
infused and non-infused arms respectively; Table 6.3).
SFLLRN caused a dose-dependent net release of t-PA antigen in non-smokers
(P<0.0005, ANOVA) but not smokers (P=0.18, ANOVA; Figure 6.2). In comparison
to non-smokers, the release of t-PA antigen and activity by SFLLRN was markedly
attenuated in smokers (P=0.02 and P=0.006, respectively, ANOVA). However,
SFLLRN induced a dose-dependent net release of PAI-1 antigen release in both non-
smokers (P=0.0002, ANOVA) and smokers (P=0.0Q1, ANOVA). The response was
similar in both groups (P=0.36, ANOVA) and was associated with no change in net
PAI-1 activity or vWF antigen release (P=NS for all, ANOVA [data not shown]).
Bradykinin caused a dose-dependent net release of t-PA antigen and activity in both
smokers and non-smokers (P<0.01 for all, ANOVA). Bradykinin also evoked a dose-
dependent increase in absolute t-PA activity in the non-infused arm of both non-
smokers (PO.OOOl, ANOVA) and smokers (P=0.008, ANOVA). Net release of t-PA
activity induced by bradykinin was less in smokers than non-smokers (P=0.032,
smokers vs. non-smokers, ANOVA; Figure 6.2). Bradykinin caused no change in net
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Figure 6.2 Net release of tissue plasminogen activator (t-PA) in smokers and non-smokers. Net
t-PA antigen (circles) and activity (squares) release induced by SFLLRN (top panels) and bradykinin
(bottom panels) in smokers (closed symbols) and non-smokers (open symbols).
*P<0.05, fP=0.005, NS=non-significant; Analysis ofvariance (ANOVA), smokers vs. non-smokers).
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PAI-1 antigen or activity and did not affect vWF antigen in either group (P=0.91,
non-smokers; P=0.98 non-smokers, ANOVA). As expected [Brown et al, 1999]
sodium nitroprusside caused no change in absolute or net release of t-PA, PAI-1 or
vWf (data not shown).
6.5 DISCUSSION
We have shown, for the first time, that thrombin-mediated vascular responses are
markedly impaired in cigarette smokers with a substantial reduction in PAR-1
mediated endothelial t-PA release and forearm arterial vasodilatation. This impaired
vasomotor and fibrinolytic response may represent an important shift in the fine
balance between intravascular thrombosis and fibrinolysis that could account for the
increased incidence of atherothrombosis in cigarette smokers.
6.5.1 Smoking and par-i induced arterial vasomotion
As reported by others [Pretorius et al, 2002], we observed no effect of smoking
status on endothelium-dependent vasodilatation to bradykinin or endothelium-
independent vasodilatation to sodium nitroprusside. One of the important novel
observations from our study is that vasodilatation evoked via PAR-1 is impaired in
smokers, especially at the higher doses of SFLLRN. Because homeostatic
mechanisms attempt to maintain vessel patency and minimise intravascular thrombus
formation in healthy arteries, we have previously hypothesised the arterial
vasodilatation to PAR-1 activation represents a protective feedback mechanism. In
the presence of a developing thrombus, PAR-1 mediated vasodilatation will increase
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blood flow to limit arterial thrombosis by facilitating its rapid clearance and
dissolution [GuQmundsdottir et al, 2006]. Thus, this specific impairment of PAR-1
induced vasodilatation may have major pathophysiological consequences during
acute thrombotic events such as myocardial infarction.
6.5.2 Smoking and par-i induced release of endothelium-derived
factors
Over and above diminished vasomotion, the major finding of our study was the
almost complete abolition of PAR-1 mediated t-PA antigen release in cigarette
smokers. Furthermore, PAR-1 activation caused only a very modest rise in t-PA
activity despite causing substantial t-PA antigen and activity release in non-smokers.
The current findings confirm previous studies from our own and other groups
reporting reduced t-PA release in cigarette smokers [Newby et al, 1999; Pretorius et
al, 2002; Takashima et al, 2007]. Although not seen with t-PA antigen, the present
finding of reduced bradykinin-induced active t-PA release is consistent with similar
observations previously reported by Pretorius et al [Pretorius et al, 2002], However,
the magnitude of the reduction in t-PA release is substantially greater for PAR-1
evoked responses than it is for bradykinin or substance P (96% vs. 40-50%) [Newby
et al, 1999; Pretorius et al, 2002]. We would therefore argue that SFLLRN-evoked
t-PA release has the potential to be a more sensitive and pathophysiologically
relevant assessment of endothelial vasomotor and fibrinolytic function.
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Of note, PAR-1 activation also caused the release of PAI-1 antigen but did not cause
an appreciable rise in PAI-1 activity and neither indices were altered by smoking
status. This rise in PAI-1 antigen without a change in activity suggests that SFLLRN
is releasing PAI-1 from platelets rather than the endothelium since platelet-derived
PAI-1 is relatively inactive due to the absence of the stabilising effects of vitronectin
[Seiffert et al, 1994; Pretorius et al, 2002]. Furthermore, recent work has
demonstrated a concomitant rise in beta-thromboglobulin suggesting degranulation
of platelet alpha granules [GuQmundsdottir et al, 2007], Therefore, the contribution
of the endogenous fibrinolytic system to the prothrombotic state found in cigarette
smokers is likely to be driven by impaired endothelial t-PA release and not by
alterations in PAI-1 release or activity.
6.5.3 PAR-1 ACTIVATION AS A PATHOPHYBIOLOGICALLY RELEVANT MARKER OF
ENDOTHELIAL FUNCTION
Previous studies to assess the endothelial release of endogenous fibrinolytic factors
have employed diverse methods. Flistorical means of stimulating t-PA release have
included systemic intravenous infusion of desmopressin and bradykinin but this
causes significant confounding effects by altering systemic haemodynamics,
activation of the sympathetic nervous system and concomitant release of other
mediators [Oliver et al, 2005], By assessing the regional release of t-PA and PAI-1 in
response to locally acting agonists, such confounding effects are avoided.
We have previously demonstrated that substance P-induced t-PA release in the
peripheral [Newby et al, 1999] and coronary [Newby et al, 2001] circulations is
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impaired in cigarette smokers, and predicts future adverse cardiovascular events in
patients with coronary heart disease [Robinson et al, 2007]. However, whilst
substance P has been a useful pharmacologic tool, it is unclear whether it is likely to
act as a major pathophysiological mediator in atherothrombosis. In contrast,
bradykinin may have a more direct role since it is released during the contact phase
of coagulation and there is enhanced activation of the kallikrein system and
bradykinin release in patients with acute coronary syndromes [Hoffmeister et al,
1995], However, we would argue that, given its central role in thrombosis and
inflammation, thrombin is the most powerful and pathophysiologically relevant
mediator in this setting. Our present results not only reinforce previous findings but
give the clearest indication yet that impaired endothelial function is of critical and
dynamic importance in the setting of coronary heart disease and acute coronary
syndromes.
6.5.4 Smoking and endothelium-dependent mechanisms
We have previously demonstrated that PAR-1 mediates arterial vasodilatation via
two endothelium-dependent mechanisms, namely NO and EDHF [GuQmundsdottir et
al, 2008]. The pathways via which PAR-1 activation causes the endothelial release of
t-PA are less clear and, in fact, inhibition of NO synthesis causes augmented
SFLLRN-induced t-PA release [Gudmundsdottir et al, 2008]. This has raised the
question as to whether EDHF is responsible for t-PA release and, in the absence of
NO, EDHF responses undergo a compensatory up-regulation. Whilst the bulk of
evidence suggests that smoking predominantly affects endothelial function by
increasing oxidative stress with consequent disruption of NO production
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[Kiowski et al, 1994; Puranik and Celermajer, 2003], studies specifically examining
the effect of smoking upon EDHF-mediated responses are lacking.
6.5.5 Study limitations
The forearm circulation has been an extremely reliable model for the assessment of
vascular physiology and pathophysiology. We do accept that our findings in the
forearm may not be accurately representative of the coronary circulation. However,
we and others have previously demonstrated consistent findings of impaired
endothelial t-PA release have been demonstrated in both the forearm [Newby et al,
1999; Pretorius et al, 2002] and coronary [Newby et al, 2001; Takashima et al, 2007]
circulations of cigarette smokers. Although the forearm vascular bed is relatively
protected from the development of atheroma, it therefore seems likely that changes
in its fibrinolytic capacity are indicative of the coronary circulation.
Establishing the receptor-mediated effects of thrombin in the vasculature is of major
physiological and therapeutic relevance. It could be argued that, in our studies, the
safety requirement for the co-administration of tirofiban with SFLLRN detracts from
these advantages. However, we used locally active doses of glycoprotein Ilb/IIIa
inhibitor that abolish SFLLRN-mediated platelet aggregation without affecting
platelet-monocyte binding, a sensitive marker of platelet activation. Furthermore, it
has no effect upon basal or fibrinolytic responses to SFLLRN [Gudmundsdottir et al,
2006], We therefore believe that SFLLRN remains an important and relevant tool to
assess these fundamental pathophysiological aspects of endothelial function.
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We have demonstrated an important impairment of fibrinolytic capacity in smokers
but it remains unclear whether this reflects an impairment of synthesis, storage and
release of t-PA, or indeed acceleration of its degradation. Addressing these questions
will be challenging and is likely to require specifically designed in vitro studies.
6.6 CONCLUSION
In healthy vessels, thrombin's powerful procoagulant and prothrombotic effects are
offset by its ability to evoke the release of t-PA and induce arterial vasodilatation.
We have shown here that cigarette smoking causes a marked impairment in PAR-1
mediated endothelial vasomotor and fibrinolytic function. Relative arterial stasis and
abolition of t-PA release will strongly enhance clot expansion and vessel occlusion.
Taken together, these findings suggest a major contribution of impaired endothelial
PAR-1 action to the increased atherothrombotic risk of smokers. These important
and novel findings are of direct relevance to our understanding of the
pathophysiology by which cigarette smoking causes an increased propensity to






The endothelium is crucial for the control of vascular function and for the
maintenance of vascular health. As such, it has been the subject of intense research
that has provided the detailed characterisation of some of its vital functions.
However, a large proportion of its actions and mediators remain unknown or
incompletely described - this is particularly true for EDHF. Consequently, EDHF
remains unmanipulated as a therapeutic target despite its involvement in a wide
variety of vascular diseases [Feletou and Vanhoutte, 2004], Furthermore, it has not
previously been possible to examine safely the in vivo interaction between
thrombotic factors and endothelium-derived mediators, including EDHF. The
elucidation of the mechanisms underlying this interaction are of great relevance not
only for our understanding of atherothrombotic processes but also to ensure the safe
and efficient development of novel drugs directed against PAR-1, the principal
thrombin receptor in man.
In this thesis, I have assessed thrombotic and endothelium-derived factors in the
mediation of vasomotion and endogenous fibrinolysis in man. Specifically, I have
examined the role of gap junctions and connexins in the EDHF mechanism and have
explored the role of EDHF in the mediation of t-PA release. Using a PAR-1
activating peptide, I have assessed the endothelial mechanisms via which thrombin
evokes its vascular effects. Having demonstrated a major interaction between PAR-1
and endothelium-derived factors, I investigated the consequences of cigarette
smoking upon vascular responses to PAR-1 activation.
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7.2 GAP JUNCTIONS AND EDHF-MEDIATED VASODILATATION
7.2.1 Gap junction blockade with connexin mimetic peptides
I have confirmed that EDHF accounts for approximately 50% of bradykinin-induced
vasorelaxation in subcutaneous resistance arteries from pregnant women. Previous
studies using early putative gap junction blockers suggested a role for gap junctions
in the human EDHF mechanism [Kenny et al, 2002; Gillham et al, 2003; Luksha et
al, 2004], However, these early gap junction antagonists have been associated with a
variety of non-specific effects and interpretation of those studies should be cautious
[Chaytor et al, 2000; Matchkov et al, 2004],
Using connexin mimetic peptides, I made the first robust examination of the role of
gap junctions and their connexin components in EDHF-mediated vasodilatation in
human resistance arteries. The specificity of the CMPs has previously been
demonstrated [Matchkov et al, 2006] and, in my study, they had no effect upon
vasorelaxation evoked by endothelium-independent agonists nor did they alter the
magnitude of constriction induced by norepinephrine. However, EDHF-mediated
vasodilatation was virtually abolished by the addition of a combination of CMPs
targeted against the three major vascular connexins (Cx37, Cx40 and Cx43) and
provides evidence for a central role of gap junctions in EDHF-mediated
vasodilatation in these human arteries. Incubation of vessels with individual CMPs
allowed the assessment of the role of single connexin subtypes in the mediation of
EDHF. Intriguingly, incubation with a single CMP targeting Cx43 virtually
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abolished EDHF-mediated vasodilatation whilst incubation with peptides targeted
against Cx37 and Cx40 was without effect. Therefore, despite immunohistochemical
evidence for the expression of the three principal vascular connexins, I have
demonstrated that only Cx43 is required for the mediation of EDHF in these human
vessels.
7.2.2 CX43 AND THE EDHF MECHANISM
The caesarean section incision margin allows ready access to human resistance
vessels that have frequently been used to further our understanding of human
physiology and, when present, the pathophysiology of pre-eclampsia [Kenny et al,
2002; Gillham et al, 2003]. It should be noted that normal pregnancy is associated
with a 50% rise in circulating blood volume that is accommodated, in part, by an up-
regulation of EDFIF. Similarly, Cx43 expression is increased under the influence of
oestrogen [Liu et al, 2002; Nawate et al, 2005]. It could be argued that these
physiologic changes render it difficult to extrapolate my findings to men and to non¬
pregnant women. Conversely, the observation that EDHF activity and Cx43 are up-
regulated simultaneously may represent further evidence of a central role for Cx43 in
EDHF-mediated vasodilatation.
Connexin 43 expression is consistently labile [Gabriels and Paul, 1998; Depaola et
al, 1999; Inai et al, 2004; Figueroa et al, 2006] and its expression and function are
particularly susceptible to alteration by pathophysiologic processes [Yeh et al, 1997;
Haefliger et al, 2006; Yeh et al, 2006], Whilst similar studies in a variety of animal
models and in a variety of vascular beds have demonstrated roles for Cx37 and Cx40
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in addition to Cx43 [De Vriese et al, 2002; Chaytor et al, 2003; Ujiie et al, 2003;
Chaytor et al, 2005], it remains conceivable that Cx43 acts as the principal
regulatory component of gap junction functionality in man. Therefore, understanding
the role of Cx43 in the EDHF mechanism is of particular interest not only to further
our understanding of physiology but also to identify it as a potential therapeutic
target. Novel strategies to improve endothelial function via the augmentation of
EDHF could herald a breakthrough in the treatment of a variety of vascular diseases.
However, their potential would be greatest in the treatment of conditions specifically
associated with impaired EDHF activity, such as pre-eclampsia [Kenny et al, 2002],
type I diabetes mellitus [Fukao et al, 1997; Wigg et al, 2001; Angulo et al, 2003] and
possibly hypertension [Fujii et al, 1993],
7.2.3 Potentiation of communication via connexin 43
Rotigaptide displays antiarrhythmic properties [Xing et al, 2003; Guerra et al, 2006;
Hemian et al, 2006; Shiroshita-1 akeshita et al, 2007] and acts by augmenting
communication via Cx43 [Axelsen et al, 2006; Clarke et al, 2006]. I obtained custom
synthesised rotigaptide and its biological activity was confirmed in an ex vivo
electrophysiological mapping system. In this model, it increased transmural cardiac
conduction velocity at a concentration similar to that predicted to be achieved in my
subsequent clinical study.
Using rotigaptide, I made the first assessment of the vascular effects of augmentation
of communication via Cx43 in man. Having demonstrated that Cx43 is required for
EDHF-mediated vasodilatation in human resistance arteries in vitro, it was
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hypothesised that rotigaptide would enhance EDHF-mediated vasodilatation by its
effects upon Cx43. However, I have shown that intra-arterial rotigaptide does not
alter basal vascular tone in the forearm arterial circulation of healthy volunteers.
Similarly, continuous intra-arterial administration of rotigaptide does not augment
endothelium-dependent agonist-induced vasodilatation, nor does it affect
endothelium-independent responses to sodium nitroprusside. Furthermore, these
findings remained consistent when the EDHF component of endothelium-dependent
vasodilatation was isolated by the inhibition of NO and PGI2 synthesis. Therefore, it
can be concluded that augmentation of communication via Cx43 with rotigaptide
does not enhance endothelial function in the forearm circulation of healthy
volunteers.
These findings should not be extended to imply that Cx43 is unimportant in the
human EDHF mechanism. In the healthy circulation, the open-state probability of
Cx43 is likely to be high and efforts directed to further opening of Cx43 may be
futile. However, the open-state probability of Cx43 is depressed by acidosis [Ek-
Vitorin et al, 1996] and rotigaptide's antiarrhythmic activity is more potent in
conditions of metabolic stress [Eloff et al, 2003], In vitro, the open-state probability
of Cx43 is depressed by hyperglycaemia [Inoguchi et al, 2001; Fernandes et al,
2004], lipopolysaccharide [Lidington et al, 2002] and during reperfusion after
ischaemia [Zhang et al, 1999]. It remains possible, although speculative at this point,
that rotigaptide augments EDHF-mediated vasodilatation in conditions of metabolic
stress including during hyperglycaemia or immediately following ischaemia.
Furthermore, it is unknown whether the enhancement of communication via Cx43 is
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an appropriate strategy for the treatment of endothelial dysfunction associated with a
wider range of pathophysiologic processes.
73 ENDOTHELIAL MEDIATORS OF VASCULAR PAR-1 RESPONSES
Thrombin is central to the pathophysiology of atherothrombosis. However, its potent
stimulatory effects upon the coagulation cascade have previously made it impossible
to safely examine its vascular effects in vivo in man. However, PAR-1 has been
identified as thrombin's major cellular receptor [Vu et al, 1991] and the therapeutic
potential of PAR-1 antagonists is currently being assessed in clinical trials [Husted,
2007]. My colleagues have previously demonstrated that SFLLRN, a synthetic PAR-
1 activating peptide, causes venoconstriction, arterial vasodilatation and t-PA release
in vivo in man [GuSmundsdottir et al, 2006], In this thesis, I have assessed the role of
the endothelium in the mediation of these effects.
SFLLRN caused constriction of the dorsal hand vein in both the presence and
absence of local endothelium. Therefore, it can be concluded that venoconstriction
evoked by PAR-1 activation is mediated by smooth muscle PAR-1 receptors and not
via the release of endothelium-derived vasoconstrictors such as endothelin or
angiotensin II.
In contrast, I have demonstrated that PAR-1 activation causes arterial vasodilatation
via an endothelium-dependent mechanism. I have shown that PAR-1 activation does
not evoke a discernible PGL-dependent vasodilator response. However, using TEA
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and 'the nitric oxide clamp' I have demonstrated major contributions from both
EDHF and NO, respectively. These findings are consistent with data from in vitro
studies [Hamilton et al, 1998; Hamilton et al, 2001; Kawabata et al, 2004a;
Kawabata et al, 2004b] and illustrate the importance of an intact endothelium for the
arterial vasculature to respond to the presence of thrombin. In the presence of
developing thrombus, arterial vasodilatation may represent an important safety
mechanism for the dispersal of thrombus whilst the associated endothelial release of
fibrinolytic factors causes its dissolution [GuSmundsdottir et al, 2006].
7.4 ENDOTHELIUM-DERTVED HYPERPOLARISING FACTOR AND
T-PA RELEASE
It has previously been suggested that the endothelial release of t-PA may be evoked
via EDHF [Brown et al, 2000; Hrafnkelsdottir et al, 2001; Oliver et al, 2005] but
direct in vivo testing of this hypothesis had not been performed. The findings
described in Chapter 5 demonstrate that inhibition of NO activity augments t-PA
release evoked by PAR-1 activation and others have shown that bradykinin-induced
t-PA release is increased during concurrent NO inhibition [Smith et al, 2003], In
isolation, these findings could be extrapolated to argue for a role of EDHF in t-PA
release. Indeed, the vasomotor actions of EDHF have consistently been shown to be
reciprocal to those of NO [Bauersachs et al, 1996] and, if EDHF is associated with
t-PA release, a similar augmented fibrinolytic response might be expected in the
absence of NO. However, I have shown that whilst TEA inhibits the EDHF
component of PAR-1 evoked vasodilatation, this is not accompanied by a similar
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alteration in t-PA release. Furthermore, bradykinin-induced t-PA release was
correspondingly unaffected by the presence of TEA. It can be concluded that, in the
healthy human forearm circulation, EDHF does not contribute to the mechanism for
endothelial t-PA release. This is consistent with the observation that t-PA release
occurs in response to inflammatory mediators including TNF-a in the absence of
vasodilatation [Chia et al, 2003] and that t-PA is released by norepinephrine which
causes vasoconstriction [Jern et al, 1994],
These findings do not, however, exclude the possibility that factors involved in the
downstream signalling mechanism of EDHF are shared by the t-PA release
mechanism. Activation of calcium-activated potassium channels is one of the earliest
events in the generation of hyperpolarisation and others have demonstrated that Kca
inhibition with TEA does not affect thrombin-induced endothelial t-PA release in
vitro [Muldowney et al, 2007], However, in that study, the elimination of isoforms of
EET inhibited t-PA release [Muldowney et al, 2007] and others have demonstrated
that application of 11,12-EET increases tissue t-PA expression in cultured
endothelial cells [Node et al, 2001]. It is of note that there is also a substantial body
of evidence to suggest that these cytochrome P450 metabolites of arachidonic acid
are involved in the mediation of EDHF activity [Fisslthaler et al, 1999; Halcox et al,
2001; Archer et al, 2003; Feletou and Vanhoutte, 2006a], An in vivo examination of
the role of EETs in t-PA release has not been made.
Using rotigaptide, I assessed the effect of augmentation of communication via Cx43
upon endothelial t-PA release and demonstrated that rotigaptide does not enhance
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bradykinin-induced endogenous fibrinolysis in healthy volunteers. Whether it has
any effect upon t-PA release in patients with impaired endothelial function remains
unknown.
7.5 CIGARETTE SMOKING AND ENDOTHELIAL PAR-1 RESPONSES
Having demonstrated that PAR-1 activation mediates arterial vasodilatation and the
release of endogenous fibrinolytic factors via endothelium-dependent mechanisms, I
hypothesised that cigarette smoking would be associated with endothelial
dysfunction and, consequently, reduced vascular PAR-1 responses. In the forearm
arterial circulation, I demonstrated that PAR-1 mediated arterial vasodilatation and
t-PA release were markedly impaired by cigarette smoking. Indeed, PAR-1 induced
t-PA antigen release was almost abolished by long-term cigarette smoking. Similarly,
PAR-1 evoked t-PA activity was substantially less in smokers than in age-matched
non-smokers. The combination of impaired PAR-1 mediated arterial vasodilatation
and t-PA release seen in smokers would favour clot expansion and vessel occlusion
with clinically relevant sequelae including myocardial infarction and stroke. This
important shift in the fine balance between clot propagation and dissolution is likely
to contribute to the elevated atherothrombotic risk associated with cigarette smoking.
The major advance represented by this study is the assessment of endothelial
responses to PAR-1 activation. By examining responses to the major cellular
receptor for thrombin, the principal mediator of atherothrombosis, I have been able
to make the most pathophysiologically relevant assessment of endothelial function
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thus far. Previous studies have demonstrated impaired substance P- and bradykinin-
induced vasodilatation and fibrinolytic capacity in the peripheral [Newby et al, 1999;
Pretorius et al, 2002] and coronary [Newby et al, 2001; Takashima et al, 2007]
circulation of smokers. Substance P and bradykinin are useful tools for the
assessment of endothelial function but, particularly in the case of substance P, their
direct pathophysiological relevance to atherothrombosis is substantially less than that
of thrombin and PAR-1 activation.
I have demonstrated that cigarette smoking is associated with impaired PAR-1
mediated arterial vasodilatation but, in the smokers studied here, this occurred in the
absence of a discernible attenuation of the vasomotor response evoked by
bradykinin. Furthermore, the magnitude of the reduction in t-PA release was
substantially greater for PAR-1 evoked responses than for responses to substance P
[Newby et al, 1999] and bradykinin [Pretorius et al, 2002], Therefore, it can be
argued that the assessment of vascular responses to PAR-1 activation is not only
pathophysiologically relevant, but also sensitive for the detection of endothelial
dysfunction.
It has previously been demonstrated that cigarette smoking impairs endothelial
function primarily via a diminution of NO bioavailability [Ambrose and Barua,
2004], However, the relative impairment of NO and EDHF activity caused by
cigarette smoking has never been assessed in vivo in man. In this thesis, I have
demonstrated that cigarette smoking is associated with reduced PAR-1 evoked t-PA
release and have also shown that PAR-1 activation mediates t-PA release via a NO-,
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PGI2- and Kca-independent mechanism. Taken together, these findings highlight that
the endothelial dysfunction arising from exposure to the constituents of cigarette
smoke is complex and constitutes more than an isolated deficiency of NO
bioavailability. It remains unknown whether cigarette smoking causes a decrease in
the bioavailability of mediators that could conceivably be common to both the EDHF
and t-PA release mechanisms, such as EETs. Furthermore, the effect of smoking
upon myoendothelial communication via gap junctions remains unknown.
7.6 FUTURE DIRECTIONS
7.6.1 EDHF AND GAP JUNCTIONS
Further understanding of the role of gap junctions and connexins in the EDHF
mechanism is required not only to unravel human physiologic mechanisms, but also
to assess their potential as therapeutic targets in a wide variety of disease states.
Although not specifically designed to do so, agents such as rotigaptide have the
potential to interact with the EDHF mechanism. Drugs of this class may not only
prove to be useful tools for the assessment of gap junctions and EDHF but may also
have therapeutic potential that is distinct from their intended utility as antiarrhythmic
agents.
7.6.2 EDHF, GAP JUNCTIONS AND CONGESTIVE HEART FAILURE
Congestive cardiac failure is common in western society, is associated with
significant morbidity and carries a prognosis that is worse than that of many cancers
[Mosterd and Hoes, 2007]. There is considerable evidence that EDHF becomes up-
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regulated and partially compensates for impaired NO bioavailability associated with
heart failure [Malmsjo et al, 1999; Katz and Krum, 2001; Ueda et al, 2005].
In a series of wire-myography studies similar to those described in Chapter 3, the
CMPs could be used to examine the role of gap junctions and connexins in
subcutaneous resistance arteries from patients with chronic heart failure and from
age- and sex-matched controls. Indeed, fat biopsies could be obtained from the
implant site of patients with a history of congestive cardiac failure undergoing
pacemaker and/or implantable defibrillator insertion. The recent increase in device
implantation in patients with congestive cardiac failure provides a large population
suitable for inclusion in this type of study. Furthermore, a large proportion of
patients undergo device insertion for non-ischaemic indications and have no history
of congestive cardiac failure. This group would, therefore, be ideal for the provision
of biopsies from age- and sex-matched control volunteers.
By examining the proportional contribution of EDHF to endothelium-dependent
vasodilatation in the presence and absence of heart failure, this study would allow the
first direct assessment of the effect of heart failure upon EDHF-mediated responses
in man. Furthermore, the role of gap junctions in the mediation of the EDHF
response could be assessed by using a combination of the three CMPs employed in
Chapter 3. Additionally, by assessing the effect of the addition of individual
peptides, the relative contributions of the three principal vascular connexins could be
assessed. It remains unknown whether Cx43 is the predominant functional connexin
isoform in the non-pregnant state and, whilst it tends to be the most labile, it is
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unknown whether its isolated up-regulation is responsible for any increase in EDHF
activity associated with heart failure.
7.6.3 Pre-eclampsia and the augmentation of communication via
connexin 43
Pre-eclampsia is defined as the association of new onset hypertension and proteinuria
during pregnancy. It affects 3-5% of all pregnancies and is associated with
significant morbidity and mortality for both mother and baby [Meis et al, 1998]. Pre¬
eclampsia frequently causes intra-uterine growth restriction and these low
birthweight babies are at increased risk of developing cardiovascular disease in
adulthood [Ozanne et al, 2004]. In the United Kingdom, hypertensive disorders of
pregnancy are the second most common cause of maternal mortality and
epidemiologic data suggest that pre-eclampsia increases the mother's future risk of
hypertension, coronary artery disease and stroke [Wilson et al, 2003].
As noted previously, normal pregnancy is associated with vascular adaptations that
permit a large rise in blood volume and cardiac output. Increased NO, and
particularly EDHF, activity provide a decrease in peripheral vascular resistance to
allow these changes to occur without a concomitant rise in blood pressure [Gillham
et al, 2003]. However, impaired EDHF-mediated vasodilatation has been observed in
resistance vessels from women with pre-eclampsia and is proposed as a major
pathogenic mechanism [Kenny et al, 2002; Gillham et al, 2003].
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Rotigpatide could be used to make the first direct assessment of the role of Cx43 in
the pathophysiology of pre-eclampsia. Subcutaneous resistance arteries from the
caesarean section incision margin of women with pre-eclampsia and normotensive
pregnant women could be obtained and vascular responses examined using wire-
myography. By examining the vascular effects of the addition of rotigaptide, the
functional role of Cx43 in the impairment of EDHF activity associated with pre¬
eclampsia could be assessed. Whilst the findings demonstrated in this thesis do not
demonstrate an effect of rotigaptide upon EDHF activity in healthy subjects, its
effects may become apparent in conditions of impaired EDHF activity when the
open-state probability of Cx43 is lower. Therefore, this experiment would allow the
testing of the hypothesis that rotigaptide restores EDHF activity in resistance vessels
from women with pre-eclampsia. In addition, immunohistochemistry would allow an
examination of the effects of pre-eclampsia upon the expression of the vascular
connexins.
A study of this type would provide important mechanistic insights to pre-eclampsia.
Furthermore, it would have the potential to highlight gap junctions as a drug target
not only in the treatment and prevention of pre-eclampsia, but also other vascular
disorders associated with impaired EDHF function, including type I diabetes
mellitus.
7.6.4 The mechanism of endothelial t-pa release
Detailed understanding of the pathway and mediators via which the endothelium
releases t-PA is still lacking. However, the endothelial capacity for t-PA release is
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now accepted as an important marker of both endothelial function and future
cardiovascular risk [Oliver et al, 2005; Robinson et al, 2007], Indeed, it is recognised
that enhanced endothelial t-PA release makes a significant contribution to the anti-
ischaemic benefits afforded by angiotensin-converting enzyme inhibition [Witherow
et al, 2002; Pretorius et al, 2003], The identification of mediators of endothelial t-PA
release would have the potential to guide the development of novel drugs designed
specifically to enhance appropriate endogenous fibrinolysis in patients at risk of
atherothrombotic disorders, such as myocardial infarction and stroke.
As discussed, in vitro evidence suggests that EETs are involved in the mediation of
endothelial t-PA release [Node et al, 2001; Muldowncy et al, 2007] but this has not
been demonstrated in vivo. Cytochrome P450 antagonists, such as miconazole and
sulphaphenazole, inhibit the in vivo synthesis of EETs. In the forearm circulation,
these antagonists attenuate EDHF-mediated vasodilatation when NO and PGI2
synthesis are inhibited [Halcox et al, 2001; Taddei et al, 2006], However, their effect
upon stimulated endothelial t-PA release has not been examined and a study to assess
the role of EETs in the in vivo mechanism for t-PA release is overdue. In the forearm
model, either of these antagonists could be used to provide useful information about
the regulation of basal t-PA release and the mechanism of t-PA release stimulated by
PAR-1 activation or bradykinin, for example.
7.6.5 Protease-activated receptor type 1 antagonists
The clinical development of the PAR-1 antagonists has been driven primarily by the
desire to create a novel anti-platelet agent that is not associated with the
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anticoagulant and bleeding effects seen with direct thrombin inhibitors
[Chackalamannil, 2006], However, the findings described in this thesis highlight the
important interaction that these drugs may have with the endothelium. In addition to
their useful anti-platelet effects, a thorough examination of their vascular effects is
warranted to ensure that any therapeutic gains are not offset, or even reversed, by
their potential to alter vascular tone and endogenous fibrinolysis.
Whilst I have demonstrated that PAR-1 activation causes local vasodilatation via the
release of endothelium-derived factors, the role of PAR-1 in the maintenance of
basal vascular tone remains unknown. By examining the effects of an intra-arterial
PAR-1 antagonist in the forearm, important information regarding the role of PAR-1
in the maintenance of basal vascular tone and endogenous fibrinolysis would be
gained. In the meantime, clinical trials should be designed and interpreted to take
into account the potential for systemic PAR-1 antagonism to be associated with
potentially harmful endothelial effects.
7.7 CONCLUDING REMARKS
The potential for the therapeutic modulation of EDHF activity relies upon a more
detailed understanding of its mechanism. In conjunction with the requirement for this
mechanistic knowledge, there is a need to further clarify its dynamic role in disease
states in man. Whilst its up-regulation has been described frequently as a protective
back-up mechanism to compensate for impaired NO bioavailability, this finding is
not universal. Indeed, specific impairment of EDHF activity has been described in a
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variety of conditions. However, a major barrier to the conclusive understanding of
these interactions includes the marked variations in EDHF activity and its interaction
with co-morbid conditions in different species. From here, research needs to focus
upon its assessment in man in order to come to relevant conclusions to guide drug
development. By making this thorough assessment, the therapeutic utility of gap
junction manipulation should become more apparent and efforts to improve
intercellular communication may be targeted to appropriate disease states.
Increased understanding of endothelium-derived factors, their mechanisms of action
and their dynamic interactions will also further highlight the potential for an array of
drugs to make unintentional interactions with the endothelium. Indeed, a wide
variety of drugs may provoke a range of endothelial effects that are distinct from
their intended therapeutic application. Whilst some of these effects may fortuitously
be beneficial, it remains vital to be alert to the risk of harmful side-effects as a result
of altered endothelial function. Indeed, the beneficial anti-platelet effects of PAR-1
antagonism may be offset by their potential to decrease endothelial PAR-1 responses.
As discussed, PAR-1 mediated local arterial vasodilatation and t-PA release may
represent an important protective mechanism in the presence of developing arterial
thrombus. It is conceivable that loss of this mechanism for clot dispersal and
dissolution could result in a paradoxical acceleration of thrombus growth and an
increased risk of clinically relevant vessel occlusion. These deleterious effects may
be further exaggerated in patients with pre-existing endothelial dysfunction in whom
PAR-1 mediated vasodilatation and t-PA release are already impaired. Of course,
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these individuals are representative of the population in whom PAR-1 antagonists are
likely to be used for their anti-platelet effects.
The requirement for an efficacious oral anti-platelet agent without a high risk of
attendant bleeding complications would represent a breakthrough in the treatment of
atherothrombotic disorders. Therefore, the clinical development of PAR-1
antagonists continues with cautious optimism. Their therapeutic utility will depend
upon the net effect of their beneficial anti-platelet effects balanced against potentially
deleterious effects upon the endothelium. These opposing effects should not be seen
as an absolute barrier to their development but they further illustrate the complexities
of endothelial function and the dynamic nature of its mediators. As long as drug
development pays credence to these interactions and is mindful of the vital roles and
the power of endothelial mediators, the endothelium should continue to yield some
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BKCa Large calcium-activated potassium channels
Ca2+ Calcium ions
cAMP Cyclic adenosine monophosphate
CMPs Connexin mimetic peptides
Cx Connexin
EDI IF Endothelium-derived hyperpolarising factor
EET Epoxyeicosatrienoic acid
eNOS Endothelial nitric oxide synthase
FBF Forearm blood flow
Hct Haematocrit
ICAM-1 Intercellular adhesion molecule-1
IKCa Intermediate calcium-activated potassium channels
K+ Potassium ions
KCa Calcium-activated potassium channels
KPSS High potassium physiological saline solutation
L-NAME V'-nitro-L-arginine-methyl ester
L-NMMA L-N -monomethyl arginine
LVDT Linear variable differential transducer
NO Nitric oxide
pai-1 Plasminogen activator inhibitor type 1
par-1 Protease-activated receptor type 1
pgi2 Prostacyclin
PSS Physiological salt solution
SKca Small calcium-activated potassium channels
SNP Sodium nitroprusside
tea Tetraethylammonium ion
TNF-a Tumour necrosis factor-alpha
t-PA Tissue-type plasminogen activator
UTP Uridine triphosphate
VCAM-1 Vascular cell adhesion molecule-1
vWF von Willebrand factor
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role of gap junctions in endothelium-derived hyperpolarizing factor
(EDHF)-mediated relaxation of human arteries was assessed using
connexin mimetic peptides (CMPs) designated 37'43Gap27, 40Gap27,
and 43Gap26 according to homology with the major vascular connex-
ins (Cx37, Cx40, and Cx43). Resistance arteries were obtained from
subcutaneous fat biopsies of healthy pregnant women undergoing
elective cesarean section. Endothelium-dependent vasodilatation to
bradykinin (BK) was assessed using wire myography. /V"*-nitro-l-
arginine methyl ester (l-NAME) and indomethacin (nitric oxide
synthase and cyclooxygenase inhibitors, respectively) attenuated max¬
imal relaxation to BK (Rmax) by —50%. Coincubation with l-NAME,
indomethacin, and the combined CMPs (37i43Gap27, 40Gap27, and
43Gap26) almost abolished relaxation to BK (Rmax = 12.2 ± 3.7%).
In arteries incubated with l-NAME and indomethacin, the addition of
either 37-43Gap27 or 40Gap27 had no significant effect on Rmax,
whereas 43Gap26 caused marked inhibition (Rmax = 21 ± 6.4%, P =
0.005 vs. l-NAME plus indomethacin alone) that was similar to that
of the triple combination. Endothelium-independent vasorelaxation
was unaffected by CMPs, l-NAME, or indomethacin. Immunohisto-
chemistry demonstrated Cx37, Cx40, and Cx43 expression in the
endothelium and vascular smooth muscle. In pregnant women,
EDHF-mediated vasorelaxation of subcutaneous resistance arteries is
dependent on Cx43 and gap junctions.
connexin mimetic peptides; gap junctions; microcirculation; bradyki¬
nin
NtTRic oxide (NO), the original endothelium-derived relaxing
factor, and prostacyclin (PGI2) have now been well character¬
ized. The elucidation of their roles in vascular physiology and
pathophysiology has been fundamental to recent advances in
the treatment and prevention of many cardiovascular diseases.
Evidence points to the existence of a third powerful vaso¬
dilator called endothelium-derived hyperpolarizing factor
(EDHF) (2, 12, 27). The contribution of EDHF to endothelium-
dependent vasorelaxation is greatest in small resistance arteries
(1) and, as such, is ideally suited to the control of systemic
blood pressure and local tissue perfusion. As well as its
involvement in normal physiological responses, EDHF is be¬
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lieved to play an important role in vascular pathophysiology. It
has been suggested to act as a "back-up" mechanism in
conditions associated with decreased NO bioavailability, such
as heart failure (13, 18). Furthermore, failure of EDHF to
compensate in this way has been implicated in the pathogenesis
of preeclampsia (14).
Despite intensive research, the exact nature of EDHF and its
mechanism of action remain unclear. This lack of understand¬
ing has precluded its manipulation as a therapeutic target (10).
Multiple candidates have been proposed, but none have been
confirmed as a unifying agent constituting EDHF. As such, the
term "endothelium-derived hyperpolarizing factor" may be
misleading, and EDHF may represent a mechanism rather than
a specific factor per se.
The case for gap junctions as a central component of the
EDHF mechanism has strengthened (12, 28). These aqueous
pores facilitate the transfer of either small hydrophilic mole¬
cules or ionic charge for the conduction of hyperpolarization
from the endothelium to smooth muscle and from smooth
muscle cell to smooth muscle cell. Gap junctions are composed
of two hemi-channels comprising six connexin (Cx) subunits
each. Cx37, Cx40, and Cx43 are particularly associated with
mammalian endothelium and vascular smooth muscle (12).
Diverse agents have been employed as putative gap junction
blockers, but their other nonspecific, EDHF-independent ef¬
fects have limited their use. In contrast, the connexin mimetic
peptides (CMPs) are highly selective and specific (12, 20).
These short synthetic peptides correspond to conserved amino
acid sequences in the first (Gap 26) and second (Gap 27)
extracellular loops of Cx37, Cx40, and Cx43 and cause dis¬
ruption of connexin function (5).
Pregnancy is associated with a decrease in peripheral vas¬
cular resistance and enhanced endothelium-dependent vasodi¬
latation (11). We have previously reported that EDHF accounts
for —50% of endothelium-dependent vasodilatation in these
arteries. Furthermore, using the putative gap junction blocker
18ot-glycyrrhetinic acid, our group identified a potential role of
gap junctions in EDHF responses (17). In this study we tested
the hypothesis that gap junction blockade with CMPs inhibits
EDHF-mediated vasorelaxation in resistance vessels from
pregnant women. Furthermore, we examined the expression of
the three main vascular connexin subtypes in these vessels. By
using CMPs, the current study represents the first assessment
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of the functional role of gap junctions and their connexin
components in EDHF-mediated relaxation in the human vas¬
culature.
MATERIALS AND METHODS
Biopsy collection and vessel preparation. The investigation was
undertaken with the approval of the local research ethics committee,
with the written informed consent of each patient, and in accordance
with the principles outlined in the Declaration of Helsinki. Subcuta¬
neous fat biopsies were obtained from healthy women undergoing
elective cesarean section. Women with a history of diabetes mellitus,
hypertension, or any other significant past medical history were
excluded from participation. Women with abnormal renal or hepatic
function also were excluded. Biopsies were taken from the incision
margin and immediately placed in cold physiological salt solution
(PSS; 119 mmol/1 NaCl, 4.7 rnmol/1 KC1, 2.5 mntol/1 CaCl2, 1.17
mmol/1 MgSC>4, 25 mmol/1 NaHCC>3, 1.18 mmol/1 KH2PO4, 0.026
mmol/1 EDTA, and 5.5 mmol/1 glucose).
Resistance arteries were dissected free of surrounding fat and
connective tissue and cut into segments ~2 mm long. All arteries
were kept in PSS at 4°C and used on the day of biopsy. Arteries were
mounted in the organ baths of a four-channel wire myograph (mul-
timyograph model 610; Danish Myo Technology, Aarhus, Denmark)
as described previously (17). Each organ bath contained warmed
(37°C) PSS and was continuously bubbled with 5% carbon dioxide-
95% oxygen. After a 30-min equilibration period, a passive circum¬
ference-tension curve was created for each segment to set optimum
resting tension. This resting tension is calculated to simulate an in
vivo transmural pressure of 100 mmHg. Arteries were then set at 90%
of this tension to enable optimal contractile conditions, as described
previously (17, 22). This semiautomated procedure also allows the
calculation of arterial diameter. Calibration and data processing were
performed using Myodac software (version 2.1; Danish Myo Tech¬
nology) on a personal computer. All solutions were refreshed every
30 min.
Constriction was elicited using norepinephrine (NE; 3 pmol/1).
Endothelium-dependent vasodilatation was assessed by the addition
of a single dose of bradykinin (BK; 1 pmol/1) to each chamber.
Arteries that did not achieve at least 60% vasorelaxation to BK were
excluded from the study.
Experimental protocols. Arteries were incubated for 40 min in
either PSS alone or with the nitric oxide synthase (NOS) inhibitor
//•"-nitro-L-arginine methyl ester (l-NAME; 300 pmol/1) and the
cyclooxygenase (COX) inhibitor indomethacin (10 p.mol/1) to block
the production of NO and PGI2, respectively. Arteries were then
preconstricted with NE (3 pmol/1), and the concentration-response
curve for BK (0.001-3 pmoi/1) was assessed. Arteries then underwent
90 min of incubation with CMPs with or without l-NAME and
indomethacin as detailed below. The concentration-response curve to
BK was then reassessed. At the end of each experiment, endothelium-
independent vasorelaxation was assessed in response to sodium nitro-
prusside (SNP; 0.1 mmol/1). The doses of the CMPs used were based
on prior published work (4, 12).
Gap junction inhibition with and without NOS/COX inhibition.
Arteries initially incubated in PSS alone were incubated with PSS plus
the combined CMPs 37'43Gap27 (300 p.mol/1), 40Gap27 (300 p.mol/1),
and 43Gap26 (300 p.mol/1). The contribution of gap junctions to
EDHF-mediated vasorelaxation with concurrent NOS/COX inhibition
was assessed by preincubating with l-NAME and indomethacin
before administering the combined CMPs (as above) in the continued
presence of l-NAME and indomethacin.
Contribution of connexin subtypes to EDHF-mediated relaxation.
Arteries preincubated with l-NAME and indomethacin alone were
incubated with l-NAME and indomethacin plus 1) 37-43Gap27 plus
40Gap27 (450 p.mol/1 each), 2) 37'43Gap27 (900 pmol/1), 3) 40Gap27
(900 pmol/1), or 4) 43Gap26 (900 pmol/1). Total peptide concentration
in each experiment was kept constant at 900 pmol/1.
Effects ofsGap26 alone on endothelium-dependent and -indepen¬
dent vasorelaxation. Arteries initially incubated in PSS alone were
incubated with 43Gap26 (900 pmol/1) for 90 min. A concentration-
response curve to BK was constructed (as above) before and after
43Gap26. In further experiments, a concentration-response curve was
constructed for either SNP (0.001-1 pmol/1) or the endothelium-
independent, ATP-sensitive potassium channel opener pinacidil
(0.001-1 pmol/1) before and after incubation with 43Gap26 (again,
without l-NAME and indomethacin).
Immunohistochemistry. Freshly isolated artery segments were cryo-
preserved in optimal cutting temperature (OCT) compound cooled by
liquid nitrogen. Transverse 10-pm cryosections were prepared and
mounted onto slides, air-dried, and stored at —20°C. Sections were
immunostained with polyclonal rabbit antibodies against mouse con-
nexins [Cx37 and Cx40 (1:50 dilution) or Cx43 (1:100 dilution) at
4°C overnight (Zymed Laboratories, San Francisco, CA)] (15, 23).
Negative control sections were incubated with nonimmune goat IgG
(SDS, Falkenberg, Sweden). All slides were counterstained with
hematoxylin, dehydrated, and mounted with Pertex (Histolab, Goth¬
enburg, Sweden),
Drugs and chemicals. All drugs and chemicals except the CMPs
and antibodies were obtained from Sigma (St. Louis, MO). The
CMPs 37'43Gap27 (SRPTEKTIF1I). 40Gap27 (SRPTEKNVFIV). and
43Gap26 (VCYDKSFPISHVR) were purchased from American Pep¬
tide (Sunnyvale, CA). All drugs except indomethacin and l-NAME
were dissolved in PSS before every experiment. Indomethacin was
dissolved in pure ethanol. l-NAME was dissolved in distilled water.
Data analysis. All data are expressed as means ± SE. Maximum
vasorelaxation (RmaJ is expressed as the percentage return to basal
tone produced by the highest concentration of BK (3 pmol/1) after NE
preconstriction. Analysis of variance (ANOVA) was used to compare
paired BK concentration-response curves before and after incubation
with CMPs and between groups. Bonferroni's correction for multiple
comparisons was used for the analysis of pooled data. Paired Stu¬
dent's t-test was used to compare NE preconstriction before and after
incubation with different agents (GraphPad Prism version 4.0). Sta¬
tistical significance was taken at the 5% level.
RESULTS
Subcutaneous fat biopsy specimens were obtained from 14
pregnant women (5 nulliparous) with a median age of 27 yr
(range 25-42 yr) and a median gestational age of 38 wk (range
37-40 wk) undergoing planned cesarean section due to breach
presentation (n = 4), previous cesarean section (n = 8), and
psychological reasons (n = 2).
A total of 31 arteries dissected from 14 biopsies were
included in the experiment. Mean internal diameter of artery
segments used was 221 ± 8 pm. Vessels with an internal
diameter of 100-300 pm were considered to represent resis¬
tance arteries, in line with previous definitions (6). There were
no significant differences between artery segments used in each
protocol with respect to internal diameter and initial constrictor
response to NE (data not shown).
Contribution of EDHF to BK-mediated vasorelaxation.
When compared with all arteries incubated in PSS alone (n =
18), incubation with l-NAME and indomethacin (n = 27)
reduced maximal vasorelaxation to BK by —50% (Rmax:
90.3 ± 2.2% in PSS alone vs. 48.1 ± 2.6% with l-NAME and
indomethacin, P < 0.0001). Pilot studies confirmed that BK
concentrations of >3 pmol/1 failed to further relax vessels
incubated in PSS alone.
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Gap junction inhibition with the combined CMPs
[37,43Gap27 plus 40Gap27 plus 43Gap26 (300 pmol/1 each)]
substantially reduced maximal relaxation to BK (Rmax: 46.6 ±
2.8% with combined CMPs vs. 89.4 ± 3.5% in PSS alone, P =
0.023, n = 6). The inhibition of gap junction-mediated com¬
munication with combined CMPs decreased maximal BK-
induced vasorelaxation to an extent similar to that of l-NAME
plus indomethacin alone (Fig. 1).
Combined NOS, COX, and gap junction inhibition with the
combined CMPs plus l-NAME and indomethacin almost abol¬
ished the vasorelaxation to BK (Rmax: 12.2 ± 3.7% with
combined CMPs plus l-NAME and indomethacin vs. 49.0 ±
5.1% with l-NAME and indomethacin, P = 0.0004, n = 6;
Fig. 1).
Contribution of different connexin subtypes to EDHF-medi¬
ated vasorelaxation. Incubation with 37,43Gap27 (450 pmol/1)
plus 40Gap27 (450 pmol/1) in addition to l-NAME and indo¬
methacin did not reduce maximal vasorelaxation to BK com¬
pared with the same vessels incubated in l-NAME and indo¬
methacin alone (Rmax: 38.2 ± 5.6% with l-NAME and indo¬
methacin plus 37'43Gap27 and 40Gap27 vs. 40.6 ±6.1% with
l-NAME and indomethacin, P = 0.319, n = 5; Fig. 2).
The addition of 37,43Gap27 (900 pmol/1) or 4QGap27 (900
p.mol/1) to l-NAME and indomethacin had no effect on max¬
imal BK-induced vasorelaxation compared with the same ar¬
teries incubated with l-NAME and indomethacin alone (Rmax:
43.6 ± 1.4% with 37,43Gap27 plus l-NAME and indomethacin
Log [BK] mol/L
Fig. 1. Concentration-response curves for bradykinin (BK) in subcutaneous
arteries incubated in physiological saline solution (PSS; n = 18), ^'"-nitro-l-
arginine methyl ester (l-NAME) plus indomethacin (n = 25), or the combined
connexin mimetic peptides (37,43Gap27, 40Gap27, and 43Gap26 at 300 p.mol/1
each) with or without l-NAME plus indomethacin (n = 6 for both). Indo,
indomethacin. *P < 0.001 vs. PSS. fP < 0.001 vs. l-NAME and indometh¬
acin alone.
Log [BK] mol/L
Fig. 2. Concentration-response curves for BK in subcutaneous arteries incu¬
bated in PSS (n = 18), l-NAME and indomethacin alone (n = 25), or
l-NAME and indomethacin plus 37,43Gap27 and 40Gap27 combined (450
p.mol/1 each; n = 5), 37,43Gap27 alone (900 p.mol/1; n = 5), or 40Gap27 alone
(900 p.mol/1; n = 4). p > 0.05, l-NAME and indomethacin alone vs. l-NAME
and indomethacin in combination with 37-43Gap27 and/or 40Gap27; ns, not
significant.
vs. 49.6 ± 4.87% with l-NAME and indomethacin alone, P =
0.39, n = 5; Rmax: 46.3 ± 5.5% with 40Gap27 plus l-NAME
and indomethacin vs. 45.0 ± 2.2% with l-NAME and indo-
methacin alone, P = 0.37, n = 4; Fig. 2). However, the
inhibition of Cx43 with 43Gap26 (900 pmol/1) in combination
with l-NAME and indomethacin resulted in a marked decrease
in maximal vasorelaxation to BK compared with the same
arteries incubated with l-NAME and indomethacin alone
(Rmax: 21.0 ± 6.4% with 43Gap26 plus l-NAME and indo¬
methacin vs. 52.45 ± 8.3% with l-NAME and indomethacin
alone, P = 0.0047, n = 5). Maximal BK-induced relaxation
after incubation with l-NAME and indomethacin plus 43Gap26
(900 pmol/1) was not different from maximal relaxation after
incubation with the three combined CMPs (each at 300 pmol/1)
(unpaired data, P = 0.397; Fig. 3).
Effects of43Gap26 alone on endothelium-dependent vasore¬
laxation. Incubation with 43Gap26 (900 pmol/1) (without l-
NAME and indomethacin) reduced maximal BK-induced re¬
laxation compared with the same arteries incubated in PSS
alone (Rmax: 40.6 ± 15.8% with 43Gap26 alone vs. 85.8 ±
5.5% in PSS alone, P = 0.039, n = 5). Maximal BK-induced
relaxation after incubation with 43Gap26 (900 pmol/1) alone
was not significantly different from that observed after incu¬
bation with the three combined CMPs (each at 300 pmol/1) in
PSS (Rmax: 40.6 ± 15.8% with 43Gap26 alone vs. 46.6 ± 2.8%
with combined CMPs in PSS, P = 0.69).
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Fig. 3. Concentration-response curves for BK in subcutaneous arteries incu¬
bated in PSS (n = 18), l-NAME and indomethacin alone (n = 25), or
l-NAME and indomethacin plus 37-43Gap27,40Gap27, and 43Gap26 combined
(300 p.mol/1 each; n = 6) or 43Gap26 alone (900 pmol/1; n = 5). *P < 0.001;
fP < 0.005 vs. l-NAME and indomethacin alone.
Endothelium-independent vasorelaxation and vasoconstric¬
tion. Relaxation evoked by the exogenous NO donor SNP (0.1
mmol/1) was unaffected throughout all studies (data not
shown). NE induced vasoconstriction of 2.1 ± 0.07 mN/mm2
and was unaffected by any of the incubation protocols.
43Gap26 alone had no effect on responses to the endothelium-
independent vasodilators SNP and pinacidil (n = 5 for both)
(Fig. 4).
Immunohistochemistry. Immunohistochemistry demonstrated
the consistent presence of Cx37, Cx40, and Cx43 in arterial
segments (Fig. 5). Connexins 37, 40, and 43 were seen in both
vascular smooth muscle and endothelial cells, although Cx40
was predominantly found in the endothelium.
DISCUSSION
We have made the first assessment of the role of gap
junctions and connexin subtypes in EDHF-mediated vasore¬
laxation of human arteries by using highly specific gap junction
inhibitors. We have shown that EDHF-mediated vasorelax¬
ation relies on gap junction communication acting principally
through the Cx43 subtype.
We have confirmed that subcutaneous resistance arteries
obtained from pregnant women retain —50% of their endothe-
lium-dependent relaxant capacity after the inhibition of endo¬
thelial NO and PGI2 synthesis with l-NAME and indometha¬
cin, respectively. This l-NAME- and indomethacin-insensitive
component of endothelium-dependent vasorelaxation is widely
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Fig. 4. Concentration-response curves for BK (A), sodium nitroprusside (SNP;
B), and pinacidil (C) in subcutaneous arteries incubated in PSS and 43Gap26
(900 p.mol/1) (n = 5 for each). *P < 0.05 vs. PSS.
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Fig. 5. Immunohistochemistry of pregnant hu¬
man subcutaneous resistance arteries. A and C:
staining for Cx43 shown in both smooth mus¬
cle and endothelial cell layers. B and D: stain¬
ing for Cx40 principally shown in the endothe¬
lium. E and F: staining for Cx37 shown in
endothelium and smooth muscle. G: control
images of arteries incubated without primary
antibodies showing no staining for connexins.
All images, magnification X40.
with a combination of 37'43Gap27, 40Gap27, and 43Gap26 (300
jxmol/1 each) attenuated vasorelaxation to BK to a similar
extent as l-NAME and indomethacin alone and revealed that
gap junctions are required for —50% of BK-induced vasore¬
laxation.
Coincubation of the triple CMP combination with l-NAME
and indomethacin virtually abolished BK-induced vasorelax¬
ation. That is, the l-NAME/indomethacin-insensitive compo¬
nent of BK-induced relaxation was inhibited by gap junction
blockade. This provides further evidence of a pivotal role for
gap junctions in EDHF-mediated relaxation in these vessels.
These findings are in keeping with our group's previous study
(17) in which BK-mediated relaxation was abolished by a
combination of l-NAME, indomethacin, and 18a-glycyrrhet-
inic acid.
We went on to assess the effects of each of the three CMPs
to infer the relative functional importance of Cx37, Cx40, and
Cx43. 43Gap26 exerted marked inhibition of EDHF-mediated
relaxation to BK. Indeed, at 900 |xmol/l, its inhibitory effect
did not differ from that seen after incubation with the triple
combination of CMPs. The marked inhibition of vasodilatation
achieved by incubation with 43Gap26 contrasts with the lack of
inhibition seen after incubation with 37-43Gap27 and 40Gap27
in combination (450 fxmol/1 each) and individually (900 p.mol/1).
Furthermore, in the absence of l-NAME and indomethacin,
43Gap26 caused a significant attenuation in maximal vasodila¬
tation to BK. Together, these findings suggest that the com¬
bined inhibitory effect of all three CMPs is derived predomi¬
nantly from 43Gap26 activity and implicate Cx43 as the dom¬
inant connexin isoform involved in the mediation of EDHF
responses in these vessels.
Data from combined endothelial NOS/COX knockout mice
imply a greater role for EDHF in females than in males (29),
whereas other animal models have demonstrated dynamic
Cx43 expression under the influence of estrogen. Pregnant rats
exhibit enhanced EDHF-mediated vasodilatation and upregu-
lation of vascular Cx43 expression (8). These effects are
markedly diminished in ovariectomized animals but can be
restored by exogenous estrogen supplementation (16). Further¬
more, an increase in Cx43 expression in response to increased
shear stress and mechanical load has been demonstrated (26).
The rise in circulating blood volume associated with normal
human pregnancy could invoke similar changes in Cx43 ex¬
pression and function and account for the predominant func-
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tional importance of Cx43 in our study. Although diversity
exists between species and the sexes, EDHF makes a large
contribution to endothelium-dependent vasodilatation in vari¬
ous vascular beds in men and nonpregnant women (3, 7, 21, 24,
25, 30, 31). The present study supports a clear role for Cx43 in
vascular responses of pregnant women (8). Whether Cx43 is of
such fundamental importance in men and nonpregnant women
and in other vascular beds remains to be established.
The interpretation of results using older putative gap junc¬
tion blockers has been limited by their nonspecific effects.
Indeed, 18a-glycyrrhetinic acid can affect ion channel conduc¬
tion to attenuate endothelial cell hyperpolarization directly.
Confidence in the CMPs is growing: they do not suppress
endothelial hyperpolarization directly and do not exert non-
gap-junctional effects (12, 19). Their exact mechanism of
action remains unclear, but they are thought to interfere with
connexin-gating properties. Unlike 18a-glycyrrhetinic acid,
they do not affect the structural integrity, number, or distribu¬
tion of connexins (1). When administered in combination and
individually in this study, the CMPs did not have any influence
on vasorelaxation to SNP or preconstriction to NE, suggesting
that they specifically inhibit endothelium-dependent vasorelax¬
ation without interfering with vascular smooth muscle func¬
tion. Whereas 43Gap26 alone significantly attenuates maximal
.relaxation to BK, it did not have any influence on the concen¬
tration-response curve obtained after exposure to the endothe-
lium-independent vasodilators SNP and pinacidil. This pro¬
vides more robust evidence that this CMP does not exert
nonspecific or toxic effects on smooth muscle function.
If Cx43 has a dominant role, then one might expect EDHF-
mediated vasorelaxation to be inhibited by 37'43Gap27 as well
as 43Gap26. 37,43Gap27 shares sequence homology with the
Gap27 domain of both Cx37 and Cx43, whereas 43Gap26
shares homology with the Gap26 domain of Cx43 only. Both
37'43Gap27 and 43Gap26 have been shown to act in a connexin-
specific manner (1,5), but our findings concur with others who
have reported differential activity between these two CMPs. In
2003, Chaytor et al. (4) reported that 37-43Gap27 and 40Gap27
partially inhibited the transmission of hyperpolarization from
endothelium to smooth muscle in the rabbit iliac artery. How¬
ever, the addition of 43Gap26 was required to abolish this
phenomenon completely, implying that 37-43Gap27 causes in¬
complete inhibition of Cx43 (4). Because each of these pep¬
tides shares homology with different extracellular loops, these
data suggest that targeting 37,43Gap27 and 43Gap26 vary in
their propensity to inhibit Cx43 by acting at different sites. It is
unclear whether Gap26 plays a greater role than Gap27 in
Cx43 gating and/or docking.
Immunohistochemistry revealed Cx37 and Cx43 expression
in both the endothelium and smooth muscle. Cx40 was also
seen in these cells, but expression was predominantly seen in
the endothelium. Although myoendothelial gap junctions are
proposed to allow the transfer of hyperpolarization generated
in the endothelium to the underlying smooth muscle, homo-
cellular gap junctions between adjacent smooth muscle or
endothelial cells are also an ideal conduit for the longitudinal
conduction of hyperpolarization and coordinated regulation of
vascular tone. Indeed, mice genetically engineered to lack
vascular Cx40 display not only hypertension but also irregular
vasomotion (9). Our own study has not differentiated whether
the inhibition of EDHF-mediated vasodilatation is due to the
inhibition of Cx43 in myoendothelial junctions, in homocellu-
lar junctions, or in both. Irrespective, we have demonstrated a
critical role for this connexin in endothelium-dependent va¬
sorelaxation. Furthermore, we have shown that endothelium-
independent vasorelaxation is unaffected by gap junction and,
specifically, Cx43 inhibition.
In summary, we have shown that EDHF accounts for ~50%
of BK-induced vasorelaxation in resistance arteries from preg¬
nant women. Using CMPs, we have provided functional evi¬
dence that EDHF mediates its vasorelaxatory actions via gap
junctions. We have demonstrated the expression of three major
connexin isoforms and highlighted a predominant functional
role for Cx43 in the mediation of EDHF responses in this
vascular bed. The extension of these studies to men, nonpreg¬
nant women, and pathophysiological states warrants further
investigation.
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Role of the Endothelium in the
Vascular Effects of the Thrombin Receptor
(Protease-Activated Receptor Type 1) in Humans
Ingibjorg J. Gudmundsdottir, MRCP,* Ninian N. Lang, MRCP * Nicholas A. Boon, MD, FRCP,f
Christopher A. Ludlam, PhD, FRCP,* David J. Webb, MD, FRCP,* Keith A. Fox, FRCP, FESC,*
David E. Newby, PhD, MRCP*
Edinburgh, United Kingdom
Objectives The purpose of this study was to determine the role of the endothelium in the vascular actions of protease-
activated receptor type 1 (PAR-1) activation in vivo in man.
Background Thrombin is central to the pathophysiology of atherothrombosis. Its cellular actions are mediated via PAR-1.
Protease-activated receptor type 1 activation causes arterial vasodilation, venoconstriction, platelet activation,
and tissue-type plasminogen activator release in man.
Methods Dorsal hand vein diameter was measured in 6 healthy volunteers before and after endothelial denudation.
Forearm arterial blood flow, plasma fibrinolytic factors, and platelet activation were measured in 24 healthy
volunteers during venous occlusion plethysmography. The effects of inhibition of prostacyclin, nitric oxide (NO),
and endothellum-derived hyperpolarizing factor on PAR-1 responses were assessed during coadministration of
aspirin, the "NO clamp" (L-N°-monomethyl arginine and sodium nitroprusside), and tetraethylammonium ion,
respectively.
Results Endothelial denudation did not affect PAR-l-evoked venoconstriction (SFLLRN; 0.05 to 15 nmol/min). Although
aspirin had no effect, SFLLRN-induced vasodilation (5 to 50 nmol/min) was attenuated by the NO clamp (p <
0.0001) and tetraethylamrnonium ion (p < 0.05) and abolished by their combination (p < 0.01). The NO clamp
augmented SFLLRN-induced tissue type plasminogen activator and plasminogen activator inhibitor type 1 anti¬
gen (p < O.OOOl) release, but tetraethylammonium ion and aspirin had no effect. SFLLRN-induced platelet acti¬
vation was unaffected by NO or prostacyclin inhibition.
Conclusions Acting via PAR-1, thrombin causes contrasting effects in the human vasculature and has a major interaction
with the endothelium. This highlights the critical importance of endothelial function during acute arterial injury
and intravascular thrombosis, as occurs in cardiovascular events including myocardial infarction and
stroke. (J Am Coll Cardiol 2008;51:1749-56) © 2008 by the American College of Cardiology Foundation
Thrombin plays a central role in the coagulation cascade and
thrombosis (1). It is one of the most powerful physiological
agonists in the cardiovascular system, and its actions are
fundamental to the processes of atherosclerosis and its
thrombotic consequences.
In addition to the enzymatic generation of fibrin, throm¬
bin stimulates a range of cell types including platelets,
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endothelial cells, and vascular smooth muscle cells. An
extensive search for thrombin receptors ultimately culmi¬
nated in the identification of a group of G-protein coupled
receptors termed protease-activated receptors (PARs).
See page 1757
These receptors are characterized by a unique mechanism of
activation whereby the receptor undergoes proteolytic cleav¬
age, unmasking a short peptide sequence that remains
tethered and auto-activates the receptor (2,3). To date, 4
different types of PARs have been identified: PAR-1, -3,
and -4 are all activated by thrombin; PAR-2 is mainly
activated by trypsin but transactivation of PAR-2 by cleaved
PAR-1 has been recognized (4,5).
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Protease-activated receptor type
1 receptors are the principal
thrombin receptors in man and
extensive studies in small animals
and cell cultures suggest that they
have a diverse and important role
in various organs. Their activation
stimulates a network of G-protein
coupled signaling pathways that
involve phospholipase C|3, protein
kinase C, calcium release, mitogen-
activated protein kinases, and po¬
tassium channels (6,7). However,
there is significant species hetero¬
geneity with pre-clinical studies of
limited relevance to man (8). Ex¬
ploring the role of PAR-1 recep¬
tors in the human vasculature
would deepen our understanding
of the physiological role of throm¬
bin and be important in the clini¬
cal development of new therapeu¬
tic strategies.
To understand the physiolog¬
ical actions of thrombin in the
human vasculature is challenging because direct thrombin
instillation has the potential to cause acute thrombosis in
situ and hence vascular occlusion. The use of a PAR-1
receptor agonist, however, permits the direct assessment of
cellular responses to thrombin without the enzymatic acti¬
vation of the coagulation cascade and fibrin formation.
Using the short peptide mimetic SFLLRN, we have re¬
cently described the in vivo effects of PAR-1 activation in
platelets, endothelium and vascular smooth muscle in man.
For the first time, we were able to show that PAR-1
activation has unique and contrasting effects in the human
vasculature including arterial dilation, venous constriction,
platelet activation, and tissue-type plasminogen activator
(t-PA) release (9). Given the central role of thrombin in the
pathophysiology of cardiovascular disease, it is important to
establish the mechanisms of these PAR- 1-mediated effects
and, in particular, the role of the endothelium. We therefore
set out to explore the role of the endothelium in the vascular
actions of PAR-1 activation in vivo in man.
Methods
Subjects. A total of 30 healthy nonsmokers (mean age 22
years; range 19 to 37 years) were recruited into the study.
The study was approved by the local research ethics com¬
mittee and conducted in accordance with the Declaration of
Helsinki and with the written informed consent of all
volunteers. Participants were screened and excluded for
clinically significant conditions including hypertension, hy-
perlipidemia, diabetes mellitus, asthma, and coagulopathy.
No participant had suffered a recent infective or inflamma¬
tory condition or had taken any medications in the 7 days
prior to the study.
Vascular assessments. All studies were carried out in a
quiet, temperature-controlled room (22°C to 24°C). Partic¬
ipants were semirecumbent (venous studies) or supine (ar¬
terial studies) and had abstained from alcohol for 24 h and
from food and caffeine-containing drinks for at least 4 h
prior to the study.
Venous studies. A 23-G needle was sited in a dorsal hand
vein and total infusion rate kept constant at 0.25 ml/min in
all studies. The hand was supported above the level of the
heart and an upper arm cuff inflated to 40 mm Hg to
obstruct venous return. The internal diameter of the dorsal
hand vein was measured by the Aellig technique (10) in 6
healthy volunteers. In brief, a magnetized lightweight rod
rested on the summit of the infused vein approximately 1
cm downstream from the tip of the infusion needle. The rod
passes through the core of a linear variable differential
transformer supported above the hand by a small tripod.
Changes in diameter of the vein caused vertical displace¬
ment of the rod, leading to a linear change in the voltage
generated by the transformer. This enabled calculation of
absolute changes in vein size.
PROTOCOL 1. VENOUS EFFECTS OF PAR-1 ACTIVATION. First,
we established the presence of functional endothelium. As
dorsal hand veins do not have resting tone, norepinephrine
(1 to 128 ng/min) was used to induce 70% reduction in vein
diameter. Once stable venoconstriction was obtained, ace¬
tylcholine (1 nmol/min; Novartis Pharmaceuticals UK Ltd,
Frimley, United Kingdom) was coinfused with norepineph¬
rine for 8 min to demonstrate endothelium-dependent
venodilation and an intact, functional endothelium. Follow¬
ing a 20-min saline infusion, the PAR-1 activating peptide,
SFLLRN-NH2 (0.05 to 15 nmol/min; Clinalfa AG,
Laufelfingen, Switzerland), was administered intravenously
before a final 20-min saline washout infusion.
PROTOCOL 2. VENOUS EFFECTS OF PAR-1 ACTIVATION FOL¬
LOWING ENDOTHELIAL DENUDATION. At the end of proto¬
col 1, the endothelium of the venous segment was denuded
as previously described (11). In brief, a second 23-G
butterfly needle was sited 3 to 4 cm downstream from the
tip of the infusion-needle, and this segment of the vein was
isolated by the use of occlusion wedges. Distilled water was
infused through the venous segment at a rate of 5 ml/min
for 15 min, thereby causing endothelial denudation that
persists for at least 2 days (11). Aspirin (300 mg orally) was
given 30 min prior to start of the first study and on each of
the 2 subsequent days to prevent venous thrombosis. On the
second day following denudation, subjects reattended and
protocol 1 was repeated.
Arterial studies. All subjects underwent cannulation of the
brachial artery with a 27-G standard wire steel needle under
controlled conditions. The intra-arterial infusion rate was
kept constant at 1 ml/min throughout all studies. Forearm
blood flow was measured in the infused and noninfiised arms
by venous occlusion plethysmography using mercury-in-
JACC Vol. 51, No. 18, 2008
May 6, 2008:1749-56
Silastic strain gauges as described previously (12,13). Supine
heart rate and blood pressure were monitored at intervals
throughout each study using a semiautomated noninvasive
oscillometric sphygmomanometer. Tirofiban (1.25 p,g/min)
was coinfused during the studies to inhibit potential PAR-1
activation-induced platelet aggregation in vivo (9). This
dose of tirofiban does not affect platelet-monocyte binding,
forearm blood flow, or baseline concentration of t-PA (9).
protocol 3: role of nitric oxide and prostacyclin in
par-1-induced vasodilation. Forearm blood flow was
measured by venous occlusion plethysmography in response
to brachial artery infusion of SFLLRN (PAR-1 agonist; 5
to 50 nmol/min) with tirofiban (1.25 jug/min) in 8 healthy
volunteers on 4 visits using a randomized controlled cross¬
over study employing a 2-by-2 factorial design: with and
without aspirin (600 mg orally; to inhibit prostacyclin
[PGI2] synthesis) and the "nitric oxide (NO) clamp."
Assuming total forearm blood flow of 25 ml/min, this will
achieve end-organ concentrations of 0.2 to 2.0 p.mol/1
SFLLRN.
The NO clamp was used to determine the contribution of
NO in PAR-l-mediated vascular effects. Following base¬
line intra-arterial tirofiban infusion, the NO synthase in¬
hibitor, L-NG-monomethyl arginine citrate (L-NMMA; 8
jumol/min), was coinfused. To compensate for L-NMMA-
induced basal vasoconstriction, forearm blood flow was
returned to baseline using a titrated dose of exogenous NO
in the form of intrabrachial sodium nitroprusside (SNP; 90
to 900 ng/min). This dose of SNP was coinfused with
L-NMMA and continued throughout the study. This
arrangement allows a constant "clamped" delivery of exog¬
enous NO while endogenous NO synthase activity is
inhibited.
protocol •»: role of calcium-activated potassium
channels/endothelium-derived hyperpolarizing fac¬
tor in par-1—induced vasodilation. Forearm blood flow
was measured in 8 other healthy volunteers in whom
intrabrachial SFLLRN (5 to 50 nmol/min), bradykinin (30
to 300 pmol/min), and SNP (2 to 8 p,g/min) were coinfused
with either saline placebo or tetraethylammonium ion
(TEA) (1 mg/min) on either of 2 visits using a randomized
double-blind crossover design. Again, agonists were coin-
fused with intra-arterial tirofiban (1.25 jug/min), which was
continued throughout the study. At the dose used, TEA is
a nonselective potassium channel antagonist (14-16).
protocol 5: role of endothelium-dependent vasodi¬
lators in par-i—induced vasodilation. In the final se¬
ries of studies, TEA or saline placebo was coinfused with
ascending doses of bradykinin and SFLLRN in 8 volunteers
using a randomized double-blind crossover design. In this
series, endothelium-derived hyperpolarizing factor (EDHF)
activity was isolated by inhibiting NO and PGI2 production
on both visits. The NO clamp was employed as described
previously (protocol 3), and cyclooxygenase activity was
inhibited with a single 600-mg dose of oral aspirin 1 h
before each study.
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blood sampling. Seventeen-gauge venous cannulae were
inserted into left and right antecubital fossae. Blood samples
were drawn simultaneously from each arm at baseline.
Blood samples were also drawn before SFLLRN or brady¬
kinin infusion and after each dose of SFLLRN or bradyki¬
nin. Blood was collected into acidified buffered citrate
(Stabilyte, Biopool International, Umea, Sweden; for t-PA
assays) and into citrate (BD Vacutainer, BD UK Ltd,
Oxford, United Kingdom; for plasminogen activator inhib¬
itor type 1 [PAI-1], beta thromboglobulin, and von Wille-
brand factor [vWF] assays). Samples were kept on ice before
centrifugation at 2,000 g for 30 min at 4°C. Platelet-free
plasma was decanted and stored at — 80°C before assay. Plasma
t-PA antigen and activity (t-PA Combi Actibind Elisa Kit,
Technoclone, Vienna, Austria), PAI-1 antigen and activity
(Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity,
HYPHEN BioMed, Neuville-sur-Oise, France), beta throm¬
boglobulin (Asserachrom Btg, Diagnostica Stago, Asnieres sur
Seine, France), and vWF (Dako, Glostrup, Denmark) concen¬
trations were determined by enzyme-linked immunosorbent
assays. Full blood count was measured at baseline and at the
end of the study.
platelet-monocyte binding. In protocols 3 and 4, blood
was collected from each arm for determination of platelet-
monocyte binding at baseline and after the highest dose of
SFLLRN. Samples of5 ml ofvenous blood were collected and
transferred into a tube containing the direct thrombin inhibi¬
tor, D-phenylalanyl-L-propyl-L-arginine chloromethylke-
tone. Five minutes after sampling, blood was incubated with
appropriate monoclonal antibodies labeled with fluorochromes
for 20 min and platelet-monocyte aggregates measured as
described previously (17).
Data analysis and statistics. Dorsal hand venous (18) and
forearm plethysmographic (12) data were analyzed as de¬
scribed previously. Variables are reported as means ± SEM
and analyzed using repeated measures analysis of variance
(ANOVA) with post hoc Bonferroni corrections and
2-tailed Student t test as appropriate. Statistical analysis was
performed with GraphPad Prism (Graph Pad Software, San
Diego, California) and statistical significance taken at the
5% level. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
Results
Endothelium and PAR-l-induced venoconstriction.
The role of the endothelium in PAR-l-induced vasomotor
effects was assessed by comparing venous responses before
and after local endothelial denudation. This was achieved
through brief instillation of distilled water in an isolated
dorsal hand vein segment. After pre-constriction with
norepinephrine, the presence or absence of functional en¬
dothelium was confirmed by the coinfusion of acetylcholine
(1 nmol/min). Acetylcholine caused venodilation in the
presence of endothelium and venoconstriction in its absence
1752 Gudmundsdottir ef aI.
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(Fig. 1) (from 35 ± 4% to 55 ± 7% in the presence of
endothelium versus 33 ± 7% to 18 ± 6% in the absence of
endothelium; p < 0.01 for both; ANOVA). After endothe¬
lial denudation, there appeared to be a trend toward
enhanced venoconstriction induced by the PAR-1 activat¬
ing peptide, SFLLRN (Fig. 1) (p = 0.09; ANOVA).
Endothelium-derived vasodilators and PAR-l-induced
vasodilation. SFLLRN caused an increase in forearm
blood flow that was unaffected by PGI2 inhibition with oral
aspirin (600 mg) (Fig. 2A). The NO synthase inhibitor,
L-NMMA, caused ~50% decrease in basal forearm blood
flow (from 3.04 ± 0.37 ml/lOOml tissue/min to 1.49 ± 0.19
ml/lOOml tissue/min; p < 0.001). Intrabrachial SNP (90 to
900 ng/min), an exogenous NO donor, was titrated to
restore forearm blood flow back to baseline levels (2.77 ±
0.24 ml/lOOml tissue/min; p = 0.46 clamp dose SNP versus
baseline; paired Student t test). The inhibition of endoge¬
nous NO synthesis by the NO clamp attenuated SFLLRN-
induced vasodilation (Fig. 2B).
Potassium channel antagonism with TEA (1 mg/min)
did not affect baseline blood flow (p = 0.76; data not
shown). It attenuated vasodilation to SFLLRN (Fig. 2C),
but the combination of PGI2, NO synthase, and potassium
channel inhibition appeared to abolish SFLLRN-induced
vasodilation (Fig. 2D).
Both with and without concurrent NO synthase and PGI2
synthase inhibition, TEA attenuated, but did not abolish
arterial vasodilation to the control endothelium-dependent
vasodilator, bradykinin (Figs. 3A and 3B). Tetraethylammo-
nium ion did not affect endothelium-independent forearm
arterial vasodilation to SNP (Fig. 3C).
Endothelium-derived vasodilators and PAR-l-induced re¬
lease of fibrinolytic and coagulant factors. The SFLLRN
increased net t-PA antigen and activity and PAI-1 antigen
release but did not affect net PAI-1 activity (Fig. 4). This
increase was augmented by the NO clamp (Fig. 4) but was
not affected by aspirin or TEA (data not shown; p = NS;
ANOVA). Bradykinin caused a dose-dependent increase in
net t-PA antigen (p < 0.05; ANOVA) and activity (p <
0.0001; ANOVA) release but did not affect PAI-1 antigen
and activity release (p = NS for both; ANOVA). Tetraeth-
ylammonium ion did not alter bradykinin-induced PAI-1 or
t-PA release (p = NS for both; ANOVA). Unpaired
analysis between the 2 subject groups (protocol 4 vs.
protocol 5) suggests that the NO clamp did not alter
bradykinin-induced t-PA or PAI-1 release (p = NS for all;
ANOVA). Neither bradykinin nor SFLLRN affected vWF
release (data not shown; p = NS; ANOVA).
Endothelium-derived vasodilators and PAR-l-induced
platelet activation. SFLLRN increased platelet-monocyte
binding but this was unaffected by inhibition of NO or
PGI2 (Table 1). In contrast, SFLLRN increased beta-
thromboglobulin (p < 0.001; ANOVA) that was aug¬
mented during the NO clamp (p < 0.01; ANOVA) (Fig. 5)
but unaffected by aspirin (p = NS; ANOVA).
Discussion
Thrombin is one of the most powerful physiological ago¬
nists in the cardiovascular system, and its actions are
fundamental to the processes of atherothrombosis. In a
series of studies, we have here described the contrasting role
of the endothelium in the PAR-l-mediated vascular actions
of thrombin in vivo in man. Although not providing a major
contribution to venoconstriction or PAI-1 release, the
endothelium mediates PAR-l-induced arterial vasodilation
and t-PA release. Our findings provide clear evidence of a
major interaction between the vascular endothelium and
thrombin in vivo in man. Furthermore, it highlights the
critical importance of endothelial function at the time of
acute arterial injury and intravascular thrombosis, such as
during acute coronary syndromes.
Role of the endothelium in PAR-l-induced vasomo-
tion. We have previously described the unexpected finding
of PAR-l-induced venoconstriction in man (9). Although
not caused by platelet aggregation (9), this effect could be
mediated by either a direct action on vascular smooth
muscle or via the release of endothelium-derived vasocon¬
strictors, such as endothelin or angiotensin II. To address
this question, we assessed PAR-1 venoconstriction before
and after endothelial denudation by instillation of distilled
water. There was a modest trend toward enhanced veno¬
constriction after endothelial denudation, and we cannot
exclude a small contribution from the endothelium that may
also include the release of venodilatory mediators such as
NO. However, PAR-1 continued to induce a marked
dose-dependent venoconstriction even in the absence of the
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In the presence (red symbols) and absence (blue symbols) of (A) aspirin (squares), NS 1 nonsignificant (p = 0.53) in the presence versus the absence of aspirin
(analysis of variance [ANOVA]); (B) the nitric oxide (NO) clamp (circles), *p < 0.0001 in the presence versus the absence of the NO clamp (ANOVA); (C) tetraethyiam-
monium (TEA) (triangles), tP < 0.05 in the presence versus the absence of TEA (ANOVA); and (0) aspirin, the NO clamp, and TEA (diamonds). #p < 0.01 in the pres¬
ence versus the absence of aspirin, the NO clamp, and TEA (ANOVA).
endothelium, which suggests a dominant and direct effect of
PAR-1 on the vascular smooth muscle cells.
In contrast to effects on the venous circulation, the
PAR-1 agonist causes potent arterial vasodilation. This
suggests a different effect on the arterial vasculature that is
likely to be mediated by the endothelium. It would be
difficult and ethically challenging to conduct comparable in
vivo endothelial denudation studies in the arterial circula¬
tion of man. We chose, therefore, to use a pharmacological
approach to the inhibition of the 3 main known mediators of
endothelium-dependent vasodilation: PGR, NO, and EDHF.
Although PGR inhibition appeared to have no effect, inhibi¬
tion of NO and potassium channels both attenuated the
PAR-l-induced vasodilation. Consistent with some cross talk
and compensatory up-regulation, combined inhibition of all
vasodilator mechanisms appeared to produce greater inhibi¬
tion, if not abolition, of the vasodilator actions of the PAR-1
agonist. This suggests that, unlike the venous circulation,
PAR-l--mediated arterial actions are dominated by, and de¬
pendent on, the vascular endothelium.
PAR-l-induced release of endothelium-derived factors.
In addition to vasomotion, PAR-1 has important effects on
the release of endothelium-derived coagulant and fibrino¬
lytic factors. In keeping with a wide range of other endo¬
thelial G-protein coupled receptor dilator agonists (19), we
confirmed our earlier findings that the PAR-1 agonist
causes endothelial t-PA release without affecting vWF.
However, we also report here that SFLLRN-induced t-PA
release appeared to be augmented by the inhibition of
endogenous NO production. Smith et al. (20) have reported
similar findings when they examined bradykinin-evoked
t-PA release in the presence and absence of L-NMMA.
Because t-PA release is independent of NO and cyclooxy-
genase activity, it has been suggested that EDHF is respon¬
sible for its release (21). One could speculate that, by
inhibiting NO activity, EDHF is up-regulated, and this
accounts for the augmented t-PA release induced by
SFLLRN in our study and by bradykinin in Smith's study.
However, in contrast to TEA's inhibitory effects on
SFLLRN-induced arterial vasodilation, it had no effect on
SFLLRN-evoked t-PA release. Similar findings have re¬
cently been reported by Muldowney et al. (22) who exam¬
ined the role of EDHF in an in vitro model of thrombin-
induced endothelial t-PA release. A variety of potassium
channel antagonists, including TEA, had no effect on
thrombin-induced t-PA release, but antagonists of specific
epoxyeicosatrienoic acids appeared to inhibit thrombin-
induced release of t-PA.
Another novel finding in our study was the increase in
PA1-1 release, especially during NO synthase inhibition. To
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TEA. *p < 0.05; tP = 0.0001; NS = nonsignificant (p = 0.41) in the presence
versus the absence of TEA (ANOVA). Abbreviations as in Figure 2.
date, there have been no reports of acute increases in plasma
PAI-1 concentrations following the administration of en¬
dothelial agonists, especially using the forearm model (19).
Even though the endothelium is an important source of
PAI-1, we believe our findings are consistent with acute
platelet release of PAI-1. There are several reasons to
support our contention. First, although PAI-1 antigen
concentrations increased, there was no corresponding rise in
PAI-1 activity. Indeed, PAI-1 activity fell during marked
release of t-PA. Plasminogen activator inhibitor type 1 is
stored in platelet a-granules where its activity is very low
(<5% of the activity seen in plasma) due to the absence of
the stabilizing effect of vitronectin. In contrast, we would
anticipate that endothelial-derived PAI-1 would remain
active. Second, there was no concurrent rise in vWF confirm¬
ing a selective effect on the endothelium with isolated t-PA
release. Third, we also demonstrated concomitant platelet
activation with marked increases in platelet-monocyte binding
and release ofbeta-thromboglobulin; the latter is also stored in
the a-granules of platelet. Finally, PAR-l-induced PAI-1
release was augmented during the NO clamp. Nitric oxide has
important antiplatelet effects and, in the presence of its inhi¬
bition, increased platelet activation may have led to greater
PAI-1 release.
Clinical relevance. Until recently, it has not been possible
to undertake a safe clinical assessment of the vasomotor
effects of thrombin due to its potent stimulatory effects upon
the coagulation cascade. However, the synthetic activating
peptide, SFLLRN, allows the examination of activation of
the human PAR-1 thrombin receptor without activation of
the coagulation cascade. This also permits the assessment
of PAR-1 actions independent of the potential confounding
effects that the activated coagulation pathway may have
upon vascular responses.
We have demonstrated that many of the arterial effects of
the PAR-1 agonist are dependent on, and mediated through,
the endothelium and can therefore be used to assess endothelial
function. To date, many endothelial G-protein-coupled recep¬
tor agonists have been used to assess endothelial function, such
as acetylcholine and substance P. However, such agents are
unlikely to have a major role in vascular physiology or patho¬
physiology and, as pharmacological tools, their relevance to the
assessment of endothelial vasomotor function has limitations.
As a more physiologically relevant tool, the PAR-1 agonist
may be a more appropriate method of assessing endothelial
function in the context of atherothrombosis. These novel
insights into the vascular actions of the PAR-1 agonist will
not only contribute to our understanding of human physi¬
ology and pathophysiology but also promise to inform the
clinical development of novel antithrombotic PAR-1 recep¬
tor antagonists.
Study limitations. We chose to use SFLLRN as a PAR-1
agonist for several reasons. First, the vast majority of
published work has employed SFLLRN as a PAR-1 acti¬
vating peptide, and its actions have been widely character¬
ized. Second, we have previous clinical experience of the in
vivo actions of SFLLRN and this has facilitated the com¬
parability of our current findings with our previous "first-
into-man" clinical studies. Finally, SFLLRN is identical to
the active cleaved sequence of the human PAR-1 receptor
and represents a more physiologically relevant agonist of the
receptor.
Although SFLLRN is selective for the PAR-1 recep¬
tor, it does have agonist activity at the PAR-2 receptor:
4-fold greater selectivity for the PAR-1 versus PAR-2
receptor (23). Therefore, there remains a possibility that
a contribution of the observed actions of SFLLRN may
represent PAR-2 antagonism. However, we do not be¬
lieve this is likely for several reasons. First, we have
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previously shown that SLIGKV, a highly selective PAR-2
activating peptide, causes only modest arterial vasodilation
at high doses and, in contrast to PAR-1 activation, causes
marked venodilation and does not cause arterial t-PA
release in vivo (24). Moreover, the predicted end-organ
concentration of the highest dose of SFLLRN used in our
current and previous studies is 4-fold lower than the median
effective dose for the PAR-2 receptor (23). However, we do
accept that, in future studies, consideration should be given
to the use of the more selective PAR-1 activating peptide,
TFLLRN (23,25).
The role of NO in bradykinin-induced t-PA release
remains controversial (19) and the present study has not
definitively addressed this issue. Although NO donors do
not induce t-PA release (26,27), inhibition of NO synthesis
has been reported either to have no effect (21), or to increase
(20), bradykinin-induced t-PA release. Our own unpaired
analysis of data from different subject populations is in
keeping with the findings of Brown et al. (21) and suggests
that bradykinin-induced t-PA release is unaffected by either
NO or prostaglandin inhibition. Further research into the
pathways involved in bradykinin-induced t-PA release is
needed to clarify the role of NO and other potential
mediators.
Conclusions
Protease-activated receptor type 1 activation causes contrasting
effects in the human vasculature. It causes endothelium-
dependent arterial vasodilation and t-PA release as well as
endothelium-independentvenoconstriction and PAI-1 release.
There appears to be a major interaction between the vascular
endothelium and thrombin's PAR-l-mediated effects in vivo
in man. This highlights the critical importance of endothelial
function particularly at the time of acute arterial injury and
intravascular thrombosis, such as occurs during many acute
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Figure 5 SFLLRN-induced Beta-Thromboglobulin Release
In the presence (red circles) and absence (blue circles) of the NO clamp.
*p < O.Ol net beta-thromboglobulin release induced by SFLLRN (50 nmol/min)
in the presence versus the absence of the NO clamp (ANOVA). Abbreviations
as in Figure 2.
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Endothelium-derived hyperpolarising factor (EDHF) causes vasorelaxation and may con¬
tribute to the release of the endogenous fibrinolytic factor, tissue-plasminogen activator
(t-PA). Rotigaptide enhances communication via the connexin 43 gap junction subunit and
may potentiate the vascular actions of EDHF. The aims of the present study were therefore
to determine whether rotigaptide influences basal and stimulated endothelium-dependent
vasodilatation and t-PA release in vivo in man.
Using venous occlusion plethysmography, forearm blood flow was measured in 27
healthy volunteers during intra-brachial infusions of rotigaptide (0.25-25 nmol/min) alone,
or co-administered with endothelium-dependent (acetylcholine [5-20 frg/min] and brady-
kinin [30-300 pmol/min]) and independent (sodium nitroprusside [2-8 v-g/min]) vasodilators
in the presence or absence of aspirin and the 'nitric oxide clamp'. The 'nitric oxide clamp'
inhibits endogenous nitric oxide synthesis with E-N-monomethylarginine and restores
resting blood flow with the exogenous nitric oxide donor, sodium nitroprusside.
Basal blood flow was unaffected by rotigaptide (P = NS). Acetylcholine, bradykinin and
sodium nitroprusside all caused dose-dependent vasodilatation in the presence and
absence of aspirin and the 'nitric oxide clamp' (P < 0.005 for all). These responses were
unaffected by rotigaptide (P = NS). Bradykinin caused t-PA antigen and activity release
(P = 0.04, P < 0.0001, respectively) that was unaffected by rotigaptide.
Augmentation of connexin 43 communication has no effect on basal vascular tone and
does not enhance endothelium-dependent or independent vasodilatation, or t-PA release in
the forearm arterial circulation of healthy men. It remains to be established whether
augmentation of connexin 43 communication improves endothelial function in patients
with vascular disease.
© 2008 Elsevier Inc. All rights reserved.
1. Introduction
The endothelium plays a major role in the regulation of
vascular tone and is responsible for the release of the
endogenous fibrinolytic factor, tissue-plasminogen activator
(t-PA). The elucidation of their roles in vascular physiology
and pathophysiology has been fundamental to recent
advances in the treatment and prevention of many cardio¬
vascular diseases.
After blockade of both nitric oxide and prostacyclin genera¬
tion, a substantial degree of endothelium-dependent vasodila¬
tation remains and is attributed to endothelium-derived
*
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hyperpolarising factor (EDHF) [1], EDHF activity has been
demonstrated in the microcirculation of a variety of human
vascular beds including the peripheral [2], mesenteric [3] and
subcutaneous [4,5] circulations in addition to the coronary [6,7]
and renal [8] vasculature. Consistently, its contribution is most
prominent in the small resistance arteries [3,9] that regulate
systemic blood pressure and local tissue perfusion. Further¬
more, the release of t-PA from the endothelium is independent
of both nitric oxide and prostacyclin production [10,11], and it
has been suggested that EDHF may mediate its release [11,12].
Thus, alterations in EDHF activity may contribute to endothelial
dysfunction and its manipulation presents an exciting oppor¬
tunity to restore vascular health and reduce the burden of
cardiovascular disease [13].
The transmission of hyperpolarisation from the endothe¬
lium to the underlying smooth muscle occurs via undefined
mediators and pathways. Various mediators have been
proposed but none has emerged as a universal EDHF in all
species and vascular beds [14,15]. However, there is
considerable evidence that gap junctions are required [15—
20]. These aqueous pores are found at points of cell-cell
contact and allow the intercellular transfer of small
molecules (<1 kDa). Myoendothelial gap junctions are,
therefore, ideally suited to the radial transfer of electronic
charge or second messenger between the endothelium and
underlying smooth muscle. Furthermore, gap junctions are
particularly abundant in the microcirculation where the
density of their expression correlates with an increasing
contribution of EDHF to endothelial vasodilatation in these
small resistance vessels [21]. Each gap junction hemichan-
nel is composed of six connexin subunits including
connexin (Cx) 37, 40 and 43 in the mammalian vasculature.
Indeed, using specific connexin antagonist peptides, we
have previously demonstrated the critical importance of
Cx43 in EDHF-mediated vasodilatation of human resistance
arteries in uitro [5].
It has not previously been possible to make a direct
assessment of the role of gap junctions in the mediation of
EDHF responses in vivo in man. However, rotigaptide (ZP-123)
is a synthetic hexapeptide (Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-
Gly-NH2) that alters the phosphorylation status of Cx43 to
potentiate communication via gap junctions [22-25], In
addition to its clinical development as an anti-arrhythmic
agent [26,27], it has been promoted as an important new tool to
aid in the dissection of the physiologic role of gap junctions
[22], Here, we have conducted the first clinical assessment
of the role of gap junctions, and specifically Cx43, in the
peripheral vascular EDHF-mediated responses. We tested the
hypothesis that, by increasing communication via gap junc¬
tions, rotigaptide would enhance EDHF-mediated vasodilata¬
tion and t-PA release in the forearm arterial circulation of
healthy man.
2. Methods
2.1. Preliminary validation study
The biological activity of rotigaptide was assessed through in
uitro measurements of its effect on transmural conduction
velocity in rabbit ventricular myocardium. Hearts from four
male New Zealand White rabbits were used for these
experiments, which conform to the standards set out in the
Animals (Scientific Procedures) Act 1986.
Rabbits (n = 4) were killed with a single intravenous
injection of 100 mg/kg pentobarbital sodium (Rhone Merieux,
France). Hearts were excised, placed in chilled Tyrode's
solution (containing [mmol/L]: Na 134.5, Mg 1.0, K 5.0, Ca
1.9, CI 101.8, S041.0, H2P04 0.7, HCO3 20, acetate 20 and glucose
10) and perfused via the left coronary artery with oxygenated
(95% 02-5% C02) Tyrode's solution maintained at pH 7.4 and
37 °C. Perfused left ventricular free wall wedge preparations
were dissected out and mounted in a custom built chamber
which allowed access to the transmural surface for imaging.
The preparation was stimulated using a bipolar electrode
placed on the epicardial surface at 1.5x diastolic threshold
using a 2 ms pulse at a basic cycle length of 350 ms. Perfusion
pressure and electrocardiogram were monitored throughout.
An optical mapping system was used to record optical action
potentials as previously described [28]. Motion artifact was
minimised using 15 mmol/L 2,3 butanedione monoxime (BDM;
Sigma Aldrich, UK). Measurements were taken at 15-min
intervals. After two control recordings the perfusate was
changed to Tyrode's solution containing BDM and 1 jxmol/L
rotigaptide for a further 15 min and measurements were
repeated.
2.2. Clinical study
This clinical study was performed with the approval of the
local research ethics committee in accordance with the
Declaration of Helsinki and with the written informed consent
of each subject.
2.2.1. Subjects
Healthy non-smokers (mean age 22 years; range 19-25 years)
were recruited into the study. Participants were excluded if
they had clinically significant conditions including hyperten¬
sion, hyperlipidemia, diabetes mellitus, asthma and coagulo¬
pathy. No participant had suffered a recent infective or
inflammatory condition, or had taken any medications in the 7
days prior to the study. On the day of study, participants had
fasted and abstained from caffeine and tobacco for at least 4 h
and from alcohol for 24 h.
2.2.2. Drugs
Pharmaceutical grade bradykinin (Clinalfa AG, Laufelfingen,
Switzerland), acetylcholine (Novartis Ltd., Middlesex, UK), L-
N(G)-monomethyl arginine citrate (Clinalfa), sodium nitro-
prusside (Hospira Inc., CA, USA) and rotigaptide (American
Peptide Inc., CA, USA) were dissolved in physiological saline.
Aspirin was obtained from Dagra Pharma, Diemen, Nether¬
lands.
2.2.3. Forearm venous occlusion plethysmography
All subjects underwent cannulation of the brachial arterywith a
27G-standard wire steel needle under controlled conditions. All
studies were performed with patients lying supine in a quiet,
temperature controlled (22-25 °C) room. The intra-arterial
infusion rate was kept constant at 1 mlVmin throughout all
1196 BIOCHEMICAL PHARMACOLOGY 76 (2008) II94-I2OO
studies. Forearm blood flow was measured in the infused and
non-infused arms by venous occlusion plethysmography using
mercury-in-silastic strain gauges as described previously
[29,30], Supine heart rate and blood pressure were monitored
at intervals throughout each study using a semi-automated
non-invasive oscillometric sphygmomanometer.
2.2.4. Intra-arterial drug administration
2.2.4.1. PROTOCOL 1. Effect of rotigaptide on basal forearm
blood flow. Five participants attended once each. They
received intra-arterial rotigaptide at 0.25, 0.75, 2.5, 7.5 and
25 nmol/min for 6 min at each dose. Assuming basal forearm
blood flow of 25 mL/min, this would give tissue rotigaptide
concentrations of 0.01-1.0 pmol/L. Forearm blood flow was
measured during the final 3 min of infusion of each dose.
2.2.4.2. PROTOCOL 2. Effect of rotigaptide on agonist-induced
uasodilatation and tissue-plasminogen activator release. T-
welve volunteers attended on each of three occasions. After
a 20-min intra-arterial infusion of 0.9% saline, participants
received either intra-arterial placebo (0.9% saline), 2.5 nmol/
min rotigaptide or 25 nmol/min rotigaptide using a rando¬
mised double-blind cross-over design. Rotigaptide or placebo
was administered alone for 20 min before being co-infused
with ascending doses of bradykinin (an endothelium-depen-
dent vasodilator that causes the release of tissue-plasminogen
activator; 30-300 pmol/min), acetylcholine (an endothelium-
dependent vasodilator that does not cause the release of t-PA;
5-20 p,g/min) and sodium nitroprusside (an endothelium-
independent vasodilator that does not cause the release of
t-PA; 2-8 |xg/min). Co-infused drugs were separated by a 20-
min infusion of 0.9% saline. The order of agonist infusion was
randomised between participants but maintained constant for
each of the three visits.
2.2.4.3. PROTOCOL 3. Effect of rotigaptide on EDHF-mediated
uasodilatation. Ten volunteers were recruited to attend on
two occasions. EDHF activity was isolated by inhibiting the
production ofboth prostacyclin and nitric oxide on each of the
two visits. Cyclo-oxygenase activity was inhibited with a
single 600 mg dose of oral aspirin 1 h prior to each study. Nitric
oxide production was inhibited with L-N(G)-monomethyl
arginine citrate (L-NMMA) in the 'nitric oxide clamp'. After a
20-min intra-arterial infusion of 0.9% saline, L-NMMA (8 (i,mol/
min) was infused via the brachial artery. To compensate for L-
NMMA induced basal vasoconstriction, forearm blood flow
was restored to baseline using a titrated dose of exogenous
nitric oxide in the form of intra-brachial sodium nitroprusside
(SNP; 90-900 ng/min). The titrated dose of SNP was co-infused
with L-NMMA throughout the study. This arrangement allows
a constant 'clamped' delivery of exogenous nitric oxide whilst
endogenous nitric oxide synthase activity is inhibited [31].
Either rotigaptide (25 nmol/min) or saline placebo was
co-infused with the 'nitric oxide clamp' in a double-blind
randomised cross-over design. Subsequently, ascending doses
of bradykinin (30-300 pmol/min), acetylcholine (5-20 ixg/min)
and sodium nitroprusside (2-8 fxg/min) were co-infused and
separated by a 20-min infusion of 0.9% saline. The order of
agonist co-infusion was randomised between participants but
maintained constant between visits.
2.2.5. Blood sampling
Seventeen-gauge venous cannulae were inserted into left
and right ante-cubital fossae during Protocol 2. Blood
samples were drawn simultaneously from each arm before
bradykinin infusion and after the maximum dose of
bradykinin (300 pmol/min). Blood was collected into acid¬
ified buffered citrate (Stabilyte, Biopool International, UK;
for t-PA assays) and into citrate (BD Vacutainer, BD UK Ltd.,
UK; for measurement of t-PA's major endogenous inhibitor,
plasminogen activator inhibitor type 1 [PAI-1]). Samples
were kept on ice before centrifugation at 2000 x g for 30 min
at 4"C. Platelet-free plasma was decanted and stored at
-80 °C before assay. Plasma t-PA antigen and activity (t-PA
Combi Actibind Elisa Kit; Technoclone, Austria) and PAI-1
antigen and activity (Elitest-PAI-1 Antigen and Zymutest
PAI-1 Activity; Flyphen Biomed, France) concentrations were
determined by enzyme-linked immunosorbant assays.
Hematocrit was measured at baseline and at the end of
the study.
2.3. Data analysis and statistics
2.3.1. Optical mapping validation study
Data analysis was performed using custom software. Activa¬
tion time was determined at the midpoint between baseline
and the peak of the action potential upstroke. Transmural
conduction velocity was calculated for each time point using
activation time from the earliest activation on the epicardial
edge of the transmural surface to the earliest activation on the
endocardial side.
2.3.2. Clinical study
Forearm plethysmographic data were analyzed as described
previously [29], Estimated net release of plasma t-PA and PAI-1
has been defined previously as the product of the infused
forearm plasma flow (based on the mean hematocrit and the
infused forearm blood flow) and the concentration difference
between the infused and non-infused arms [32].
Variables are reported as mean ± S.E.M. and analyzed
using repeated measures ANOVA with post hoc Bonferroni
corrections and two-tailed Students t-test as appropriate.
Statistical analysis was performed with GraphPad Prism
(Graph Pad Software) and statistical significance taken at
the 5% level.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agree to the manuscript as written.
3. Results
3.1. Effect of rotigaptide on myocardial conduction
velocity in uitro
In all experiments, transmural conduction velocity remained
constant during control perfusion (20.8 ± 1.7 cm/s versus
21.4 ± 1.6 cm/s, P = NS). Following perfusion with rotigaptide,
an increase in transmural conduction velocity was observed in
rabbit ventricular tissue in uitro (29.4 ± 1.7 cm/s, P < 0.001,
ANOVA; Fig. 1).


























Fig. 1 - Effect of 1 jxmol/L rotigaptide oil transmural
conduction velocity in perfused rabbit ventricular
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Fig. 2 - Forearm blood flow during intra-brachial infusion of
rotigaptide (0.25-25 nmol/min).
P < 0.0001, ANOVA) but this was unaffected by either 2.5 or
25 nmol/min rotigaptide (P = NS for all, ANOVA).
Net release of PA1-1 antigen and activity was unaffected by
bradykinin (300 pmol/min) in the presence or absence of
rotigaptide (P = NS for all, ANOVA; data not shown).
3.4. Effect of rotigaptide on EDHF-mediated vasodilatation
3.2. Effect of rotigaptide on basal forearm blood flow
At doses of 0.25-25 nmol/min, rotigaptide had no effect upon
basal forearm blood flow (P = NS, ANOVA: Fig. 2).
3.3. Effect of rotigaptide on agonist-induced vasodilatation
and tissue-plasminogen activator release
Acetylcholine, bradykinin and sodium nitroprusside each
caused dose-dependent arterial vasodilatation (P < 0.0001 for
all, ANOVA) that was unaffected by either 2.5 or 25 nmol/min
rotigaptide (P = NS for both, in the presence versus the absence
of rotigaptide; ANOVA: Fig. 3).
At baseline, net t-PA antigen release was 0.09 ± 0.05 ng/
lOOmL/min and net release of t-PA activity was 0.54 ± 1.4 IU/
100 mL/min. This was unchanged by the presence of rotigap¬
tide (P = NS for all; ANOVA). Bradykinin (300 pmol/min) caused
the release of t-PA antigen (7.62 ± 5.56 ng/100 mL/min;
P = 0.04, ANOVA) and activity (6.15 ± 2.20 IU/100 mL/min;
Intra-arterial L-NMMA (8 p.mol/min) reduced basal forearm
blood flow by approximately 38% (from 2.40 ± 0.20 reduced to
1.50 ± 0.20 mL/100 mL tissue/min; P < 0.0001) and was unaf¬
fected by rotigaptide (P = NS, 2-way ANOVA). Forearm blood
flow was restored to baseline levels by the titration of sodium
nitroprusside (P = NS, ANOVA).
After the inhibition of endothelial nitric oxide and
prostacyclin synthesis, dose-dependent vasodilatation was
evoked by acetylcholine, bradykinin and sodium nitroprusside
(P < 0.005 for all, ANOVA).This response was notaltered by the
presence of rotigaptide (P = NS, ANOVA; Fig. 4).
4. Discussion
For the first time, we have assessed the role of connexin 43 and
gap junctions in the control ofvascular tone and t-PA release in
vivo in man. We have shown, in healthy volunteers, that
potentiation of connexin 43-mediated intercellular commu¬
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Fig. 3 - Forearm blood flow during intra-brachial infusion of acetylcholine (left hand panel), bradykinin (middle panel) and
sodium nitroprusside (right hand panel) in the presence of placebo (squares), 2.5 nmol/min rotigaptide (triangles) or
25 nmol/min rotigaptide (circles). P = NS for rotigaptide versus placebo, ANOVA.
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Fig. 4 - In the presence of the 'nitric oxide clamp' and oral aspirin, forearm blood flow during intra-brachial infusion of
acetylcholine (left hand panel), bradykinin (middle panel) and sodium nitroprusside (right hand panel) in the presence of
placebo (squares) or 25 nmol/min rotigaptide (circles). P = NS for rofigaptide versus placebo, ANOVA.
blood flow or agonist-induced vasodilatation and t-PA release
in the presence or absence of concomitant inhibition of
prostacyclin and nitric oxide production.
To date, there has been no direct assessment of the role
of gap junctions, nor individual connexin subtypes, in the
regulation of vascular function in vivo in man. The use of
connexin antagonists has been limited by concerns about
the potential for toxicity and older putative gap junction
blockers exert a range of non-endothelial effects and alter
ion channel permeability [33,34], However, rotigaptide offers
a novel means for the assessment of gap junction-
dependent phenomena in uiuo. Not only has it been safely
administered to healthy humans [26,27] but its actions are
specific to Cx43. Indeed, it augments communication via gap
junctions in the absence of changes in membrane conduc¬
tion or basal current [35], and it exhibits no binding to a
large array of receptors including numerous ion channels
[36], It enhances intercellular dye transfer between HeLa
cells expressing Cx43 but not between those expressing
Cx26 or Cx32 [23] and promotes electrical coupling between
ventricular myocytes via alterations in the phosphorylation
status of Cx43 [25,37], Indeed, phopshorylation of Cx43
maintains it an open state [38] and Kjplbye et al. have
recently demonstrated that the anti-arrhythmic effects of
rotigaptide are associated with the inhibition of Cx43
dephosphorylation [25],
We have previously demonstrated that EDHF-mediated
vasodilatation of subcutaneous resistance arteries from
pregnant women depends upon the presence of functional
Cx43 whilst Cx37 and Cx40 are not required [5], Indeed, in
comparison to Cx37 and Cx40, the vascular expression of
Cx43 appears to be particularly labile. It is up-regulated by
oestrogen [39], at the leading edge of atherosclerotic plaques
[40], after vascular injury [41] and at sites of increased shear
stress [42,43], Furthermore, type I diabetes mellitus is
associated with an impairment of EDHF-mediated vascular
responses [13,44], and elevated glucose concentrations cause
the isolated down-regulation of Cx43 expression [45] and
permeability [46] in uitro. The examination of Cx43-mediated
responses is, therefore, of particular relevance not only to our
understanding of vascular physiology, but might also repre¬
sent a major therapeutic target to attenuate endothelial
dysfunction and improve vascular health.
Despite theoretical indications, we have failed to demon¬
strate a major vascular effect of rotigaptide even during
inhibition of both nitric oxide and prostacyclin production.
Was the rotigaptide inactive or used at an inadequate dose?
Our preliminary in uitro electrophysiological optical mapping
study provided important information confirming the biolo¬
gical activity of our preparation of rotigaptide at 1 (imoVL. The
maximum dose of rotigaptide assessed in the clinical study
was 25 nmol/min which, based upon forearm blood flow of
25 mL/min, equates to an estimated tissue concentration of
approximately 1 pmol/L. This concentration is in excess of the
effective anti-arrhythmic concentration employed in previous
animal models [24,47-49] and is similar to the maximum
tissue concentration of rotigaptide achieved in clinical trials
[27], Furthermore, it is in excess of the concentration recently
shown to be required for the prevention of Cx43 depho¬
sphorylation [25]. We therefore do not believe that the
preparation was inactive or used at the wrong dose.
Connexin 43 is expressed abundantly in a wide range of
resistance arteries obtained from a variety of species [15]
including humans [5]. Whilst our previous assessment of the
role of connexin subtypes in human EDHF-mediated
responses demonstrated a critical role for connexin 43 and
not connexin 37 or 40 [5], it is possible that, in the non¬
pregnant state, the vasomotor and EDHF mechanism requires
a contribution from all of these subtypes. Rotigaptide
specifically augments connexin 43-mediated signalling but
the augmentation of vascular gap junction mediated com¬
munication may therefore require the combined potentiation
of all three of the major vascular connexin subtypes.
The present study made an examination of vascular
responses in healthy young men. It is conceivable that
vasomotor and endogenous fibrinolytic responses cannot be
augmented because the endothelium is already maximally
active with a high baseline open-state probability for connexin
43. Indeed, the anti-arrhythmic activity of rotigaptide is
particularly potent in the context of acidosis and metabolic
stress during which the open-state probability of Cx43 is
relatively low [36], Furthermore, we were careful to dissect out
EDHF-mediated activity by the inhibition of prostacyclin and
nitric oxide with oral aspirin and the nitric oxide clamp
respectively. EDHF has activity that is reciprocal to nitric oxide
[50] and becomes up-regulated to compensate for impaired
nitric oxide bioavailability in a variety of disease states [13],
Therefore, the argument that EDHF is maximally active in the
studied population becomes more pertinent in the presence of
nitric oxide inhibition.
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The EDHF mechanism may differ between vascular beds
but the forearm arterial model employed here has been
predictive of the behaviour of the coronary vasculature in prior
studies of other aspects of endothelial function [30,51,52].
However, whilst the present study provides important data
regarding rotigaptide in the peripheral resistance vasculature,
caution should still be applied when considering extrapolation
of the results to infer similar pharmacodynamic effects in
other vascular beds.
In conclusion, we have demonstrated that intra-arterial
rotigaptide does not' augment vasomotion or endogenous
fibrinolysis in healthy subjects. Whether enhancement of
connexin 43-mediated intercellular communication influ¬
ences vascular function in conditions associated with specific
impairment ofEDHF-mediated activity, such as type I diabetes
mellitus, remains to be evaluated. Not only would this
assessment provide important mechanistic insights to the
pathophysiology of endothelial dysfunction but could also
highlight an important novel therapeutic target.
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Marked Impairment of Protease-Activated
Receptor Type 1-Mediated Vasodilation
and Fibrinolysis in Cigarette Smokers
Smoking, Thrombin, and Vascular Responses In Vivo
Ninian N. Lang, MRCP,* Ingibjorg J. Gudmundsdottir, MRCP,* Nicholas A. Boon, MD, FRCP,f
Christopher A. Ludlam, PhD, FRCP,* Keith A. Fox, FRCP, FESC,* David E. Newby, PhD, FRCP*
Edinburgh, United Kingdom
Objectives We sought to test the hypothesis that cigarette smoking adversely alters protease-activated receptor type 1
(PAR-l)-mediated vascular effects in vivo in humans.
Background Distinct from its role in the coagulation cascade, thrombin exerts its major cellular and cardiovascular actions
via PAR-1. The activation of PAR-1 causes endothelium-dependent arterial vasodilation and the release of en¬
dogenous fibrinolytic factors.
Methods Forearm blood flow was measured with venous occlusion plethysmography in 12 cigarette smokers and 12 age-
and gender-matched nonsmokers during intrabrachial infusions of PAR-l-activating-peptide (SFLLRN; 5 to 50
nmol/'min), bradykinin (100 to 1,000 pmol/min), and sodium nitroprusside (2 to 8 pg/min). Plasma tissue plas¬
minogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity concentrations were mea¬
sured throughout the experiment.
Results All agonists caused dose-dependent increases In forearm blood flow (p < 0.0001 for all). Although bradykinin
and sodium nitroprusside caused similar vasodilation, sfllrn-lnduced vasodilation was attenuated in smokers
(p = 0.04). Smokers had modest reductions in bradykinln-induced active t-PA release (reduced by 37%, p =
0.03) and had a marked impairment of SFLLRN-induced t-PA antigen (p = 0.02) and activity (p = 0.006) re¬
lease, with a 96% reduction in overal! net t-PA antigen release. The use of SFLLRN also caused similar (p = NS)
increases in inactive plasminogen activator inhibitor 1 in both smokers and nonsmokers (p £ 0.002 for both).
Conclusions Cigarette smoking causes marked impairment of PAR-l-mediated endothelial vasomotor and fibrinolytic func¬
tion. Relative arterial stasis and near abolition of t-PA release will strongiy promote clot propagation and vessel
occlusion. These findings suggest a major contribution of impaired endothelial PAR-1 action to the increased
atherothrombotic risk of cigarette smokers. (J Am Coll Cardiol 2008;52:33-9) © 2008 by the American
College of Cardiology Foundation
Smoking tobacco remains one of the most important and
consistent modifiable risk factors for myocardial infarc¬
tion and fatal coronary artery disease (1). The recent
INTERHEART (A Study of Risk Factors for First
Myocardial Infarction in 52 Countries and Over 27,000
Subjects) study revealed that smoking tobacco increases
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the risk of nonfatal myocardial infarction by as much as
7-fold (2). The pathophysiological mechanisms underly¬
ing this association are likely to be a combination of
accelerated atherosclerosis (3) and a propensity to acute
coronary thrombosis (1,4).
The endogenous fibrinolytic system is responsible for the
dissolution of arterial thrombi that are frequently found on
the surface of atherosclerotic plaques at areas of endothelial
denudation (5,6). It is regulated by the profibrinolytic
factor, tissue plasminogen activator (t-PA), and its endog¬
enous inhibitor, plasminogen-activator inhibitor type 1
(PAI-1) (7-9). The rapid mobilization of t-PA from the
endothelium is crucial, with thrombus dissolution being
much more effective if t-PA is incorporated during, rather
than after, thrombus formation (10). Indeed, acute stimu-
34 Lang et al.
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lated t-PA release predicts the
future risk of cardiovascular
events (11).
Thrombin plays a central role
in the coagulation cascade and
thrombosis. It is one of the most
powerful physiological agonists
in the cardiovascular system, and
its actions are fundamental to the
processes of atherothrombosis.
Distinct from its enzymatic role
in the coagulation cascade,
thrombin causes direct cellular
activation through stimulation of
a novel family of G-protein-
coupled receptors, protease-
activated receptors (PARs) (12).
These receptors have a unique mechanism of activation
whereby agonist-induced proteolytic cleavage of the extra¬
cellular domain reveals a short peptide sequence that re¬
mains tethered and causes autoactivation of the receptor. To
date, 4 different types of PARs have been identified:
PAR-1, -3, and -4 are all activated by thrombin whereas
PAR-2 is mainly activated by trypsin (13).
PAR-1 is the principal receptor that mediates the cardio¬
vascular actions of thrombin. The hexapeptide, SFLLRN,
represents the short peptide sequence revealed during
PAR-1 activation and can be used as a selective agonist of
the human PAR-1 thrombin receptor without activation of
the coagulation cascade. Using SFLLRN, we have recently
described the in vivo effects ofPAR-1 activation in platelets,
endothelium, and vascular smooth muscle in humans. For
the first time, we were able to show that thrombin has
unique and contrasting effects in the human vasculature,
including arterial dilation, venous constriction, platelet ac¬
tivation, and tissue-type plasminogen activator (t-PA) re¬
lease (14).
We, and others, have previously reported that pharma¬
cological stimulation of acute t-PA release in the peripheral
(15,16) and coronary (17,18) arterial circulations is mark¬
edly attenuated in smokers. In this study, we hypothesized
that smokers have impaired PAR-l-mediated vascular re¬
sponses. We, therefore, examined PAR-l-mediated t-PA
release and vasomotor responses in the forearm circulation
of cigarette smokers and healthy nonsmoking control
subjects.
Methods
Subjects. Twelve healthy cigarette smokers (5 to 20 ciga¬
rettes/day) and 12 age- and gender-matched nonsmokers
between ages 20 and 46 years participated in the study,
which was undertaken with the approval of the local
research ethics committee and in accordance with the
Declaration of Helsinki. The written informed consent of
each subject was obtained before entry into the study.
Exclusion criteria included a history of asthma, hyperten¬
sion, diabetes mellitus, coagulopathy, hyperlipidemia, or
vascular disease. Control subjects were lifelong nonsmokers
and were not exposed to regular environmental tobacco
smoke. Smokers had a history of regular daily cigarette
smoking of at least 5 years and maintained their normal
smoking habits in the week before attendance.
None of the subjects received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study, and
all abstained from alcohol for 24 h before and from food,
tobacco, and caffeine-containing drinks on the day of the
study. All studies were performed in a quiet, temperature-
controlled room maintained at 22°C to 24°C.
Intra-arterial drug administration. All subjects under¬
went brachial artery cannulation with a 27 standard-wire-
gauge steel needle. The intra-arterial infusion rate was kept
constant at 1 ml/min throughout all studies. Forearm blood
flow was measured in the infused and noninfused arms by
venous occlusion plethysmography with mercury-in-silastic
strain gauges as described previously (15,19). Supine heart
rate and blood pressure were monitored at intervals
throughout each study with the use of a semiautomated
noninvasive oscillometric sphygmomanometer.
After a 20-min intra-arterial infusion of 0.9% saline, the
glycoprotein Ilb/IIIa antagonist, tirofiban (1.25 jug/min;
Merck, Sharp and Dohme, Hoddesdon, United Kingdom),
was infused and continued throughout the study to inhibit
potential PAR-1-induced platelet aggregation. This dose of
tirofiban does not affect forearm blood flow (14).
During tirofiban administration, subjects received intra¬
arterial infusions of the PAR-l-activating peptide,
SFLLRN (5, 15, and 50 nmol/min; Clinalfa, Laufelfingen,
Switzerland), bradykinin (an endothelium-dependent vaso¬
dilator that causes the release of t-PA; 100, 300, and 1,000
pmol/min; Clinalfa), and sodium nitroprusside (an
endothelium-independent vasodilator that does not release
t-PA; 2, 4, and 8 /xg/min; David Bull Laboratories, War¬
wick, United Kingdom). Study drugs were infused in
random order for 10 min at each dose and were separated by
a 20-min infusion of 0.9% saline.
Blood sampling. Venous cannulae (17-gauge) were in¬
serted into large subcutaneous veins of the antecubital fossae
of both arms. Blood samples were drawn simultaneously
from each arm at the beginning of the study and during
infusion of each dose of PAR-l-activating peptide
(SFLLRN), bradykinin, and sodium nitroprusside. Venous
blood was collected into acidified buffered citrate (Stabilyte,
Trinity Biotech Pic, Co., Wicklow, Ireland; for t-PA assays)
and into citrate (BD Vacutainer, BD UK Ltd., Oxford,
United Kingdom; for PAI-1 and von Willebrand factor
[vWF] assays). Samples were kept on ice before centrifuga-
tion at 2,000 g for 30 min at 4°C. Platelet-free plasma was
decanted and stored at 80°C before assay. Plasma t-PA
antigen and activity (t-PA Combi Actibind Elisa Kit,
Technoclone, Vienna, Austria), PAI-1 antigen and activity
(Elitest PAI-1 antigen and Zymutest PAI-1 Activity, Hy-
JACC Vol. 52, No. 1, 2008
July 1, 2008:33-9
Lang et a/. 35
PAI-1 Vasodilation and Fibrinolysis in Smokers
phen Biomed, Neuville-Sur-Oise, France), and vWF anti¬
gen (Dako A/S, Glostrup, Denmark) concentrations were
determined with the use of enzyme-linked immunosorbent
assays. Full blood count and hematocrit were measured at
baseline and the end of the study.
Data analysis and statistics. Forearm plethysmographic
data were analyzed as described previously (19). Estimated
net release of plasma t-PA, PAI-1, and vWF has been
defined previously as the product of the infused forearm
plasma flow (based on the mean hematocrit and the infused
forearm blood flow) and the concentration difference be¬
tween the infused and noninfused arms (19). Variables are
reported as mean ± SEM and analyzed with repeated
measures analysis of variance (ANOVA) and a 2-tailed
Student t test as appropriate. Statistical analysis was per¬
formed with GraphPad Prism (GraphPad Software, San
Diego, California) and statistical significance taken at the
5% level. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the report as written.
Results
There were no differences in baseline characteristics be¬
tween cigarette smokers and nonsmokers (Table 1). There
were no changes in blood pressure, heart rate, or hematocrit
(data not shown) during the study. Smokers had a mean
cigarette consumption of 15 ± 1 cigarettes per day over a
mean period of 9 ± 2 years (7 ± 2 pack-years).
Forearm blood flow. The use of tirofiban did not affect
forearm blood flow (data not shown). Intra-arterial sodium
nitroprusside, bradykinin, and the PAR-l-activating pep¬
tide, SFLLRN, all caused dose-dependent vasodilation in
the infused arm of smokers and nonsmokers (p < 0.0001 for
all; ANOVA). There were no changes in blood flow in the
noninfused arm (data not shown).
Although there was no difference with bradykinin (p =
0.64; ANOVA smokers vs. nonsmokers), vasodilatation to
SFLLRN was attenuated in smokers (p = 0.044; ANOVA
smokers vs. nonsmokers). Endothelium-independent vaso¬
dilation evoked by the use of sodium nitroprusside was
similar in both groups (p = 0.74; ANOVA smokers vs.
nonsmokers) (Fig. 1).
Plasma fibrinolytic and hemostatic factors. Baseline
plasma t-PA antigen and activity (Table 2) and vWF
antigen (Table 3) concentrations were similar in smokers
and nonsmokers. There appeared to be a trend toward
Baseline Subject Characteristics
Nonsmokers Smokers
Age, yrs 26 ± 2 29 ± 2
Gender, male/female 12/0 12/0
Body mass index, kg/m2 24 ± 1 27 ± 1
Mean arterial pressure, mm Hg 97 ± 2 99 ± 2
Heart rate, beats/min 66 ± 2 64 ± 2
Baseline hematocrit 0.42 ± 0.01 0.42 ± 0.01
greater absolute plasma PAI-1 antigen and activity concen¬
trations in smokers, but this difference did not reach
statistical significance (smokers vs. nonsmokers: PAI-1
antigen, p = 0.07 and p = 0.10, and PAI-1 activity, p =
0.18 and p = 0.24; infused and noninfused arms, respec¬
tively) (Table 4).
The use of SFLLRN caused a dose-dependent net release
of t-PA antigen in nonsmokers (p < 0.0005; ANOVA) but
not smokers (p = 0.18; ANOVA) (Fig. 2). In comparison
with nonsmokers, the release of t-PA antigen and activity by
SFLLRN was markedly attenuated in smokers (p = 0.02
36 Lang et a/,
Pfll-1 Vasodilation and Fibrinolysis in Smokers
JACC Vol. 52, No. 1, 2008
July 1, 2008:33-9
Absolute Plasma t-PA Antigen and Activity Concentrations
t-PA Antigen (ng/ml) t-PA Activity (Ill/ml)
Nonsmokers Smokers Nonsmokers Smokers
Arm Infused Noninfused Infused Noninfused Infused Nonlnfused Infused Noninfused
Baseline 8.15 -p 2.18 8.33 ± 2.24 10.83 ± 1.94 10.93 2.23 0.48 0.08 0.45 ± 0.06 0.36 ± 0.07 0.35 ± 0.07
Pre-SFLLRN 8.08 jp 2.07 8.41 1.92 11.35 ± 2.2 11.15 ± 2.29 0.54 0.08 0.44 + 0.05 0.41 0.07 0.40 ± 0.07
SFLLRN 5 nmol/min 7.84 ± 2.23 7.68 ± 1.76 9.91 ± 2.08 11.51 2.70 0.63 0.07 0.51 0.05 0.44 ± 0.08 0.44 ± 0.08
SFLLRN 15 nmol/min 7.46 ± 2.08 7.74 ± 2.00 10.56 ± 1.85 10.83 ± 2.52 0.84 ± 0.11 0.59 ± 0.06 0.56 ± 0.11 0.50 ± 0.08
SFLLRN 50 nmol/min 11.54 + 2.82* 6.93 1.87 12.08 ± 2.58 11.17 ± 2.73 2.01 0.38* 0.65 ■± 0.09 0.78 ± 0.18tt 0.49 ± 0.10
Pre-BK 7.14 1.68 8.17 ± 2.43 10.66 1.99 10.54 ± 2.12 0.55 0.06 0.53 0.07 0.35 0.08 0.40 ± 0.08
BK 100 pmol/min 9.39 -p 1.76 7.55 + 2.19 12.82 ± 2.76 10.44 ± 2.11 1.55 0.21 0.54 0.07 0.84 ± 0.15 0.45 ± 0.07
BK 300 pmol/min 9.32 ± 1.55 8.23 ± 2.42 13.66 ± 2.66 12.42 ± 2.78 2.15 ± 0.31 0.74 ± 0.10 1.60 ± 0.29 0.57 ± 0.12
BK 1000 pmol/min 11.55 ± 1.77* 8.44 1.57 17.82 ± 3.49| 12.48 ± 2.70 3.51 ± 0.40* 0.97 0.12 2.25 ± 0.45** 0.73 ± 0.13§
One-way analysis of variance for dose response: *p < 0.005, fp < 0.01; 2-way analysis: tp < 0.001, §p < 0.05 smokers versus nonsmokers.
BK = bradykinin; t-PA = tissue-type plasminogen activator.
and p = 0.006, respectively; ANOVA). However,
SFLLRN induced a dose-dependent net release of PAI-1
antigen release in both nonsmokers (p = 0.0002; ANOVA)
and smokers (p = 0.001; ANOVA). The response was
similar in both groups (p = 0.36; ANOVA) and was
associated with no change in net PAI-1 activity (p = NS for
all; ANOVA [data not shown]) or vWF antigen release (p —
NS; ANOVA) (Table 3).
Bradykinin caused a dose-dependent net release of t-PA
antigen and activity in both smokers and nonsmokers (p <
0.01 for all; ANOVA). Bradykinin also evoked a dose-
dependent increase in absolute t-PA activity in the nonin¬
fused arm of both nonsmokers (p < 0.0001; ANOVA) and
smokers (p = 0.008; ANOVA). Net release of t-PA activity
induced by bradykinin was less in smokers than nonsmokers
(p = 0.032, smokers versus nonsmokers; ANOVA) (Fig. 2).
Bradykinin caused no change in net PAI-1 antigen or
activity and did not affect vWF antigen in either group (p =
0.91, nonsmokers; p = 0.98 nonsmokers; ANOVA). As
expected (20). sodium nitroprusside caused no change in
absolute or net release of t-PA, PAI-1 or vWf (data not
shown).
Discussion
To our knowledge, we have shown for the first time that
thrombin-mediated vascular responses are markedly im¬
paired in cigarette smokers, with a substantial reduction
observed in PAR-l-mediated endothelial t-PA release and
forearm arterial vasodilation. This impaired vasomotor and
fibrinolytic response may represent an important shift in the
fine balance between intravascular thrombosis and fibrino¬
lysis that could account for the increased incidence of
atherothrombosis in cigarette smokers.
Smoking and PAR-1-induced arterial vasomotion. As
reported by others (16), we observed no effect of smoking
status on endothelium-dependent vasodilation to bradyki¬
nin or endothelium-independent vasodilation to sodium
nitropmsside. One of the important novel observations from
our study is that vasodilation evoked via PAR-1 is impaired
in smokers, especially at the greater doses of SFLLRN.
Because homeostatic mechanisms attempt to maintain ves¬
sel patency and minimize intravascular thrombus formation
in healthy arteries, we have previously hypothesized the
arterial vasodilation to PAR-1 activation represents a pro-
Plasma von Willebrand Factor
Concentrations During SFLLRN and Bradykinin Infusions
von Willebrand Factor Antigen (ng/ml)
Nonsmokers Smokers
Arm Infused Noninfused Infused Noninfused
Baseline 0.72 ± 0.05 0.75 ± 0.19 0.77 ± 0.09 0.78 ± 0.13
Pre-SFLLRN 0.71 ± 0.06 0.80 ± 0.06 0.79 ± 0.07 0.71 ± 0.09
SFLLRN 5 nmol/min 0.70 ± 0.03 0.74 ± 0.05 0.72 ± 0.10 0.73 ± 0.06
SFLLRN 15 nmol/min 0.64 ± 0.03 0.73 ± 0.03 0.78 ± 0.06 0.63 ± 0.06
SFLLRN 50 nmol/min 0.70 ± 0.04 0.74 ± 0.04 0.78 ± 0.06 0.63 ± 0.06
Pre-BK 0.74 ± 0.06 0.74 ± 0.05 0.84 ± 0.10 0.74 ± 0.08
BK 100 pmol/min 0.76 ± 0.07 0.73 ± 0.05 0.78 ± 0.08 0.71 ± 0.05
BK 300 pmol/min 0.76 ± 0.06 0.74 ± 0.05 0.83 ± 0.08 0.68 ± 0.08
BK 1000 pmol/min 0.78 ± 0.06 0.76 ± 0.05 0.83 ± 0.08 0.76 ± 0.07
One-way analysis of variance for dose response, p = NS for all; 2-way analysis of variance, p = NS for all.
BK = bradykinin.
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Table 4 Absolute Plasma PAI-1 Antigen and Activity Concentrations
PAI-1 Antigen (ng/ml) PAI-1 Activity (AU/ml)
Nonsmokers Smokers Nonsmokers
Arm Infused Noninfused Infused Noninfused Noninfused Infused Noninfused
Baseline 23.58 ± 3.93 23.46 ± 3.71 40.09 8.13 34.56 ± 5.50 0.80 ± 0.15 0.86 ±: 0.15 t-* 00 + 0.48 1.55 ± 0.60
Pre-SFLLRN 21.25 ± 3.35 21.68 3.12 33.9 ± 7.19 33.08 ± 5.06 0.63 + 0.12 0.73 0.13 1.52 ± 0.56 1.57 ± 0.63
SFLLRN 5 nmol/min 21.03 ± 3.23 21.81 3.36 38.52 ± 10.65 32.03 6.04 0.62 Hh 0.12 0.71 0.14 1.52 0.56 1.80 0.61
SFLLRN 15 nmol/min 22.28 -+- 3.55 21.13 ± 3.18 37.63 ± 9.06 32.92 ± 6.07 0.58 ± 0.12 0.72 ± 0.13 1.65 ± 0.53 1.63 ± 0.63
SFLLRN 50 nmol/min 31.56 4.33* 20.52 ± 3.20 53.64 10.201* 34.97 ± 5.86 0.55 0.13 0.72 0.14 1.59 ± 0.50 1.60 ± 0.67
Pre-BK 24.16 ± 3.86 21.58 3.27 38.44 ± 9.67 37.41 ± 8.37 0.79 ± 0.17 0.81 0.16 1.74 ± 0.57 1.70 ± 0.69
BK 100 pmol/min 24.83 4.30 21.83 3.13 38.13 ± 9.93 37.44 ± 7.90 0.66 0.18 0.77 ± 0.17 1.54 ± 0.53 1.78 ± 0.75
BK 300 pmol/min 22.13 -+- 3.24 23.68 ± 4.17 39.42 ± 0.39 37.10 ± 8.23 0.56 ± 0.16 0.76 ± 0.19 1.58 ± 0.56 1.35 ± 0.47
BK 1,000 pmol/min 20.57 ± 3.20 20.62 ± 2.91 34.53 ± 8.63 32.11 6.57 0.45 ± 0.13 0.62 0.16 1.33 0.50 1.19 ± 0.40
One-way analysis of variance for dose response: *p < 0.05, tP < 0.0005; 2-way analysis of variance, p = NS for all, smokers versus nonsmokers.
BK = bradykinin; PAI-1 - plasminogen activator inhibitor type 1.
tective feedback mechanism. In the presence of a developing
thrombus, PAR-l-mediated vasodilation will increase
blood flow to limit arterial thrombosis by facilitating its
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Figure 2
Net Release of t-PA Activator
in Smokers and Nonsmokers
Net t-PA antigen (circles) and activity (squares) release induced by SFLLRN
(top panels) and bradykinin (bottom panels) in smokers (blue symbols) and
nonsmokers (red symbols). *p < 0.05, tP — 0.005. NG = nonsignificant
(analysis of variance, smokers vs. nonsmokers); t-PA = tissue-type plasmino¬
gen activator.
impairment of PAR-l-induced vasodilation may have ma¬
jor pathophysiological consequences during acute throm¬
botic events such as myocardial infarction.
Smoking and PAR-l-induced release of endothelium-
derived factors. Over and above diminished vasomotion,
the major finding of our study was the almost complete
abolition of PAR- 1—mediated t-PA antigen release in
cigarette smokers. Furthermore, PAR-1 activation caused
only a very modest increase in t-PA activity despite causing
substantial t-PA antigen and activity release in nonsmokers.
The current findings confirm previous studies from our
own and other groups reporting reduced t-PA release in
cigarette smokers (15,16,18). Although not demonstrated
with t-PA antigen, the present finding of reduced bradyki¬
nin induced active t-PA release is consistent with similar
observations previously reported by Pretorius et al. (16)
However, the magnitude of the reduction in t-PA release is
substantially greater for PAR-1-evoked responses than it is
for bradykinin or substance P (96% vs. 40% to 50%) (15,16).
We would therefore argue that SFLLRN-evoked t-PA
release has the potential to be a more sensitive and patho-
physiologically relevant assessment ofendothelial vasomotor
and fibrinolytic function.
Of note, PAR-1 activation also caused the release of
PAI-1 antigen but did not cause an appreciable increase in
PAI-1 activity, and neither indices were altered by smoking
status. This increase in PAI-1 antigen without a change in
activity suggests that SFLLRN is releasing PAI-1 from
platelets rather than the endothelium because platelet-
derived PAI-1 is relatively inactive as a result of the absence
of the stabilizing effects ofvitronectin (16,21). Furthermore,
our own recent work has demonstrated a concomitant
increase in beta-thromboglobulin, suggesting degranulation
of platelet alpha granules (22). Therefore, the contribution
of the endogenous fibrinolytic system to the prothrombotic
state found in cigarette smokers is likely to be driven by
impaired endothelial t-PA release and not by alterations in
PAI-1 release or activity.
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PAR-1 activation as a pathophysiologically relevant
marker of endothelial function. The authors of previous
studies to assess the endothelial release of endogenous
fibrinolytic factors have used diverse methods. Historical
means of stimulating t-PA release have included the sys¬
temic intravenous infusion of desmopressin and bradykinin,
but this method causes significant confounding effects by
altering systemic hemodynamics, activation of the sympa¬
thetic nervous system, and concomitant release of other
mediators (6). By assessing the regional release of t-PA and
PAI-1 in response to locally acting agonists, we can avoid
such confounding effects.
We have previously demonstrated that substance
P-induced t-PA release in the coronary (17) and peripheral
(15) arterial circulations is impaired in cigarette smokers,
and allows one to predict future adverse cardiovascular
events in patients with coronary heart disease (11). How¬
ever, although substance P has been a useful pharmacologic
tool, it is unclear whether substance P is likely to act as a
major pathophysiological mediator in atherothrombosis. In
contrast, bradykinin may have a more direct role because it
is released during the contact phase of coagulation and there
is enhanced activation of the kallikrein system and brady¬
kinin release in patients with acute coronary syndromes
(23). However, we would argue that, given its central role in
thrombosis and inflammation, thrombin is the most pow¬
erful and pathophysiologically relevant mediator in this
setting. Our present findings not only reinforce previous
findings but give the clearest indication yet that impaired
endothelial function is of critical and dynamic importance in
the setting of coronary heart disease and acute coronary
syndromes.
Smoking and endothelium-dependent mechanisms. We
have previously demonstrated that PAR-1 mediates ar¬
terial vasodilation via 2 endothelium-dependent mecha¬
nisms, namely nitric oxide (NO) and endothelium-
derived hyperpolarizing factor (EDHF) (22). The
pathways via which PAR-1 activation causes the endo¬
thelial release of t-PA are less clear and, in fact, inhibi¬
tion of NO synthesis causes augmented SFLLRN-
induced t-PA release (22). This discrepancy has raised
the question as to whether EDHF is responsible for t-PA
release and, in the absence of NO, whether EDHF
responses undergo a compensatory up-regulation. Al¬
though the bulk of evidence suggests that smoking
predominantly affects endothelial function by increasing
oxidative stress with consequent disruption of NO pro¬
duction (24,25), studies specifically examining the effect
of smoking upon EDPIF-mediated responses are lacking.
Study limitations. The forearm circulation has been an
extremely reliable model for the assessment of vascular physi¬
ology and pathophysiology. Wc do accept that our findings in
the forearm may not be accurately representative of the
coronary circulation. Flowever, we and others have previously
demonstrated consistent findings of impaired endothelial t-PA
release in both the forearm (15,16) and coronary (17,18)
circulations of cigarette smokers. Although the forearm vascu¬
lar bed is relatively protected from the development of ather¬
oma, it therefore seems likely that changes in its fibrinolytic
capacity are indicative of the coronary circulation.
Establishing the receptor-mediated effects of thrombin in
the vasculature is of major physiological and therapeutic
relevance. It could be argued that, in our studies, the safety
requirement for the coadministration of tirofiban with
SFLLRN detracts from these advantages. However, we
used locally active doses of glycoprotein Ilb/IIIa inhibitor
that abolish SFLLRN-mediated platelet aggregation with¬
out affecting platelet-monocyte binding, a sensitive marker
of platelet activation. Furthermore, it has no effect upon
basal forearm blood flow or fibrinolytic responses to
SFLLRN (14). We therefore believe that SFLLRN remains
an important and relevant tool to assess these fundamental
pathophysiological aspects of endothelial function.
We have demonstrated an important impairment of
fibrinolytic capacity in smokers, but it remains unclear
whether this reflects an impairment of synthesis, storage,
and release of t-PA, or indeed acceleration of its degrada¬
tion. Addressing these questions will be challenging and is
likely to require specifically designed in vitro studies.
Conclusions
In healthy vessels, thrombin's powerful procoagulant and
prothrombotic effects are offset by its ability to evoke the
release of t-PA and induce arterial vasodilation. We have
shown here that cigarette smoking causes a marked impair¬
ment in PAR-l-mediated endothelial vasomotor and fi¬
brinolytic function. Relative arterial stasis and abolition of
t-PA release will strongly enhance clot expansion and vessel
occlusion. Taken together, these findings suggest a major
contribution of impaired endothelial PAR-1 action to the
increased atherothrombotic risk of smokers. These impor¬
tant and novel findings are of direct relevance to our
understanding of the pathophysiology by which cigarette
smoking causes an increased propensity to atherothrombotic
disorders including acute myocardial infarction and stroke.
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